

# CITATION REPORT

List of articles citing

## Reporting results of cancer treatment

DOI: 10.1002/1097-0142(19810101)47:13.O.co;2-6  
Cancer, 1981, 47, 207-14.

**Source:** <https://exaly.com/paper-pdf/15274912/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #    | Paper  | IF  | Citations |
|------|--|-----|-----------|
| 2301 | CT in Esophageal Cancer. 62-84   |     |           |
| 2300 | Feasibility of Ultrasound-Guided Injection of TNF into Liver Metastases. <b>1992</b> , 253-261   |     |           |
| 2299 | Chemotherapie des metastasierenden Harnblasenkarzinoms: Nebenwirkungen der Kombinationstherapie von Cyclophosphamid, Adriamycin und Cis-Platinum. <b>1982</b> , 13, 335-338  |     |           |
| 2298 | Meta AMSA (m-AMSA) in patients with advanced ovarian carcinoma. <b>1982</b> , 22, 107-9  |     | 3         |
| 2297 | Radiotherapy of metastases from renal cancer. <b>1982</b> , 8, 340-2   |     | 30        |
| 2296 | [Short-term induction and cyclic maintenance therapy in inoperable small cell bronchial cancer]. <b>1982</b> , 60, 829-38  |     | 24        |
| 2295 | Treatment of advanced gastric cancer with 5-fluorouracil versus mitomycin C. <b>1982</b> , 21, 94-6  |     | 10        |
| 2294 | Breast cancer without axillary metastases. Are there high-risk biologic subpopulations?. <i>Cancer</i> , <b>1982</b> , 50, 1820-7  | 6.4 | 48        |
| 2293 | Occupational status and the journey-to-work. <b>1982</b> , 11, 251   |     | 16        |
| 2292 | VM26: phase I and II studies. <b>1982</b> , 7, 87-91   |     | 9         |
| 2291 | [Angiotensin-converting enzyme activity during cytostatic therapy in patients with primary inoperable bronchial carcinoma]. <b>1983</b> , 61, 923-7  |     | 1         |
| 2290 | Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA). <b>1983</b> , 11, 130-3 |     | 5         |
| 2289 | cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma. <b>1983</b> , 11, 35-7  |     | 9         |
| 2288 | Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapy. <b>1983</b> , 23, 223-7  |     | 5         |
| 2287 | Chlorozotocin treatment of advanced gastrointestinal cancer. <b>1983</b> , 11, 365-6   |     |           |
| 2286 | Chemotherapy for metastatic transitional carcinoma of the urinary tract. A prospective trial of methotrexate, adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure. <i>Cancer</i> , <b>1983</b> , 51, 216-9                              | 6.4 | 19        |
| 2285 | Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. <i>Cancer</i> , <b>1983</b> , 52, 2185-92  | 6.4 | 83        |

|      |   |     |
|------|---|-----|
| 2284 | Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group. <b>1983</b> , 19, 473-5   | 4   |
| 2283 | VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. <b>1983</b> , 19, 49-52   | 17  |
| 2282 | Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. <b>1983</b> , 10 Suppl A, 129-35   | 19  |
| 2281 | Whole-body hyperthermia in cancer therapy: a report of a phase I-II study. <b>1983</b> , 19, 1189-200   | 36  |
| 2280 | Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer. <b>1983</b> , 19, 195-201 | 17  |
| 2279 | Care of cancer patients in thirty-one Italian general hospitals. Methodological aspects and general findings. <b>1983</b> , 19, 179-85  | 7   |
| 2278 | On the receiving end--patient perception of the side-effects of cancer chemotherapy. <b>1983</b> , 19, 203-8  | 637 |
| 2277 | On the receiving end--II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. <b>1983</b> , 19, 1633-7             | 126 |
| 2276 | Cervical carcinoma: a drug-responsive tumor--experience with combined cisplatin, vinblastine, and bleomycin therapy. <b>1983</b> , 16, 275-81   | 94  |
| 2275 | Prostacyclin and thromboxane in ovarian cancer: effect of cytostatics and prostaglandin synthesis inhibitors. <b>1983</b> , 16, 340-5   | 12  |
| 2274 | Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. <b>1983</b> , 4, 43-52                          | 63  |
| 2273 | Adriamycin combinations as salvage therapy in advanced MOPP-resistant Hodgkin's disease. <b>1983</b> , 13, 369-73   | 4   |
| 2272 | Decreased Cisplatin-Induced Nausea and Vomiting with Chronic Alcohol Ingestion. <b>1983</b> , 309, 796-796  | 21  |
| 2271 | Confirmed Activity of Fam Polychemotherapy in Advanced Gastric Carcinoma. <b>1983</b> , 69, 59-64   | 1   |
| 2270 | Results of Combined Treatment of Patients with Locally Advanced Breast Cancer. <b>1983</b> , 69, 249-253  | 16  |
| 2269 | 5-Fluorouracil, Adriamycin and Cyclophosphamide Combined with High-Dose Medroxyprogesterone Acetate in Advanced Breast Cancer. <b>1983</b> , 69, 545-551                                    | 2   |
| 2268 | Chemotherapy of squamous cell cancer of the head and neck. <b>1983</b> , 1, 463-6   | 5   |
| 2267 | Clinical significance of routine follow-up examinations in patients with metastatic cancer of the prostate under hormone treatment. <b>1983</b> , 9, 262-6                                  | 7   |

|      |   |     |     |
|------|---|-----|-----|
| 2266 | A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer. <b>1984</b> , 2, 1012-6  |     | 32  |
| 2265 | A Retrospective Study of Fam Regimen in 38 Patients with Advanced Gastric Cancer. <b>1984</b> , 70, 375-379   |     | 1   |
| 2264 | Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. <b>1984</b> , 100, 671-6  |     | 246 |
| 2263 | Serum selenium in patients with ovarian cancer during and after therapy. <b>1984</b> , 5, 731-4   |     | 31  |
| 2262 | Multi-modality treatment of advanced malignant germ cell tumours in males. I. Experience with cis-platinum-based combination chemotherapy. <b>1984</b> , 18, 13-9                           |     | 15  |
| 2261 | Design of phase I and II clinical trials in cancer: a statistician's view. <b>1984</b> , 2, 483-91  |     | 57  |
| 2260 | Platinum Coordination Complexes in Cancer Chemotherapy. <b>1984</b> ,   |     | 43  |
| 2259 | Multi-modality treatment in males with advanced malignant germ cell tumours. II. Experience with surgery and radiotherapy following cis-platinum-based chemotherapy. <b>1984</b> , 18, 21-6 |     | 5   |
| 2258 | Reporting Results From Chemotherapy Trials. <b>1984</b> , 252, 2722   |     | 40  |
| 2257 | Clinical and biochemical studies of high-dose thymidine treatment in patients with solid tumors. <b>1984</b> , 107, 211-6   |     | 7   |
| 2256 | Estrogen receptors in mammary cancer: correlation with age, menopausal status, and response to therapy. <b>1984</b> , 107, 221-4  |     |     |
| 2255 | Carcinoma of the prostate with soft tissue or non-regional lymphatic metastases at the time of diagnosis: a review of 47 cases. <b>1984</b> , 56, 385-90                                    |     | 35  |
| 2254 | Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma. <i>Cancer</i> , <b>1984</b> , 53, 1467-72                                      | 6.4 | 12  |
| 2253 | A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients. <i>Cancer</i> , <b>1984</b> , 54, 393-6                      | 6.4 | 18  |
| 2252 | Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. <i>Cancer</i> , <b>1984</b> , 54, 961-4                                      | 6.4 | 64  |
| 2251 | Reduction of infection frequency by intravenous gammaglobulins during intensive induction therapy for small cell carcinoma of the lung. <b>1984</b> , 12, 167-70                            |     | 19  |
| 2250 | Problems in evaluating response of primary breast cancer to systemic therapy. <b>1984</b> , 4, 309-13   |     | 87  |
| 2249 | 5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer. <b>1984</b> , 12, 194-7  |     | 12  |

|      |  |     |
|------|--|-----|
| 2248 | A phase I toxicity study of human rDNA interferon in patients with solid tumours. <b>1984</b> , 13, 100-5  | 8   |
| 2247 | Phase II study of epirubicin in advanced malignant melanoma. <b>1984</b> , 2, 315-7  | 11  |
| 2246 | Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. <b>1984</b> , 2, 319-22   | 10  |
| 2245 | Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. <b>1984</b> , 2, 594-600                            | 192 |
| 2244 | WHO COOPERATIVE TRIAL ON PRIMARY PREVENTION OF ISCHAEMIC HEART DISEASE WITH CLOFIBRATE TO LOWER SERUM CHOLESTEROL: FINAL MORTALITY FOLLOW-UP. <b>1984</b> , 324, 600-604 | 23  |
| 2243 | Current status of chemotherapy of breast cancer. <b>1984</b> , 28, 93-8  | 2   |
| 2242 | Moderate to high dose cyclophosphamide and intercalated <i>Corynebacterium parvum</i> in patients with metastatic lung cancer. <b>1984</b> , 78, 89-97                   | 7   |
| 2241 | The subrenal capsule tumor implant assay as a predictor of clinical response to chemotherapy: 3 years of experience. <b>1984</b> , 19, 336-47                            | 20  |
| 2240 | Mitoxantrone treatment in advanced breast cancer. <b>1984</b> , 54, 21-4   | 5   |
| 2239 | Dose-response relationship for radiation therapy of recurrent, residual, and primarily inoperable colorectal cancer. <b>1984</b> , 1, 217-25                             | 115 |
| 2238 | New preoperative chemotherapy for bladder cancer using combination hemodialysis and direct hemoperfusion: preliminary report. <b>1984</b> , 131, 36-40                   | 10  |
| 2237 | The assessment of response to therapy of bone metastases in breast cancer. <b>1984</b> , 14, 19-22   | 43  |
| 2236 | Lonidamine in primary malignant brain tumors. Preliminary report. <b>1984</b> , 41 Suppl 1, 82-5   | 10  |
| 2235 | Small cell anaplastic carcinoma of the lung. The Aarhus experience 1976-1981. <b>1984</b> , 23, 153-8  | 1   |
| 2234 | Treatment with danazol and plasma glucagon concentration. <b>1985</b> , 291, 1155-6  | 10  |
| 2233 | Clinically derived dose effect relationship for hyperthermia given in combination with low dose radiotherapy. <b>1985</b> , 58, 243-50                                   | 43  |
| 2232 | MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. <b>1985</b> , 102, 596-602  | 474 |
| 2231 | Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study. <b>1985</b> , 15, 161-3   | 9   |

|      |  |        |
|------|--|--------|
| 2230 | Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine. <b>1985</b> , 14, 277-8  | 5      |
| 2229 | Cisplatin and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. <b>1985</b> , 15, 283-9 | 114    |
| 2228 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. <b>1985</b> , 3, 163-6  | 3      |
| 2227 | Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. <b>1985</b> , 51, 815-26            | 56     |
| 2226 | Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer. <b>1985</b> , 51, 319-33   | 27     |
| 2225 | Chemotherapy of metastatic seminoma. <b>1985</b> , 51, 467-72  | 26     |
| 2224 | Failure of mitomycin-vindesine combination chemotherapy as salvage treatment for metastatic breast cancer. <b>1985</b> , 110, 77-8   |        |
| 2223 | Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy. <i>Cancer</i> , <b>1985</b> , 56, 2512-8                         | 6.4 80 |
| 2222 | Clinical Toxicity of 4?-Epi-Doxorubicin (Epirubicin). <b>1985</b> , 71, 233-240  | 23     |
| 2221 | Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. <b>1985</b> , 103, 32-6  | 137    |
| 2220 | Phase II Trial of Oral VP 16-213 (Etoposide) in Patients with Advanced Head and Neck Cancer. <b>1985</b> , 71, 499-500   | 2      |
| 2219 | Recombinant human gamma-interferon in primary hepatocellular carcinoma. <b>1985</b> , 78, 826-9  | 17     |
| 2218 | High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study. <b>1985</b> , 11, 11-6                                     | 21     |
| 2217 | Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer. <b>1985</b> , 40, 346-50   | 4      |
| 2216 | Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. <b>1985</b> , 291, 1153-5  | 40     |
| 2215 | Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung. <b>1985</b> , 21, 587-9   | 1      |
| 2214 | Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. <b>1985</b> , 21, 1175-7                                      | 10     |
| 2213 | Cisplatin-containing chemotherapy in advanced head and neck cancer. <b>1985</b> , 36, 607-10   | 5      |

|      |   |     |
|------|---|-----|
| 2212 | Chemotherapy of esophageal cancer. <b>1985</b> , 21, 5-7  | 6   |
| 2211 | Phase I pharmacologic study of a new Vinca alkaloid: navelbine. <b>1985</b> , 27, 285-93  | 63  |
| 2210 | Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer. <b>1985</b> , 21, 803-6  | 30  |
| 2209 | Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. <b>1985</b> , 1, 395-404  | 33  |
| 2208 | Phase II trial of VP-16-213 in advanced ovarian carcinoma. <b>1985</b> , 22, 162-6  | 25  |
| 2207 | Continuous-infusion vinblastine in refractory carcinoma of the cervix: a phase II trial. <b>1985</b> , 21, 211-4  | 15  |
| 2206 | Combined cyclophosphamide, adriamycin and cis-platinum in advanced ovarian cancer resistant to chlorambucil and cis-platinum. <b>1985</b> , 21, 215-9                                   | 4   |
| 2205 | Carboplatin: the clinical spectrum to date. <b>1985</b> , 12 Suppl A, 125-36  | 150 |
| 2204 | A phase II study of tamoxifen in ovarian cancer. <b>1986</b> , 22, 309-12   | 39  |
| 2203 | Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. <b>1986</b> , 1, 256-8   | 207 |
| 2202 | Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. <b>1986</b> , 22, 1431-4  | 42  |
| 2201 | Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. <b>1986</b> , 7, 199-204   | 19  |
| 2200 | Combination chemotherapy with fluorouracil, adriamycin, cis-platinum and VM-26 in advanced transitional cell carcinoma of the urinary tract. <b>1986</b> , 22, 1457-60                  | 2   |
| 2199 | A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488). <b>1986</b> , 22, 1325-9   | 5   |
| 2198 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. <b>1986</b> , 22, 97-100   | 5   |
| 2197 | Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. <b>1986</b> , 172, 275-82   | 60  |
| 2196 | Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience). <b>1986</b> , 22, 1015-27 | 35  |
| 2195 | A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer. <b>1986</b> , 24, 23-6   | 5   |

|      |  |        |
|------|--|--------|
| 2194 | Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin. <b>1986</b> , 25, 302-10 | 6      |
| 2193 | Chemotherapy of advanced ovarian adenocarcinoma: a randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin. <b>1986</b> , 23, 1-13                 | 28     |
| 2192 | A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer. <b>1986</b> , 23, 40-3   | 1      |
| 2191 | Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, adriamycin, and BCNU. <b>1986</b> , 43, 288-91   | 12     |
| 2190 | [Polychemotherapy of advanced soft tissue sarcomas with 4'-epi-doxorubicin (4'-Epi-DX) and cisplatin (DDP)]. <b>1986</b> , 9 Suppl 1, 24-8   | 2      |
| 2189 | Neoadjuvant Chemotherapy with Vincristine, Bleomycin and Methotrexate Combined with Radiotherapy in Advanced Head and neck Squamous Cell Carcinoma. <b>1986</b> , 72, 301-306              |        |
| 2188 | Drug resistance in clinical practice: patterns of treatment failure in advanced breast and ovarian cancer. <b>1986</b> , 4, 952-7  | 12     |
| 2187 | Phase I study of taxol using a 5-day intermittent schedule. <b>1986</b> , 4, 762-6   | 53     |
| 2186 | A comparison of mitoxantrone and doxorubicin in breast cancer. <b>1986</b> , 4, 672-7  | 92     |
| 2185 | Bibliography. <b>1986</b> , 46, 204-256  |        |
| 2184 | Combination chemotherapy with dacarbazine and lomustine in disseminated malignant melanoma. <b>1986</b> , 25, 177-9  | 2      |
| 2183 | Malignant Effusions. <b>1986</b> ,   |        |
| 2182 | A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia. <b>1986</b> , 16, 48-51                                      | 19     |
| 2181 | Intra-arterial continuous infusion of cis-diamminedichloroplatinum in untreated head and neck cancer patients. <i>Cancer</i> , <b>1986</b> , 57, 1118-23                                   | 6.4 23 |
| 2180 | Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma. <i>Cancer</i> , <b>1986</b> , 57, 1666-74  | 6.4 33 |
| 2179 | Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. <i>Cancer</i> , <b>1986</b> , 57, 1700-4  | 6.4 79 |
| 2178 | Non-Hodgkin's lymphoma in the elderly. A retrospective clinicopathologic study of 50 patients. <i>Cancer</i> , <b>1986</b> , 57, 2185-9  | 6.4 31 |
| 2177 | Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. <i>Cancer</i> , <b>1986</b> , 57, 2389-96  | 6.4 73 |



|      |   |     |
|------|---|-----|
| 2176 | Staging and treatment with cyclophosphamide, vincristine and prednisone (CVP) in advanced cutaneous T-cell lymphomas. <b>1986</b> , 4, 83-90  | 5   |
| 2175 | Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin. <b>1986</b> , 14, 73-7  | 10  |
| 2174 | Phase II trial with oral idarubicin in advanced breast cancer. <b>1986</b> , 4, 39-42   | 23  |
| 2173 | Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. <b>1986</b> , 4, 85-105   | 61  |
| 2172 | Recombinant gamma interferon in advanced breast cancer: a phase II trial. <b>1986</b> , 4, 377-81   | 10  |
| 2171 | Phase II study of spirogermanium in patients with advanced colorectal carcinoma. <b>1986</b> , 4, 383-5   | 4   |
| 2170 | Oral idarubicin in non-Hodgkin's lymphomas. <b>1986</b> , 4, 263-7  | 21  |
| 2169 | Canopy structure, light microclimate and leaf gas exchange of <i>Quercus coccifera</i> L. in a Portuguese macchia: measurements in different canopy layers and simulations with a canopy model. <b>1986</b> , 1, 25 | 119 |
| 2168 | Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. <b>1986</b> , 16, 160-4   | 8   |
| 2167 | A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. <b>1986</b> , 18, 157-61   | 2   |
| 2166 | Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA). <b>1986</b> , 18, 223-5   | 4   |
| 2165 | Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluridine (5'-dFUrd) 3 g/m <sup>2</sup> VS 5 g/m <sup>2</sup> QD x 5 per month. <b>1986</b> , 18, 252-6                     | 7   |
| 2164 | Bioavailability of ifosfamide in patients with bronchial carcinoma. <b>1986</b> , 18, 261-4   | 18  |
| 2163 | Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG). <b>1986</b> , 16, 264-8        | 3   |
| 2162 | Small cell lung cancer: results of a phase II study of 1,2,4 triglycidylurazol. <b>1986</b> , 17, 85-6  | 7   |
| 2161 | Neoadjuvant chemotherapy and surgery of cancer of the esophagus. <b>1986</b> , 2, 170-6   | 19  |
| 2160 | Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents. <b>1986</b> , 9, 327-42  | 22  |
| 2159 | Retrospective analysis of the response of tumours in patients treated with a combination of radiotherapy and hyperthermia. <b>1986</b> , 2, 337-49  | 71  |

|      |  |     |
|------|--|-----|
| 2158 | Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin. <b>1986</b> , 315, 894-5   | 17  |
| 2157 | Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. <b>1986</b> , 6, 1-4  | 42  |
| 2156 | Hyperthermia as an adjuvant to radiotherapy in the treatment of malignant melanoma. <b>1987</b> , 3, 483-501   | 88  |
| 2155 | Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate. <b>1987</b> , 21, 13-6  | 16  |
| 2154 | Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. <b>1987</b> , 317, 1490-5                    | 472 |
| 2153 | Pre-cystectomy chemotherapy in patients with muscle infiltrating bladder carcinoma. A multicentre feasibility study. <b>1987</b> , 21, 39-42   | 7   |
| 2152 | Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatin. <b>1987</b> , 12, 167-76   | 5   |
| 2151 | Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma. <b>1987</b> , 27, 341-2  | 5   |
| 2150 | Chemotherapy for small cell lung cancer: induction and reinduction with VOCA. <b>1987</b> , 17, 279-82   | 4   |
| 2149 | M-VAC beim Urothelkarzinomrezidiv nach Radikaloperation. <b>1987</b> , 18, 18-21   | 1   |
| 2148 | Chemotherapy in advanced breast cancer. <b>1987</b> , 26, 81-7   | 1   |
| 2147 | Sequential 5-fluorouracil and methotrexate. Negative experience in metastatic colorectal cancer. <b>1987</b> , 26, 289-93  |     |
| 2146 | Neoadjuvant therapy for advanced squamous cell carcinoma of the cervix: cisplatin followed by radiation therapy--a pilot study of the Gynecologic Oncology Group. <b>1987</b> , 26, 35-40    | 18  |
| 2145 | A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinoma. <b>1987</b> , 26, 236-9   | 4   |
| 2144 | Whole Body Hyperthermia as a Treatment Modality. <b>1987</b> , 420-440   | 1   |
| 2143 | The Design of Clinical Trials in Hyperthermic Oncology. <b>1987</b> , 598-620  | 6   |
| 2142 | Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: therapeutic and endocrine effects in postmenopausal advanced breast cancer patients. <b>1987</b> , 23, 1451-9 | 11  |
| 2141 | A randomized trial comparing vindesine and cisplatin to vindesine and methotrexate in advanced non small cell lung carcinoma. <b>1987</b> , 23, 1615-9                                       | 7   |

|      |  |    |
|------|--|----|
| 2140 | A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer. <b>1987</b> , 23, 391-4   | 12 |
| 2139 | Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia. <b>1987</b> , 23, 1673-8                                      | 11 |
| 2138 | Palliative chemotherapy for relief of subocclusive symptoms. <b>1987</b> , 2, 578  | 4  |
| 2137 | Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. <b>1987</b> , 23, 535-40                       | 36 |
| 2136 | Toxic shock syndrome and staphylococcal pneumonia. <b>1987</b> , 2, 578  | 5  |
| 2135 | Vincristine and etoposide: an effective chemotherapy regimen with reduced toxicity in extensive small-cell lung cancer. <b>1987</b> , 23, 619-21                           | 10 |
| 2134 | High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. <b>1987</b> , 23, 1391-7  | 55 |
| 2133 | Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone. <b>1987</b> , 23, 1659-64            | 43 |
| 2132 | Phase II double-blind randomized study of lonidamine and radiotherapy in epidermoid carcinoma of the lung. <b>1987</b> , 10, 285-90  | 19 |
| 2131 | Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. <b>1987</b> , 157, 88-92  | 85 |
| 2130 | Quality of life. <b>1987</b> , 2, 161-2  | 1  |
| 2129 | Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. <b>1987</b> , 23, 1645-8                                   | 36 |
| 2128 | Influence of sympathetic nervous system on hypoglycaemic warning symptoms. <b>1987</b> , 2, 359-63   | 75 |
| 2127 | Drug resistance in clinical practice: patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer. <b>1987</b> , 23, 1601-5            | 4  |
| 2126 | Phase II trial of VP16-213 in squamous cell carcinoma of the head and neck. <b>1987</b> , 23, 577  |    |
| 2125 | RANDOMISED COMPARISON OF CISPLATIN WITH CYCLOPHOSPHAMIDE/CISPLATIN AND WITH CYCLOPHOSPHAMIDE/DOXORUBICIN/ CISPLATIN IN ADVANCED OVARIAN CANCER. <b>1987</b> , 330, 353-359 | 10 |
| 2124 | Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study. <b>1987</b> , 23, 657-61                       | 7  |
| 2123 | Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone. <b>1987</b> , 23, 557-61                            | 11 |

|      |   |    |
|------|---|----|
| 2122 | High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. <b>1987</b> , 23, 1303-6   | 14 |
| 2121 | LONG TERM FOLLOW-UP AND THERAPY MONITORING OF CANCER: IS THE SIMULTANEOUS DOSAGE OF CEA AND TPA USEFUL?. <b>1987</b> , 613-620  | 1  |
| 2120 | Hodgkin's disease in the elderly: a retrospective clinicopathologic study of 61 patients aged over 60 years. <b>1987</b> , 78 Suppl 1, 163-70   | 10 |
| 2119 | Cisplatin and Low-Dose Cytosine Arabinoside in Advanced Cancer. <b>1987</b> , 73, 493-497   |    |
| 2118 | Applicability of Local Hyperthermia as Adjuvant to Systemic Chemotherapy. <b>1987</b> , 73, 629-633   | 6  |
| 2117 | Phase II Trial of Mitomycin plus Cisplatin in the Treatment of Advanced Colorectal Adenocarcinoma. <b>1987</b> , 73, 505-506  | 1  |
| 2116 | The treatment of advanced recurrent carcinoma of the uterine cervix with platinum based cytotoxic chemotherapy. <b>1987</b> , 27, 146-9   | 3  |
| 2115 | Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) Study. <b>1987</b> , 44, 159-63                               | 2  |
| 2114 | Phase 2 Study of High Dose Etoposide (VP16-213) in Hepatocellular Carcinoma. <b>1987</b> ,  |    |
| 2113 | Epirubicin in Combination Chemotherapy in the Treatment of Advanced Stage Non-Hodgkin's Lymphomas. <b>1987</b> , 73, 43-47  | 5  |
| 2112 | The Role of Combination Cyclophosphamide, Doxorubicin and Cisplatin (Cap) Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <b>1987</b> , 73, 345-349  | 3  |
| 2111 | Cyclophosphamide, Methotrexate, 5-Fluorouracil, Alternating with Adriamycin and Mitomycin C in Metastatic Breast Cancer: A Pilot Study. <b>1987</b> , 73, 303-307   | 1  |
| 2110 | Radiotherapy versus Radiotherapy plus Cisplatin Treatment for Locally Advanced Non Small Cell Lung Cancer: Preliminary Results of a Randomized Study. <b>1987</b> , 73, 627-628   |    |
| 2109 | High-Dose Cisplatin in the Outpatient Clinic: A Feasibility Study. <b>1987</b> , 73, 341-344  | 1  |
| 2108 | Phase II Trial of Weekly 4-EPI-Doxorubicin (Epirubicin) in Squamous Cell Carcinoma of the Head and Neck. <b>1987</b> , 73, 65-67  |    |
| 2107 | [Effectiveness of gamma interferon and alpha interferon in hairy cell leukemia]. <b>1987</b> , 65, 706-12   | 5  |
| 2106 | Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. <b>1987</b> , 2, 26-9 | 21 |
| 2105 | Preoperative chemotherapy in esophageal carcinoma. <b>1987</b> , 11, 433-8  | 25 |

|      |   |     |    |
|------|---|-----|----|
| 2104 | High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies. <b>1987</b> , 55, 49-53   |     | 20 |
| 2103 | Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion. <b>1987</b> , 5, 365-71   |     | 3  |
| 2102 | Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma. <b>1987</b> , 5, 307-9  |     | 4  |
| 2101 | A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours. <b>1987</b> , 25, 54-8  |     | 18 |
| 2100 | Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b. <b>1987</b> , 5 Suppl, S19-25  |     | 17 |
| 2099 | Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin. <b>1987</b> , 20, 230-4   |     | 6  |
| 2098 | Etoposide combination therapy for small cell carcinoma of the lung. <b>1987</b> , 20, 83-4  |     | 6  |
| 2097 | Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies. <b>1987</b> , 19, 250-2   |     | 2  |
| 2096 | A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma. <i>Cancer</i> , <b>1987</b> , 59, 2011-5                                    | 6.4 | 30 |
| 2095 | Intermittent pelvic arterial infusion with peptichemio, doxorubicin, and cisplatin for locally advanced and recurrent carcinoma of the uterine cervix. <i>Cancer</i> , <b>1987</b> , 60, 25-30      | 6.4 | 34 |
| 2094 | Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. <i>Cancer</i> , <b>1987</b> , 60, 42-50 | 6.4 | 71 |
| 2093 | Intensive cytoreductive therapy followed by autologous bone marrow transplantation for patients with hematologic malignancies or solid tumors. <i>Cancer</i> , <b>1987</b> , 60, 289-95             | 6.4 | 7  |
| 2092 | Management of cancer patients receiving interferon alfa-2a. <b>1987</b> , 1, 21-30  |     | 10 |
| 2091 | Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: a progress report. <b>1987</b> , 1, 36-40   |     | 21 |
| 2090 | The murine subrenal capsule human tumor implant assay. <b>1987</b> , 1, 62-66   |     | 1  |
| 2089 | Value of CA 15:3 in the follow-up of breast cancer patients. <b>1987</b> , 55, 567-9  |     | 86 |
| 2088 | Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer. <b>1987</b> , 56, 820-4  |     | 37 |
| 2087 | Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer. <b>1987</b> , 94, 583-8   |     | 42 |

|      |   |     |    |
|------|---|-----|----|
| 2086 | Sequential combination chemotherapy for malignant germ cell tumors of the ovary. <i>Cancer</i> , <b>1988</b> , 61, 913-8  | 6.4 | 14 |
| 2085 | Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). <i>Cancer</i> , <b>1988</b> , 61, 1977-82 | 6.4 | 79 |
| 2084 | Long-term survival of 1035 cases of nasopharyngeal carcinoma. <i>Cancer</i> , <b>1988</b> , 61, 2338-41   | 6.4 | 38 |
| 2083 | Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VlhP regimen. <i>Cancer</i> , <b>1988</b> , 62, 24-7   | 6.4 | 45 |
| 2082 | Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up. <i>Cancer</i> , <b>1988</b> , 62, 233-9   | 6.4 | 25 |
| 2081 | Is there any clinical relevance of serial determinations of serum carcinoembryonic antigen in small cell lung cancer patients?. <i>Cancer</i> , <b>1988</b> , 62, 1348-54   | 6.4 | 17 |
| 2080 | Observer error in the characterization of hepatic lesions in patients with neoplastic liver disease. <b>1988</b> , 16, 577-9  |     | 1  |
| 2079 | Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil. <b>1988</b> , 16, 304-7  |     | 2  |
| 2078 | Combination chemotherapy with carboplatin and bleomycin for advanced and recurrent head and neck cancer: a phase II study. <b>1988</b> , 39, 215-6  |     | 2  |
| 2077 | Aminoterminal propeptide of type-III procollagen in serum--an indicator of clinical behavior of advanced ovarian carcinoma?. <b>1988</b> , 41, 409-14   |     | 24 |
| 2076 | Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. <b>1988</b> , 41, 537-41  |     | 58 |
| 2075 | Kaposi's sarcoma in AIDS patients: long-term treatment with recombinant interferon alpha-2a and chemotherapy. <b>1988</b> , 66, 437-42  |     | 4  |
| 2074 | Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. <b>1988</b> , 6, 47-50  |     | 5  |
| 2073 | Phase I--preliminary phase II trial of iproplatin, a cisplatin analogue. <b>1988</b> , 6, 199-206   |     | 4  |
| 2072 | A phase II trial of oral 4'-demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer. <b>1988</b> , 6, 219-21  |     | 6  |
| 2071 | Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats. <b>1988</b> , 94, 178-82  |     | 31 |
| 2070 | Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer. <b>1988</b> , 6, 87-91  |     | 7  |
| 2069 | A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy. <b>1988</b> , 22, 141-6  |     | 6  |

|      |  |     |
|------|--|-----|
| 2068 | Phase II study of divided-dose vinblastine in advanced breast cancer patients. <b>1988</b> , 21, 65-7  | 3   |
| 2067 | Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitogiquone. <b>1988</b> , 21, 343-6   | 8   |
| 2066 | A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. <b>1988</b> , 21, 351-4   | 13  |
| 2065 | Is interferon with or without vinblastine the "treatment of choice" in metastatic renal cell carcinoma? The Norwegian Radium Hospital's experience 1983-1986. <b>1988</b> , 4, 178-83                      | 16  |
| 2064 | Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses. <b>1988</b> , 4, 184-90  | 18  |
| 2063 | Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. <b>1988</b> , 57, 115-6  | 30  |
| 2062 | A phase II study of carboplatin in adenocarcinoma of the oesophagus. <b>1988</b> , 58, 500-1   | 11  |
| 2061 | Tumour-associated trypsin inhibitor (TATI) in ovarian cancer. <b>1988</b> , 57, 304-7  | 49  |
| 2060 | Oral urea in the treatment of secondary tumours in the liver. <b>1988</b> , 57, 317-8  | 3   |
| 2059 | Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma. <b>1988</b> , 57, 319   | 15  |
| 2058 | Important prognostic factors influencing outcome of combined radiation and hyperthermia. <b>1988</b> , 15, 959-72  | 95  |
| 2057 | Low dose reirradiation in combination with hyperthermia: a palliative treatment for patients with breast cancer recurring in previously irradiated areas. <b>1988</b> , 15, 1407-13                        | 62  |
| 2056 | Nasopharyngeal carcinoma: result of treatment with cis-diamminedichloroplatinum II, 5 fluorouracil, and radiation therapy. <b>1988</b> , 14, 461-9   | 38  |
| 2055 | Radical radiation alone versus radical radiation plus microwave hyperthermia for N3 (TNM-UICC) neck nodes: a prospective randomized clinical trial. <b>1988</b> , 15, 13-24                                | 141 |
| 2054 | Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial. <b>1988</b> , 114, 95-100 | 44  |
| 2053 | Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma. <b>1988</b> , 114, 108-9   | 13  |
| 2052 | Increased serum concentrations of cholesterol and triglycerides in the progression of breast cancer. <b>1988</b> , 114, 514-8  | 24  |
| 2051 | Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer. <b>1988</b> , 114, 602-4  | 9   |

|      |   |     |
|------|---|-----|
| 2050 | Role of monoclonal antibodies in the therapy of solid tumours. <b>1988</b> , 58, 843-9  | 0   |
| 2049 | Cisplatin plus VP 16-213 in advanced ovarian carcinoma. <b>1988</b> , 30, 159-62  | 1   |
| 2048 | Concordance of combination and single agent chemosensitivity prediction in ovarian carcinoma using the subrenal capsule xenograft assay (SRCA). <b>1988</b> , 30, 416-21                  | 1   |
| 2047 | Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. <b>1988</b> , 318, 1414-22 | 813 |
| 2046 | Alpha-interferon therapy for essential thrombocythaemia. <b>1988</b> , 2, 70-2  | 87  |
| 2045 | Comparison of mammary serum antigen (MSA) with beta 2-microglobulin (beta 2M) and carcinoembryonic antigen (CEA) assays in patients with breast cancer. <b>1988</b> , 24, 1633-40         | 8   |
| 2044 | Application of Hyperthermia in the Treatment of Cancer. <b>1988</b> ,   | 5   |
| 2043 | Response rates and survival in patients with head and neck cancer treated with a combination of cisplatin and 5-fluorouracil prior to radiotherapy. <b>1988</b> , 39, 551-4               | 5   |
| 2042 | The metabolic basis for combination chemotherapy. <b>1988</b> , 38, 73-127  | 13  |
| 2041 | A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. <b>1988</b> , 6, 179-88  | 21  |
| 2040 | The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. <b>1988</b> , 24, 1567-72                    | 84  |
| 2039 | Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717. <b>1988</b> , 24, 769-75  | 19  |
| 2038 | Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial. <b>1988</b> , 41, 771-85   | 75  |
| 2037 | Aclarubicin in advanced thyroid cancer: a phase II study. <b>1988</b> , 24, 1271-5  | 18  |
| 2036 | Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. <b>1988</b> , 24, 785-90  | 82  |
| 2035 | Etoposide (VP16-213) in the treatment of advanced nasopharyngeal carcinoma. <b>1988</b> , 24, 797-8   | 4   |
| 2034 | Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. <b>1988</b> , 2, 72-4   | 231 |
| 2033 | Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer. <b>1988</b> , 24, 633-5  | 6   |



|      |  |    |
|------|--|----|
| 2032 | Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment. <b>1988</b> , 24, 1839-43           | 15 |
| 2031 | Treatment of Ph'-positive chronic myelogenous leukemia (CML) with recombinant interferon alfa-2b (Intron A). <b>1988</b> , 15 Suppl A, 21-6                        | 4  |
| 2030 | Chemotherapy of gastric cancer. <b>1988</b> , 15, 257-77   | 78 |
| 2029 | Prognostic factors in stage I and II high and intermediate grade non-Hodgkin's lymphoma. <b>1988</b> , 24, 1617-22   | 17 |
| 2028 | Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days. <b>1988</b> , 8, 717-25  | 14 |
| 2027 | Short-course neutron therapy for advanced head and neck cancer. <b>1988</b> , 61, 857-8  | 4  |
| 2026 | Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. <b>1988</b> , 6, 1-5  | 24 |
| 2025 | High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. <b>1988</b> , 6, 133-8  | 11 |
| 2024 | Phase II study of intravenous menogaril in patients with advanced breast cancer. <b>1988</b> , 80, 1066-9  | 8  |
| 2023 | EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. <b>1988</b> , 27, 541-3                   |    |
| 2022 | Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC). <b>1988</b> , 6, 409-11  | 7  |
| 2021 | Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer. <b>1988</b> , 93, 565-70  | 46 |
| 2020 | Doxorubicin and 4'-epidoxorubicin in combination chemotherapy of extensive small cell lung cancer. <b>1988</b> , 27, 75-6  | 7  |
| 2019 | Oral etoposide for Kaposi's Mediterranean sarcoma. <b>1988</b> , 177, 365-9  | 14 |
| 2018 | Results of a five-drug combination chemotherapy in non-small cell lung cancer. A phase II trial. <b>1988</b> , 27, 537-9   | 2  |
| 2017 | Psychosocial well-being of patients with inoperable non-small cell lung cancer. The importance of treatment- and disease-related factors. <b>1988</b> , 27, 829-35 | 29 |
| 2016 | Review of Methodological Problems in the Interpretation of Phase II Trials in Nonsmall-Cell Lung Cancer. <b>1988</b> , 41, 57-64                                   | 1  |
| 2015 | Early and long-term toxicity in the management of advanced germ cell testicular tumors. <b>1988</b> , 15, 205-8  | 2  |

- 2014 Chemotherapy of Advanced Head and Neck Squamous Carcinoma with Cisplatin, Fluorouracil and Bleomycin Administered in an Outpatient Schedule. **1988**, 74, 559-562
- 2013 Bleomycin, Vincristine, Mitomycin and Cisplatin Alternated with Cyclophosphamide, 4'-Epidoxorubicin and Procarbazine in Advanced Non-small-cell Lung Cancer. **1988**, 74, 563-566 2
- 2012 Deoxycoformycin in therapy of refractory lymphoid neoplasms. **1988**, 11, 35-7 1
- 2011 4-Demethoxydaunorubicin Administered Orally in Advanced Breast Cancer. **1988**, 74, 65-70 2
- 2010 Weekly Epirubicin in Advanced Breast Cancer. **1988**, 74, 689-692 7
- 2009 Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. **1988**, 11, 118-20 15
- 2008 Diffuse well-differentiated lymphocytic lymphoma: chemotherapy with BCNU, cyclophosphamide, vincristine, melphalan and prednisone. **1988**, 45, 417-20
- 2007 Phase II Trial of 4?-Epi-Doxorubicin in Locally Advanced or Metastatic Gastric Cancer. **1988**, 74, 313-315 2
- 2006 The Efficacy of High-Dose 4?Epidoxorubicin in Hepatocellular Carcinoma. **1988**,
- 2005 Performance of General Hospitals in Delivering Adjuvant Chemotherapy to Breast Cancer Patients. **1988**, 74, 377-386 3
- 2004 Results of a Combined Chemo-Radiotherapeutic Program in 61 Patients Affected by Small Cell Lung Cancer. **1988**, 74, 207-211
- 2003 Non-Hodgkin's Lymphoma in the Elderly: A Retrospective Evaluation of Toxicity Related to Aggressive vs. Conservative Treatments. **1988**, 74, 433-438 3
- 2002 Carboplatin (JM 8), Adriamycin and Cyclophosphamide (JAC) in Advanced Ovarian Carcinoma: A Pilot Study. **1988**, 74, 217-220 3
- 2001 CA 15.3 and CEA Plasma Level Monitoring in Patients with Breast Cancer. **1988**, 3, 154-158 8
- 2000 Four-year analysis of platinum and anthracycline combination for ovarian cancer. **1989**, 46, 109-16 12
- 1999 CHOP versus CNOP: Ergebnisse einer Vergleichsstudie. **1989**, 107-112
- 1998 Behandlung von therapierefrakten und rezidierten Non-Hodgkin-Lymphomen mit Mitoxantron und hochdosiertem Cytarabin. **1989**, 113-120
- 1997 Phase II Trial Using Tauromustine in Patients with Extended Non-Small Cell Lung Cancer. **1989**, 37, 152-156

|      |   |     |
|------|---|-----|
| 1996 | VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma. <b>1989</b> , 12, 27-9  | 2   |
| 1995 | VP16, Epirubicin and Procarbazine in the Treatment of Advanced Non-Small-Cell Lung Cancer. <b>1989</b> , 75, 168-170  | 1   |
| 1994 | Phase II Trial with Alternating Two Drug Schedules, CAP/MEC', For Advanced (Stage III Mo/MI) Non-Small-Cell Lung Cancer. <b>1989</b> , 75, 486-488  | 2   |
| 1993 | Phase II Study of Divided-Dose Vinblastine in Advanced Cancer Patients. <b>1989</b> , 75, 248-251   | 2   |
| 1992 | Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study. <b>1989</b> , 12, 13-5             | 10  |
| 1991 | Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer. <b>1989</b> , 12, 161-3   | 2   |
| 1990 | Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. <b>1989</b> , 46, 96-8  | 38  |
| 1989 | Effectiveness and Toxicity of «Beld» Polychemotherapy in Advanced Malignant Melanoma. <b>1989</b> , 75, 229-232   | 3   |
| 1988 | Analysis of 16 Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck: Implications for Treatment. <b>1989</b> , 75, 597-599   | 1   |
| 1987 | Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. <b>1989</b> , 7, 1533-8 | 69  |
| 1986 | A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. <b>1989</b> , 7, 706-9   | 91  |
| 1985 | 4'Epidoxorubicin Plus Verapamil in Anthracycline - Refractory Cancer Patients. <b>1989</b> , 75, 245-247  | 10  |
| 1984 | Cisplatin, Epirubicin and 5-Fluorouracil Combination Chemotherapy for Recurrent Carcinoma of the Salivary Gland. <b>1989</b> , 75, 252-256  | 21  |
| 1983 | Diagnosis and First-Line Treatment of Patients with Lung Cancer in Italian General Hospitals. <b>1989</b> , 75, 163-167   | 8   |
| 1982 | Lonidamine in Advanced Colorectal Cancer: A Phase II Study of the Italian Oncology Group for Clinical Research (Goirc). <b>1989</b> , 75, 277-279   | 2   |
| 1981 | Retrospective Analysis of the Cyvadic Regimen in Advanced Soft Tissue Sarcomas. <b>1989</b> , 75, 152-155   | 1   |
| 1980 | Chemo-Radiotherapeutic Management of Advanced Head and Neck Cancer. <b>1989</b> , 75, 600-604   |     |
| 1979 | Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. <b>1989</b> , 80, 935-40                                       | 159 |

|      |  |     |     |
|------|--|-----|-----|
| 1978 | Hepatic perfusion with FUDR utilizing an implantable system in patients with liver primary cancer or metastatic cancer confined to the liver. <b>1989</b> , 7, 1-6   |     | 13  |
| 1977 | Combination chemo-radiation therapy for jaundice due to focal malignant obstruction of the major bile ducts. <b>1989</b> , 5, 81-91  |     | 4   |
| 1976 | Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. <b>1989</b> , 81, 359-61   |     | 78  |
| 1975 | Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. <b>1989</b> , 81, 1735-8  |     | 23  |
| 1974 | Correlation between lectin binding and clinical factors in seminoma patients. <b>1989</b> , 115, 96-100  |     | 3   |
| 1973 | Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. <b>1989</b> , 115, 189-92   |     | 50  |
| 1972 | Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study. <b>1989</b> , 64, 468-71   |     | 19  |
| 1971 | Mitoxantrone and high-dose ara-C in refractory malignancies: a phase I trial. <b>1989</b> , 17, 159-63   |     | 1   |
| 1970 | Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. <i>Cancer</i> , <b>1989</b> , 63, 428-32 | 6.4 | 75  |
| 1969 | Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial. <i>Cancer</i> , <b>1989</b> , 63, 638-42   | 6.4 | 36  |
| 1968 | Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. <i>Cancer</i> , <b>1989</b> , 63, 742-7  | 6.4 | 99  |
| 1967 | Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. <i>Cancer</i> , <b>1989</b> , 63, 1065-9   | 6.4 | 15  |
| 1966 | Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?. <i>Cancer</i> , <b>1989</b> , 63, 1271-8   | 6.4 | 193 |
| 1965 | Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer. <i>Cancer</i> , <b>1989</b> , 63, 1927-30  | 6.4 | 26  |
| 1964 | Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. <i>Cancer</i> , <b>1989</b> , 64, 1388-92  | 6.4 | 29  |
| 1963 | Treatment of high-risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide. <i>Cancer</i> , <b>1989</b> , 64, 1824-8   | 6.4 | 45  |
| 1962 | Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors. <i>Cancer</i> , <b>1989</b> , 64, 1829-32  | 6.4 | 43  |
| 1961 | A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. <i>Cancer</i> , <b>1989</b> , 64, 2024-9   | 6.4 | 150 |

|      |  |     |    |
|------|--|-----|----|
| 1960 | A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. <i>Cancer</i> , <b>1989</b> , 64, 2431-6   | 6.4 | 43 |
| 1959 | Radiation therapy for early glottic cancer (T1N0M0): I. Results of conventional open field technique. <b>1989</b> , 17, 1199-202   |     | 22 |
| 1958 | A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). <b>1989</b> , 9, 351-61                           |     | 35 |
| 1957 | Phase II study of mitoxantrone for liver metastases from breast cancer. <b>1989</b> , 25, 73-4   |     | 10 |
| 1956 | Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis. <b>1989</b> , 23, 348-52   |     | 4  |
| 1955 | A phase II study of mitozantrone in advanced carcinoma of the ovary. <b>1989</b> , 24, 200-2   |     | 13 |
| 1954 | The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study. <b>1989</b> , 7, 103-8  |     | 11 |
| 1953 | Phase I clinical trial of doxorubicin and iproplatin combination chemotherapy in patients with breast cancer. <b>1989</b> , 7, 189-93  |     | 2  |
| 1952 | Phase I study of vincristine and escalating doses of etoposide. <b>1989</b> , 7, 203-7   |     | 2  |
| 1951 | A phase II study of spirogermanium in patients with advanced malignant lymphoma. <b>1989</b> , 7, 219-22   |     | 3  |
| 1950 | Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial. <b>1989</b> , 7, 247-50           |     | 2  |
| 1949 | Combined interferon and vinblastine treatment of advanced melanoma: evaluation of the treatment results and the effects of the treatment on immunological functions. <b>1989</b> , 28, 213-7 |     | 13 |
| 1948 | Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide. <b>1989</b> , 23, 263-5   |     | 6  |
| 1947 | Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. <b>1989</b> , 24, 41-4  |     | 2  |
| 1946 | Experience with intermediate-dose (110-120 mg/m <sup>2</sup> ) epirubicin. <b>1989</b> , 24, 61-4  |     | 7  |
| 1945 | Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. <b>1989</b> , 24, 67-8  |     | 6  |
| 1944 | Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer. <b>1989</b> , 24, 381-5                                       |     | 4  |
| 1943 | A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. <b>1989</b> , 24, 246-50   |     | 7  |

|      |   |    |
|------|---|----|
| 1942 | Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. <b>1989</b> , 23, 51-3  | 4  |
| 1941 | Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study. <b>1989</b> , 23, 115-6   | 4  |
| 1940 | The role of postoperative alkylating agent therapy in early-stage epithelial ovarian cancer. <b>1989</b> , 96, 353-7  | 3  |
| 1939 | Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. <b>1989</b> , 60, 98-101                            | 49 |
| 1938 | Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. <b>1989</b> , 60, 413-8   | 28 |
| 1937 | The impact of computed tomography and ultrasonography on the management of patients with carcinoma of the ovary. <b>1989</b> , 60, 751-4  | 2  |
| 1936 | Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. <b>1989</b> , 60, 764-6   | 72 |
| 1935 | Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. <b>1989</b> , 60, 770-4   | 25 |
| 1934 | Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. <b>1989</b> , 60, 938-41   | 27 |
| 1933 | Phase II study of lonidamine in metastatic breast cancer. <b>1989</b> , 59, 251-3   | 23 |
| 1932 | Clindamycin with primaquine for <i>Pneumocystis carinii</i> pneumonia. <b>1989</b> , 1, 1046-8  | 58 |
| 1931 | Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer. <b>1989</b> , 25, 1067-72   | 15 |
| 1930 | Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens. <b>1989</b> , 25, 829-35  | 46 |
| 1929 | Phase II trial of esorubicin in advanced renal carcinoma. Clinical Screening Group of the EROTC. <b>1989</b> , 25, 995-6  | 1  |
| 1928 | A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer. <b>1989</b> , 25, 141-3   | 10 |
| 1927 | Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. <b>1989</b> , 25, 861-5   | 19 |
| 1926 | Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer. <b>1989</b> , 25, 173-6   | 10 |
| 1925 | Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. The Clinical Screening Group of the European Organization for Research and Treatment of Cancer. <b>1989</b> , 25, 423-8 | 8  |

|      |   |     |
|------|---|-----|
| 1924 | A test object for assessing pulse oximeters. <b>1989</b> , 1, 1048-9  | 6   |
| 1923 | Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. <b>1989</b> , 2, 585-8  | 111 |
| 1922 | Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. <b>1989</b> , 1, 577-80  | 248 |
| 1921 | Complications of uterine cervix carcinoma treatments: the problem of a uniform classification. <b>1989</b> , 14, 9-17   | 33  |
| 1920 | Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. <b>1989</b> , 25, 965-72   | 18  |
| 1919 | Morphometric analysis, ploidy and response to chemotherapy in squamous carcinomas of the head and neck. <b>1989</b> , 185, 755-9  | 7   |
| 1918 | Carboplatin in lung cancer. <b>1989</b> , 5, 8-14   |     |
| 1917 | Field testing and comparative evaluation of rapid, visually read screening assays for antibody to human immunodeficiency virus. <b>1989</b> , 1, 580-4  | 58  |
| 1916 | Phase II study of intravenous menogaril in advanced ovarian carcinoma. EORTC Early Clinical Trials Group. <b>1989</b> , 25, 751-2   | 2   |
| 1915 | Low-dose methotrexate for the Sjögren syndrome. <b>1989</b> , 21, 757-62  | 65  |
| 1914 | Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. <b>1989</b> , 34, 339-44  | 32  |
| 1913 | Cerebral metastases in patients with ovarian cancer treated with chemotherapy. <b>1989</b> , 33, 296-300  | 56  |
| 1912 | Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay. <b>1989</b> , 32, 55-9 | 3   |
| 1911 | Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. <b>1989</b> , 25, 1795-803   | 92  |
| 1910 | Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. <b>1989</b> , 2, 580-5   | 533 |
| 1909 | Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies. <b>1989</b> , 7, 113-6  | 2   |
| 1908 | Epithelioid Hemangioendothelioma of the Liver with Myocardial Metastases. <b>1989</b> ,   |     |
| 1907 | Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil. <b>1989</b> , 19, 83-4   | 1   |

|      |   |    |
|------|---|----|
| 1906 | Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. <b>1989</b> , 1, 338-41   |    |
| 1905 | Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. <b>1989</b> , 142, 253-6  | 31 |
| 1904 | A phase II study with teniposide (VM26) in patients with progressed or relapsed small cell lung cancer (SCLC). <b>1989</b> , 1, 64-7  | 2  |
| 1903 | Neoadjuvant treatment of stages T2 to T4 bladder cancer with cis-platinum, cyclophosphamide and doxorubicin. <b>1989</b> , 141, 849-52  | 21 |
| 1902 | The ailments of cancer registries: a proposal for remedial education. <b>1989</b> , 4, 17-31  | 3  |
| 1901 | A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report. <b>1989</b> , 1, 197-202 | 4  |
| 1900 | Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I). <b>1989</b> , 28, 237-40               | 6  |
| 1899 | Combined chemotherapy for recurrent and metastatic nasopharyngeal carcinoma. <b>1989</b> , 1, 272-6   | 5  |
| 1898 | Levamisole or placebo after effective chemotherapy for remission and survival prolongation in advanced human solid tumors--a double-blind randomized trial. <b>1989</b> , 28, 105-6           |    |
| 1897 | Comparative study of two neoadjuvant protocols (VBM and DDP-BLM) combined with radiation therapy in advanced head and neck cancer. <b>1989</b> , 1, 68-71                                     | 4  |
| 1896 | Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1. <b>1989</b> , 35, 64-8  | 11 |
| 1895 | Management of malignant lymphoma in the elderly. An EORTC retrospective evaluation. <b>1989</b> , 28, 199-201   | 13 |
| 1894 | Prediction of objective response to recombinant interferon-alpha with or without vinblastine in metastatic renal cell carcinoma. <b>1990</b> , 29, 303-6                                      | 6  |
| 1893 | Cisplatin plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancer. <b>1990</b> , 2, 62-6   | 4  |
| 1892 | Quality of life in oncology patients. <b>1990</b> , 54, 145-60  | 29 |
| 1891 | Induction chemo-radiotherapy and maintenance alternating chemotherapy for small cell lung cancer. <b>1990</b> , 29, 417-20  | 1  |
| 1890 | Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. <b>1990</b> , 29, 1025-8   | 45 |
| 1889 | Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer. <b>1990</b> , 29, 421-4   | 3  |



|      |  |     |
|------|--|-----|
| 1888 | Significance of laboratory values in detection and follow-up of metastatic breast cancer. <b>1990</b> , 29, 313-4  |     |
| 1887 | Five-day continuous infusion of cisplatin and etoposide in non-small cell lung cancer. A phase II trial. <b>1990</b> , 29, 989-94  | 2   |
| 1886 | A scoring system for the quantitative evaluation of oral mucositis during bone marrow transplantation. <b>1990</b> , 10, 190-5   | 20  |
| 1885 | Phase II trial of methyl-gag and melphalan in metastatic adult renal cell carcinoma. <b>1990</b> , 8, 623-4  | 2   |
| 1884 | Treatment of disseminated malignant melanoma with cisplatin in combination with whole-body hyperthermia and doxorubicin. <b>1990</b> , 6, 511-5  | 12  |
| 1883 | Phase I-II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients. <b>1990</b> , 1, 189-93   | 7   |
| 1882 | Alternating cisplatin and VAC ineffective in end stage squamous cell carcinoma of the head and neck. <b>1990</b> , 104, 631-3  | 8   |
| 1881 | A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). <b>1990</b> , 1, 36-44                                    | 18  |
| 1880 | Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group. <b>1990</b> , 29, 995-9 | 9   |
| 1879 | Flutamide in hormone-resistant prostatic cancer. <b>1990</b> , 144, 1411-4   | 26  |
| 1878 | Unexpectedly high serum methotrexate levels in cystectomized bladder cancer patients with an ileal conduit treated with intermediate doses of the drug. <b>1990</b> , 143, 498-501   | 39  |
| 1877 | Elevated CA125 levels in patients with metastatic breast carcinoma. <b>1990</b> , 62, 668-70   | 16  |
| 1876 | Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide. <b>1990</b> , 2, 199-202   | 1   |
| 1875 | Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol. <b>1990</b> , 2, 123-6  | 7   |
| 1874 | A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC). <b>1990</b> , 2, 401-4  | 2   |
| 1873 | A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. <b>1990</b> , 61, 608-11   | 142 |
| 1872 | Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study. <b>1990</b> , 61, 618-21  | 14  |
| 1871 | Ploidy as a prognostic indicator in end stage squamous cell carcinoma of the head and neck region treated with cisplatin. <b>1990</b> , 61, 759-62   | 28  |

|      |  |     |
|------|--|-----|
| 1870 | Adjuvant chemotherapy in head and neck cancer. <b>1990</b> , 61, 779-87  | 136 |
| 1869 | Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer. <b>1990</b> , 61, 133-6   | 2   |
| 1868 | Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. <b>1990</b> , 62, 840-1   | 23  |
| 1867 | A phase III randomised trial of cisplatin, methotrexate, cisplatin + methotrexate and cisplatin + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. <b>1990</b> , 61, 311-5 | 111 |
| 1866 | Phase II study of lonidamine in non-small cell lung cancer: final report. <b>1990</b> , 61, 316-8  | 13  |
| 1865 | Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. <b>1990</b> , 116, 21-3  | 82  |
| 1864 | Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. <b>1990</b> , 116, 503-6  | 21  |
| 1863 | Evaluation of chromosomal aberrations in lymphocytes and micronuclei in lymphocytes, oral mucosa and hair root cells of patients under antineoplastic therapy. <b>1990</b> , 228, 157-69                                     | 50  |
| 1862 | Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid. <b>1990</b> , 26, 159-62  | 5   |
| 1861 | Phase I study of mitozolomide on a once daily for 5 days schedule. <b>1990</b> , 26, 237-8   | 3   |
| 1860 | 4'-O-tetrahydropyranil-doxorubicin in advanced breast cancer: a phase II study. <b>1990</b> , 26, 293-6  | 7   |
| 1859 | Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin. <b>1990</b> , 26, 306-9   | 6   |
| 1858 | The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. <b>1990</b> , 26, 105-11  | 48  |
| 1857 | Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer. <b>1990</b> , 26, 389-92   | 12  |
| 1856 | Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas. <b>1990</b> , 26, 453-6   | 10  |
| 1855 | Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. <b>1990</b> , 26, 457-60   | 10  |
| 1854 | Phase II trial of carboplatin and vinblastine in advanced squamous-cell carcinoma of the head and neck. <b>1990</b> , 26, 464-6  | 2   |
| 1853 | A randomized study of combined 5-fluorouracil and plasma perfusion over protein A-sepharose in human advanced colorectal carcinoma. <b>1990</b> , 2, 87-94   | 2   |

|      |   |    |
|------|---|----|
| 1852 | The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene. <b>1990</b> , 31, 381-6                | 9  |
| 1851 | Viral reactivation as a cause of unexplained fever in patients with progressive metastatic breast cancer. <b>1990</b> , 31, 191-5               | 7  |
| 1850 | Methotrexate, vinblastine, 4?-epirubicin and cisplatin in advanced urothelial tract tumors: Efficacy and toxicity. <b>1990</b> , 8, 51-54       | 4  |
| 1849 | Neoadjuvant chemotherapy and surgery of cancer of the esophagus. <b>1990</b> , 6, 268-73  | 22 |
| 1848 | A phase 1 and pharmacokinetic study using the aromatic retinoic acid analogue dichloroetretinate (Ro 12-7554). <b>1990</b> , 25, 279-85         | 2  |
| 1847 | A phase II study of ifosfamide in endometrial cancer. <b>1990</b> , 26 Suppl, S4-6  | 16 |
| 1846 | Phase II studies of ifosfamide alone and in combination in cancer of the cervix. <b>1990</b> , 26 Suppl, S12-6                                  | 6  |
| 1845 | Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer. <b>1990</b> , 26 Suppl, S33-5                                   | 23 |
| 1844 | Treatment of gynecological malignancies with a combination of cisplatin, adriamycin and ifosfamide. <b>1990</b> , 26 Suppl, S39-42              | 4  |
| 1843 | Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. <b>1990</b> , 26 Suppl, S59-62  | 31 |
| 1842 | Carboplatin and etoposide in advanced lung cancer:--a phase I study. <b>1990</b> , 27, 229-33   | 5  |
| 1841 | Toxicity of intra-arterial doxorubicin in locally advanced breast cancer. <b>1990</b> , 25, 459-62  | 8  |
| 1840 | Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer. <b>1990</b> , 25, 367-70 | 17 |
| 1839 | Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination. <b>1990</b> , 27, 131-4  | 6  |
| 1838 | Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule. <b>1990</b> , 8, 269-74                               | 1  |
| 1837 | Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer. <b>1990</b> , 8, 299-304 | 28 |
| 1836 | A phase II study of mitoxantrone in advanced gastric cancer. <b>1990</b> , 8, 305-6   | 2  |
| 1835 | Phase I trial of a 5-day course of carbetimer. <b>1990</b> , 8 Suppl 1, S41-9   | 2  |

|      |  |     |     |
|------|--|-----|-----|
| 1834 | Combination high-dose etoposide and vincristine infusion. <b>1990</b> , 8 Suppl 1, S59-64  |     | 1   |
| 1833 | Phase I trial of tallysomyin S10b, a bleomycin analogue. <b>1990</b> , 8, 171-80   |     | 2   |
| 1832 | 3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity. <b>1990</b> , 8, 369-76   |     | 1   |
| 1831 | Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. <b>1990</b> , 8, 391-2  |     | 17  |
| 1830 | A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck. <b>1990</b> , 8, 109-11  |     | 3   |
| 1829 | A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. <b>1990</b> , 8, 125-30  |     | 30  |
| 1828 | Integration of chemotherapy in an MFD--radiotherapy plan for advanced inoperable squamous cell carcinoma of the head and neck. <b>1990</b> , 12, 60-5  |     | 5   |
| 1827 | Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. <b>1990</b> , 12, 753-60  |     | 202 |
| 1826 | Serum hyaluronan (hyaluronic acid) in breast cancer patients. <b>1990</b> , 46, 388-90   |     | 66  |
| 1825 | Diethylstilbestrol revisited in advanced breast cancer management. <b>1990</b> , 18, 317-20  |     | 10  |
| 1824 | Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. <i>Cancer</i> , <b>1990</b> , 65, 400-4                                  | 6.4 | 80  |
| 1823 | A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. <i>Cancer</i> , <b>1990</b> , 65, 1692-9 | 6.4 | 30  |
| 1822 | A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association Study. <i>Cancer</i> , <b>1990</b> , 65, 1700-3                 | 6.4 | 3   |
| 1821 | Continuous cyclophosphamide, doxorubicin, vincristine, and prednisolone. A new, innovative protocol for diffuse aggressive lymphomas. <i>Cancer</i> , <b>1990</b> , 65, 1704-10                                      | 6.4 | 2   |
| 1820 | Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia. <i>Cancer</i> , <b>1990</b> , 65, 1891-4                                   | 6.4 | 10  |
| 1819 | Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study. <i>Cancer</i> , <b>1990</b> , 65, 2451-4        | 6.4 | 26  |
| 1818 | Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. <i>Cancer</i> , <b>1990</b> , 65, 2635-40  | 6.4 | 18  |
| 1817 | Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. <i>Cancer</i> , <b>1990</b> , 66, 119-29                 | 6.4 | 214 |

|      |   |     |     |
|------|---|-----|-----|
| 1816 | Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. <i>Cancer</i> , <b>1990</b> , 66, 214-9 | 6.4 | 74  |
| 1815 | Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study. <i>Cancer</i> , <b>1990</b> , 66, 423-30                            | 6.4 | 42  |
| 1814 | A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. <i>Cancer</i> , <b>1990</b> , 66, 659-63  | 6.4 | 67  |
| 1813 | Management of malignant ovarian immature teratoma. Role of adriamycin. <i>Cancer</i> , <b>1990</b> , 66, 882-6  | 6.4 | 10  |
| 1812 | Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. <i>Cancer</i> , <b>1990</b> , 66, 1697-702   | 6.4 | 98  |
| 1811 | Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma. <i>Cancer</i> , <b>1990</b> , 66, 2399-406                     | 6.4 | 16  |
| 1810 | Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial. <i>Cancer</i> , <b>1990</b> , 66, 2465-9   | 6.4 | 133 |
| 1809 | Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. <b>1990</b> , 8, 899-905   |     | 52  |
| 1808 | Prognostic Factors in Stage IV Ovarian Carcinoma Treated with Platinum-Based Regimens. <b>1990</b> , 76, 274-277  |     | 3   |
| 1807 | Phase II Trial of Cytarabine, Cisplatin and Vindesine for Advanced Non-Small Cell Lung Cancer. <b>1990</b> , 76, 35-37  |     |     |
| 1806 | Sequential and Synchronous Chemo-Radiotherapy in the Management of Locally Advanced Carcinoma of the Head and Neck. <b>1990</b> , 76, 238-243   |     |     |
| 1805 | High-Dose Epirubicin-Cisplatin Chemotherapy for Advanced Soft Tissue Sarcoma. <b>1990</b> , 76, 467-471   |     | 7   |
| 1804 | Mitoxantrone (M) and Vinblastine (V) in the Treatment of Advanced Breast Cancer. <b>1990</b> , 76, 196-198  |     | 2   |
| 1803 | MCA in Patients with Breast Cancer: Correlation with CEA and CA15-3. <b>1990</b> , 5, 14-21   |     | 10  |
| 1802 | Evaluating Radiation in Combination with Hyperthermia Trials: The Importance of Clinical and Technical Parameters. <b>1990</b> , 76, 205-211  |     | 1   |
| 1801 | Alpha-2 Interferon and 5-Fluorouracil in Advanced Colorectal Cancer. <b>1990</b> , 76, 385-388  |     | 16  |
| 1800 | Comparison between CEA, TPA, CA 15/3 and Hydroxyproline, Alkaline Phosphatase, Whole Body Retention of 99mTc MDP in the follow-up of Bone Metastases in Breast Cancer. <b>1990</b> , 5, 65-72       |     | 18  |
| 1799 | Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy. <b>1990</b> , 76, 480-483   |     | 79  |

|      |   |     |
|------|---|-----|
| 1798 | [Combination therapy with adriamycin, cisplatin and vindesine in C cell carcinoma of the thyroid].<br><b>1990, 13, 198-202</b>  | 4   |
| 1797 | [Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer].<br><b>1990, 13, 359-62</b>  | 2   |
| 1796 | Management of patients with poor-prognosis nonseminomatous germ cell cancer. <b>1990, 47, 234-40</b>  | 6   |
| 1795 | Cisplatin and Mitomycin C in Advanced Chemotherapy-Refractory Breast Cancer. <b>1990, 76, 234-237</b>   | 3   |
| 1794 | Phase II Study with High Doses of Epirubicin in Patients with Advanced Rectal Cancer. <b>1990, 76, 503-504</b>  | 4   |
| 1793 | Concomitant administration of 4-hydroxypyrazolopyrimidine (allopurinol) and high-dose continuous infusion 5-fluorouracil. <b>1990, 47, 70-4</b>   | 6   |
| 1792 | Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).<br><b>1990, 18 Suppl 3, 48-53</b> | 17  |
| 1791 | Chemotherapy with tauromustine in advanced non-small cell lung cancer. A trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society. <b>1990, 13, 186-8</b>                         | 2   |
| 1790 | Recombinant human erythropoietin for patients with AIDS treated with zidovudine. <b>1990, 322, 1488-93</b>  | 287 |
| 1789 | Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.<br><b>1990, 8, 327-34</b>  | 108 |
| 1788 | Epirubicin in Childhood Acute Lymphoblastic and Myeloid Leukemia in Relapse. <b>1990, 1, 203-8</b>  |     |
| 1787 | Oropharynx carcinoma: irradiation alone versus induction chemotherapy plus irradiation--5 year results. <b>1990, 63, 340-5</b>  | 5   |
| 1786 | Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma. <b>1990, 8, 1-5</b>   | 7   |
| 1785 | Cisplatin and medium dose methotrexate in advanced transitional cell carcinoma of the urinary tract. <b>1990, 24, 199-204</b>   | 4   |
| 1784 | Management of malignant pleural effusions. <b>1990, 45, 81-2</b>  | 19  |
| 1783 | Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma. <b>1990, 22, 115-21</b>                              | 16  |
| 1782 | A phase I trial of combination chemotherapy employing carboplatin, vinca alkaloids, with or without bleomycin in patients with advanced malignant tumors. <b>1990, 8, 135-41</b>  |     |
| 1781 | Design of Phase I and II Trials in Cancer. <b>1990, 24, 341-349</b>   | 5   |

|      |  |     |
|------|--|-----|
| 1780 | Comprehensive criteria for assessing therapy-induced toxicity. <b>1990</b> , 8, 147-59   | 184 |
| 1779 | Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group. <b>1990</b> , 26, 137-8                   | 19  |
| 1778 | Phase II study of carboplatin in untreated inoperable advanced stomach cancer. <b>1990</b> , 26, 1108-9  | 12  |
| 1777 | Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. <b>1990</b> , 6, 87-98   | 29  |
| 1776 | Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. <b>1990</b> , 26, 727-9   | 34  |
| 1775 | Results of treatment in irradiated testicular seminoma patients. <b>1990</b> , 18, 1-7   | 21  |
| 1774 | Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. <b>1990</b> , 26, 691-4                                    | 6   |
| 1773 | High-dose epirubicin for untreated patients with advanced tumours: a phase I study. <b>1990</b> , 26, 1137-40  | 12  |
| 1772 | Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma. <b>1990</b> , 26, 1054-6       | 2   |
| 1771 | Epirubicin for pretreated advanced ovarian cancer. <b>1990</b> , 26, 850-1   | 15  |
| 1770 | Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. <b>1990</b> , 22, 802-10                                  | 120 |
| 1769 | Carboplatin for advanced bladder cancer. <b>1990</b> , 26, 849-50  | 11  |
| 1768 | Pirarubicin in advanced breast cancer: a French cooperative phase II study. <b>1990</b> , 26, 821-3  | 8   |
| 1767 | Placebo-controlled study on the efficacy of the pyrimido-pyrimidine derivative RA 233 in ovarian cancer. <b>1990</b> , 36, 226-31                        | 3   |
| 1766 | Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. <b>1990</b> , 39, 358-63 | 16  |
| 1765 | Combination chemotherapy in advanced adenocarcinoma of the fallopian tube. <b>1991</b> , 40, 268-73  | 15  |
| 1764 | Acute blindness during treatment of recurrent or metastatic nasopharyngeal carcinoma with doxorubicin and CCNU. <b>1990</b> , 26, 857                    | 4   |
| 1763 | A phase II study of iproplatin in advanced or metastatic stomach cancer. The EORTC Early Clinical Trial Group. <b>1990</b> , 26, 61-2                    | 2   |

|      |   |    |
|------|---|----|
| 1762 | Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. <b>1990</b> , 26, 824-7   | 10 |
| 1761 | Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication. <b>1990</b> , 36, 227-8   | 8  |
| 1760 | Safety and efficacy of toremifene in breast cancer patients. A phase II study. <b>1990</b> , 36, 229-31   | 5  |
| 1759 | Angiotensin-induced hypertension chemotherapy in children with advanced solid tumors. <b>1991</b> , 33, 381-3   | 3  |
| 1758 | Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer. <b>1991</b> , 27, 1589-93  | 1  |
| 1757 | Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. <b>1991</b> , 27, 565-8   | 10 |
| 1756 | Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means?. <b>1991</b> , 27, 1597-601   | 54 |
| 1755 | Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma. <b>1991</b> , 27, 1620-2   | 6  |
| 1754 | Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma. <b>1991</b> , 27, 1564-6   | 7  |
| 1753 | A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. <b>1991</b> , 27, 750-5 | 84 |
| 1752 | Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide. <b>1991</b> , 27, 866-70                       | 6  |
| 1751 | Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncológico (GGETO). <b>1991</b> , 27, 864-6   | 31 |
| 1750 | Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. <b>1991</b> , 45, 203-7   | 16 |
| 1749 | Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study. <b>1991</b> , 27, 1583-9   | 45 |
| 1748 | Excessive toxicity of mitoxantrone combined with etoposide in advanced non-small cell lung cancer. <b>1991</b> , 27, 1334-5   | 1  |
| 1747 | Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. <b>1991</b> , 27, 1617-20   | 21 |
| 1746 | Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma. <b>1991</b> , 9, 249-55                                   | 12 |
| 1745 | Induction chemotherapy (cisplatin + 5-fluorouracil) and radiotherapy in advanced squamous cell carcinoma of the head and neck. <b>1991</b> , 30, 27-32  | 11 |



|      |   |     |
|------|---|-----|
| 1744 | Adjuvant chemotherapy for T1-2NOMO small cell lung cancer: single-agent or combination chemotherapy?. <b>1991</b> , 9, 19-25  | 1   |
| 1743 | Evaluation of two consecutive regimens in advanced gastric cancer. <b>1991</b> , 9, 257-62  | 4   |
| 1742 | Concomitant Cisplatin and Recombinant Interferon $\beta$ -2b in Head and Neck Cancer. <b>1991</b> , 3, 341-343  | 2   |
| 1741 | Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. <b>1991</b> , 324, 1297-304                        | 339 |
| 1740 | Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma. <b>1991</b> , 43, 242-6   | 2   |
| 1739 | Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy. <b>1991</b> , 43, 159-63 | 14  |
| 1738 | Chemotherapy in recurrent and advanced cervical cancer. <b>1991</b> , 40, 107-11  | 37  |
| 1737 | Ifosfamide-induced neurotoxicity. <b>1991</b> , 42, 193-6; discussion 191-2   | 41  |
| 1736 | Single institutional experience with non-seminomatous germ cell tumours of the testis: local perspectives on a curable cancer. <b>1991</b> , 21, 857-62   | 5   |
| 1735 | Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. <b>1991</b> , 64, 451-6  | 66  |
| 1734 | Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. <b>1991</b> , 27, 831-5  | 37  |
| 1733 | Phase II study of combination vincristine, epirubicin and cyclophosphamide in advanced breast cancer in Chinese patients. <b>1991</b> , 27, 1710  | 1   |
| 1732 | Activity of high-dose epirubicin in advanced non-small cell lung cancer. <b>1991</b> , 27, 1231-4   | 24  |
| 1731 | Combined interferon alfa and doxorubicin in the treatment of advanced cervical cancer. <b>1991</b> , 165, 284-90; discussion 290-1  | 13  |
| 1730 | Adjuvant thoracic radiotherapy in small cell lung cancer: ten-year follow-up of a randomized study. <b>1991</b> , 7, 235-241  | 15  |
| 1729 | MMAF for advanced gastric cancer. <b>1991</b> , 27, 1234-8  | 6   |
| 1728 | Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification. <b>1991</b> , 2, 663-6                 | 15  |
| 1727 | Epirubicin in the Treatment of Malignant Mesothelioma: A Phase II Cooperative Study. <b>1991</b> , 77, 49-51  | 36  |

|      |  |    |
|------|--|----|
| 1726 | High-Dose Epirubicin as a Single Agent in the Treatment of Patients with Advanced Breast Cancer. <b>1991, 77, 232-236</b>  | 12 |
| 1725 | Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. <b>1991, 48, 353-5</b>   | 6  |
| 1724 | Inflammatory Component: A Worsening Factor in Locally Advanced Breast Cancer Treated by Radiotherapy and Systemic Therapy. <b>1991, 77, 331-335</b>                                | 1  |
| 1723 | Intensive Alternating Combination Chemotherapy and High Dose Chest Radiotherapy in Small Cell Lung Cancer. <b>1991, 77, 437-441</b>  | 1  |
| 1722 | Lonidamine in Non-Small-Cell Lung Cancer: A Phase II Study. <b>1991, 77, 52-55</b>   | 3  |
| 1721 | 5-Fluorouracil, epirubicin and cyclophosphamide (FEC combination) in advanced breast cancer. <b>1991, 3, 126-9</b>   | 3  |
| 1720 | Intra-Arterial Hepatic Chemotherapy for Liver Metastases. <b>1991, 24-37</b>   |    |
| 1719 | Hormone-Resistant Metastatic Prostate Cancer. <b>1991, 19, 12-15</b>   | 17 |
| 1718 | Epirubicin and DTIC (EDIC) for advanced soft-tissue sarcomas. <b>1991, 48, 230-3</b>   | 8  |
| 1717 | Role of recombinant alpha-interferon in the treatment of advanced cutaneous malignant melanoma. <b>1991, 48, 365-8</b>   | 12 |
| 1716 | A Randomized Study of On-Line Plasma Perfusion over Protein A-Sepharose and 5-Fluorouracil Chemotherapy in Patients with Metastatic Colorectal Carcinoma. <b>1991, 14, 109-115</b> |    |
| 1715 | Activity and toxicity of 4'-iodo-4'-deoxydoxorubicin in patients with advanced breast cancer. <b>1991, 2, 719-25</b>   | 9  |
| 1714 | 5-fluorouracil + folinic acid with cisplatin and bleomycin in the treatment of advanced head and neck squamous cell carcinoma. <b>1991, 2, 379-81</b>                              | 7  |
| 1713 | Breast Liver Metastases [Incidence, Diagnosis and Outcome. <b>1991, 84, 714-716</b>  | 97 |
| 1712 | Combination Chemotherapy with Vinblastine, Bcnu and Cisplatin in Advanced Malignant Melanoma. <b>1991, 77, 216-218</b>   | 1  |
| 1711 | A Role for Tumor Markers in Therapeutic Decisions after Chemotherapy Induction of Objective Remission in Stage III Epithelial Ovarian Neoplasms. <b>1991, 6, 107-114</b>           |    |
| 1710 | Phase II trial of oral carmofur in advanced pancreatic carcinoma. <b>1991, 2, 765-6</b>  | 6  |
| 1709 | Primary Radiotherapy versus Surgery and Radiotherapy in the Management of Postmenopausal Locally Advanced Breast Cancer. <b>1991, 77, 141-144</b>                                  | 1  |

|      |   |    |
|------|---|----|
| 1708 | Salvage Chemotherapy with Ccnu and Methotrexate for Small Cell Lung Cancer Resistant to Cav/Pe Alternating Chemotherapy. <b>1991</b> , 77, 506-510                  | 3  |
| 1707 | Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck. <b>1991</b> , 48, 270-6                  | 13 |
| 1706 | Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. <b>1991</b> , 3, 55-60                            | 6  |
| 1705 | Primary systemic therapy for operable breast cancer. <b>1991</b> , 63, 561-6  | 59 |
| 1704 | Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer. <b>1991</b> , 63, 84-6  | 4  |
| 1703 | Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. <b>1991</b> , 63, 463-5  | 33 |
| 1702 | 5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study. <b>1991</b> , 3, 51-4                             | 5  |
| 1701 | Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients. <b>1991</b> , 3, 328-31           | 27 |
| 1700 | Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?. <b>1991</b> , 99, 1433-7  | 26 |
| 1699 | Estrogen receptors in gastric cancer. <b>1991</b> , 30, 870-2   | 3  |
| 1698 | Single agent epirubicin in squamous cell cervical cancer. A phase II trial. <b>1991</b> , 30, 325-7   | 10 |
| 1697 | Epirubicin in patients with inoperable non-small cell lung cancer--a phase II study. <b>1991</b> , 30, 869-70   | 2  |
| 1696 | Leukocyte interferon in the treatment of chronic myelogenous leukemia in second chronic phase. <b>1991</b> , 30, 611-5  | 1  |
| 1695 | Concurrent radiotherapy and carboplatin in non small-cell lung cancer: a pilot study using conventional and accelerated fractionation. <b>1991</b> , 35, 66-7       | 9  |
| 1694 | Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. <b>1991</b> , 2, 727-31                                  | 10 |
| 1693 | Phase I study of the combination of monthly carboplatin and weekly cisplatin. <b>1991</b> , 2, 123-9  | 12 |
| 1692 | Fortgeschrittenes Blasenkarzinom (Stadien pT3b, pT4a, pN1, pN2). <b>1991</b> , 22, 201-208  | 3  |
| 1691 | Alternating Chemotherapy with Cyclophosphamide/Adriamycin/Vincristine (CAV) and Cisplatin/Etoposide (PVP) against Small Cell Lung Cancer. <b>1991</b> , 21, 435-439 |    |

|      |   |        |
|------|---|--------|
| 1690 | The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]. <b>1991</b> , 63, 275-8  | 57     |
| 1689 | Limited small cell lung cancer: the effect of radiotherapy on local control following response to chemotherapy. <b>1991</b> , 21, 459-62  | 4      |
| 1688 | Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia. <b>1991</b> , 117, 489-92                  | 3      |
| 1687 | Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate. <b>1991</b> , 117, 151-5   | 33     |
| 1686 | Laboratory evaluation during high-dose vitamin A administration: a randomized study on lung cancer patients after surgical resection. <b>1991</b> , 117, 156-62   | 15     |
| 1685 | Combination chemotherapy with oral idarubicin and cyclophosphamide for metastatic breast cancer. <b>1991</b> , 117, 61-4  | 11     |
| 1684 | Continuous intravenous infusion of high dose recombinant interleukin 2 for advanced lymphomas--a phase II study. <b>1991</b> , 15, 435-40   | 12     |
| 1683 | Association between chemotherapy response and rate of disease progression in disseminated melanoma. <b>1991</b> , 63, 154-6   | 6      |
| 1682 | Factors associated with increased frequency of HIV-related oral candidiasis. <b>1991</b> , 20, 332-6  | 82     |
| 1681 | Factors influencing 20-hour increments after platelet transfusion. <b>1991</b> , 31, 392-6  | 85     |
| 1680 | Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. <b>1991</b> , 78, 488-93  | 48     |
| 1679 | Treatment of Diamond-Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: sustained remissions following IL-3. <b>1991</b> , 79, 316-21 | 45     |
| 1678 | Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies. <b>1991</b> , 79 Suppl 1, 60-6                          | 15     |
| 1677 | The effect of toremifene therapy on serum immunoglobulin levels in breast cancer. <b>1991</b> , 99, 849-53  | 12     |
| 1676 | The effects of anti-estrogen therapy on lymphocyte functions in breast cancer patients. <b>1991</b> , 99, 163-70  | 16     |
| 1675 | Induction intra-arterial cisplatin and bleomycin in head and neck cancer. <b>1991</b> , 13, 291-7   | 15     |
| 1674 | Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. A feasibility study. <i>Cancer</i> , <b>1991</b> , 67, 357-62   | 6.4 19 |
| 1673 | Plasma postheparin diamine oxidase in patients with small intestinal lymphoma. <i>Cancer</i> , <b>1991</b> , 67, 511-5  | 6.4 8  |

|      |   |     |     |
|------|---|-----|-----|
| 1672 | A pilot study of suramin in the treatment of metastatic renal cell carcinoma. <i>Cancer</i> , <b>1991</b> , 67, 1509-13   | 6.4 | 40  |
| 1671 | Successful reinduction therapy with amsacrine and cycloctidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group. <i>Cancer</i> , <b>1991</b> , 67, 2235-40                          | 6.4 | 21  |
| 1670 | A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer. <i>Cancer</i> , <b>1991</b> , 67, 2448-53  | 6.4 | 14  |
| 1669 | A comparison of treatment outcomes for black patients and white patients with metastatic breast cancer. The Piedmont Oncology Association experience. <i>Cancer</i> , <b>1991</b> , 67, 2850-4                                    | 6.4 | 28  |
| 1668 | Chemotherapy for invasive thymoma. A 13-year experience. <i>Cancer</i> , <b>1991</b> , 68, 30-3   | 6.4 | 193 |
| 1667 | A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer. <i>Cancer</i> , <b>1991</b> , 68, 40-3   | 6.4 | 4   |
| 1666 | A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer. <i>Cancer</i> , <b>1991</b> , 68, 284-8  | 6.4 | 9   |
| 1665 | Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. <i>Cancer</i> , <b>1991</b> , 68, 706-13   | 6.4 | 163 |
| 1664 | A clinicopathologic study of lymphoid neoplasias associated with human immunodeficiency virus infection in Italy. <i>Cancer</i> , <b>1991</b> , 68, 842-52  | 6.4 | 77  |
| 1663 | Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. <i>Cancer</i> , <b>1991</b> , 68, 959-64  | 6.4 | 12  |
| 1662 | A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. <i>Cancer</i> , <b>1991</b> , 68, 965-9          | 6.4 | 70  |
| 1661 | A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. <i>Cancer</i> , <b>1991</b> , 68, 1230-7   | 6.4 | 24  |
| 1660 | Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. <i>Cancer</i> , <b>1991</b> , 68, 1874-7   | 6.4 | 86  |
| 1659 | Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. <i>Cancer</i> , <b>1991</b> , 68, 2561-5   | 6.4 | 72  |
| 1658 | Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results. <b>1991</b> , 2, 108-11   |     | 8   |
| 1657 | Preliminary report of high dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. <b>1991</b> , 2, 137-40 |     | 1   |
| 1656 | Muscle edema in musculoskeletal tumors: MR imaging characteristics and clinical significance. <b>1991</b> , 1, 441-9  |     | 62  |
| 1655 | Combined treatment with zidovudine and lymphoblast interferon-alpha in patients with HIV-related Kaposi's sarcoma. <b>1991</b> , 69, 360-7  |     | 13  |

|      |   |    |
|------|---|----|
| 1654 | Search for immunobiological parameters predictive of clinical effects of OK-432 in patients with malignant ascites. <b>1991</b> , 3, 193-201  | 1  |
| 1653 | Initial treatment of acute graft-versus-host disease with a murine monoclonal antibody directed to the human alpha/beta T cell receptor. <b>1991</b> , 34, 97-102                         | 6  |
| 1652 | Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. <b>1991</b> , 34, 111-4 | 20 |
| 1651 | Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): a phase II study in advanced gastric carcinoma. <b>1991</b> , 3, 214-6     |    |
| 1650 | A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma. <b>1991</b> , 28, 51-4   | 9  |
| 1649 | Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study. <b>1991</b> , 28, 59-62  | 6  |
| 1648 | Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. <b>1991</b> , 27, 481-3  | 19 |
| 1647 | Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy. <b>1991</b> , 28, 199-204   | 19 |
| 1646 | Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity. <b>1991</b> , 28, 402-4   | 0  |
| 1645 | Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. <b>1991</b> , 28, 405-7   | 6  |
| 1644 | Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. <b>1991</b> , 29, 83-4   | 26 |
| 1643 | Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting. <b>1991</b> , 29, 145-9   | 42 |
| 1642 | Cancer chemotherapy in the elderly: a series of 51 patients aged greater than 70 years. <b>1991</b> , 29, 159-63  | 17 |
| 1641 | High-dose 1,2,4-triglycidylurazol given in regimens preparatory to bone marrow transplantation. A preclinical pharmacology study. <b>1991</b> , 27, 361-6                                 | 1  |
| 1640 | Pharmacokinetics of recombinant interferon alpha-C. <b>1991</b> , 27, 406-8   | 2  |
| 1639 | Assessment of chemotherapy-associated nephrotoxicity in children with cancer. <b>1991</b> , 28, 81-92   | 52 |
| 1638 | Sequential chemotherapy in good-prognosis patients with small-cell lung cancer. <b>1991</b> , 28, 139-41  | 10 |
| 1637 | Leaf physiological aspects of nitrogen-use efficiency in <i>Brassica campestris</i> L.: quantitative genetic variation across nutrient treatments. <b>1991</b> , 81, 64-70                | 20 |

|      |  |     |
|------|--|-----|
| 1636 | Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. <b>1991</b> , 9, 245-52   |     |
| 1635 | Crisnatol mesylate: phase I dose escalation by extending infusion duration. <b>1991</b> , 9, 41-7  | 3   |
| 1634 | Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer. <b>1991</b> , 9, 65-7  | 3   |
| 1633 | Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study. <b>1991</b> , 9, 77-8   | 1   |
| 1632 | Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck. <b>1991</b> , 9, 89-91                                      | 1   |
| 1631 | Phase II trial of N-methylformamide in patients with metastatic melanoma. <b>1991</b> , 9, 97-100  | 3   |
| 1630 | Phase II trial of cisplatin and etoposide in patients with metastatic melanoma. <b>1991</b> , 9, 101-3   | 1   |
| 1629 | Phase II trial of echinomycin in advanced colorectal cancer. A Southwest Oncology Group study. <b>1991</b> , 9, 113-4  | 2   |
| 1628 | A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. <b>1991</b> , 164, 43-52 | 52  |
| 1627 | High Dose, Short Duration Combination Chemotherapy (MEGA III) for Patients with High Grade Poor Prognosis Non-Hodgkin's Lymphoma-A Phase I/II Study. <b>1991</b> , 6, 53-9                           |     |
| 1626 | Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. <b>1991</b> , 83, 1164-8                         | 232 |
| 1625 | Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. <b>1991</b> , 74, 905-9                  | 69  |
| 1624 | A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. <b>1991</b> , 2, 49-54                              | 20  |
| 1623 | Effect of recombinant interferon alfa on bone metastases of renal-cell carcinoma. <b>1991</b> , 324, 633-4   | 10  |
| 1622 | Demonstrated Benefit of Continuous Interferon-Alpha-2b Therapy in Hairy Cell Leukemia. A Two-Year Follow-Up. <b>1991</b> , 5, 23-31  | 5   |
| 1621 | Feasibility of total body irradiation in chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphomas. <b>1991</b> , 9, 403-7  | 8   |
| 1620 | Assessment of the response to chemotherapy in oesophageal cancer. <b>1991</b> , 5, 519-22  | 16  |
| 1619 | Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. <b>1991</b> , 72, 455-61  | 77  |

|      |  |     |
|------|--|-----|
| 1618 | Simultaneous disseminated herpes zoster and bacterial infection in cancer patients. <b>1992</b> , 31, 681-3  | 2   |
| 1617 | Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. <b>1992</b> , 327, 1115-21  | 244 |
| 1616 | Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. <b>1992</b> , 84, 1039-40  | 13  |
| 1615 | Salvage therapy with clindamycin/primaquine for <i>Pneumocystis carinii</i> pneumonia. <b>1992</b> , 14, 183-8   | 47  |
| 1614 | Treatment of pelvic osteosarcoma. <b>1992</b> , 3 Suppl 2, S19-21  | 11  |
| 1613 | Chemofiltration and chemoembolization: new techniques in advanced pelvic bone malignancies. Case report on three cases. <b>1992</b> , 3 Suppl 2, S37-8   | 1   |
| 1612 | Erratum. <b>1992</b> , 84, 1040-1040   |     |
| 1611 | Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. <b>1992</b> , 77, 78-83  | 48  |
| 1610 | A Pilot Study of Piritrexim in Mycosis Fungoides. <b>1992</b> , 128, 561   | 1   |
| 1609 | Chemotherapy of Metastatic Breast Cancer in the Elderly. <b>1992</b> , 268, 57   | 130 |
| 1608 | Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. <b>1992</b> , 10, 259-64   | 15  |
| 1607 | General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. <b>1992</b> , 31, 645-51                                     | 30  |
| 1606 | Site-specific effect of chemotherapy in patients with breast cancer. <b>1992</b> , 31, 225-9   | 5   |
| 1605 | MACOP-B regimen in non-Hodgkin's lymphoma. <b>1992</b> , 31, 657-61  |     |
| 1604 | Carboplatin and etoposide (CarE) combined with radiotherapy and vincristine, doxorubicin and cyclophosphamide (VAC) in limited small cell lung cancer. A phase II study. <b>1992</b> , 31, 761-5 | 1   |
| 1603 | Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. <b>1992</b> , 3, 301-5                        | 100 |
| 1602 | Prognostic factors in hormone-resistant progressing cancer of the prostate. <b>1992</b> , 3, 361-6   | 38  |
| 1601 | Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination. <b>1992</b> , 4, 185-8   | 4   |



|      |  |    |
|------|--|----|
| 1600 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. <b>1992</b> , 4, 46-9  | 3  |
| 1599 | Evaluation of toxicity in 22 patients treated with subcutaneous interleukin-2, alpha-interferon with and without chemotherapy. <b>1992</b> , 4, 394-8  | 5  |
| 1598 | <sup>89</sup> Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. <b>1992</b> , 66, 177-80   | 32 |
| 1597 | Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial. <b>1992</b> , 66, 204-10   | 54 |
| 1596 | Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck. <b>1992</b> , 66, 405-7   | 11 |
| 1595 | CA-125 is not a useful marker in metastatic breast cancer. <b>1992</b> , 66, 875-6   | 6  |
| 1594 | Phase II Evaluation of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: A Japanese Esophageal Oncology Group Trial. <b>1992</b> ,  | 1  |
| 1593 | A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. <b>1992</b> , 7, 165-71  | 34 |
| 1592 | Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response. <b>1992</b> , 71, 293-7  | 9  |
| 1591 | A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. <b>1992</b> , 3, 167-8  | 15 |
| 1590 | Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors. <b>1992</b> , 3, 645-9   | 8  |
| 1589 | Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.). <b>1992</b> , 3, 861-3           | 11 |
| 1588 | A phase II study of high-dose epirubicin plus cisplatin in advanced non-small-cell lung cancer (NSCLC). <b>1992</b> , 3, 864-6   | 14 |
| 1587 | Book review. <b>1992</b> , 3, 866  |    |
| 1586 | Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer. <b>1992</b> , 3, 549-52   | 20 |
| 1585 | Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. <b>1992</b> , 3, 319-20   | 13 |
| 1584 | A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report. <b>1992</b> , 3, 217-22   | 13 |
| 1583 | A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group. <b>1992</b> , 3, 223-6 | 9  |

|      |   |     |
|------|---|-----|
| 1582 | Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. <b>1992, 3, 237-8</b>   | 27  |
| 1581 | Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. <b>1992, 3, 445-9</b>  | 20  |
| 1580 | An outpatient phase I study of a subcutaneous interleukin-2 and intramuscular alpha-2a-interferon combination in advanced malignancies. <b>1992, 3, 559-63</b>  | 8   |
| 1579 | A phase II study of cisplatin versus cisplatin + nifedipine in end-stage carcinoma of the head and neck. <b>1992, 17, 501-4</b>   | 4   |
| 1578 | Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. <b>1992, 117, 739-48</b> | 130 |
| 1577 | Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. <b>1992, 65, 723-6</b>   | 18  |
| 1576 | Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. <b>1992, 327, 516-23</b>  | 198 |
| 1575 | Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma. <b>1992, 28A, 1820-3</b>  | 17  |
| 1574 | Natural interferon alfa as maintenance therapy for small cell lung cancer. <b>1992, 28A, 1387-91</b>  | 71  |
| 1573 | Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group. <b>1992, 28, 473-6</b>                                       | 6   |
| 1572 | Chronic oral etoposide in non-small cell lung carcinoma. <b>1992, 28A, 835-7</b>  | 18  |
| 1571 | Simultaneous radiotherapy and chemotherapy with carboplatin in inoperable squamous cell carcinoma of the head and neck: a phase II study. <b>1992, 10, 349-55</b>   | 17  |
| 1570 | Interferons 1992. How much of the promise has been realised?. <b>1992, 43, 285-94</b>   | 11  |
| 1569 | Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck. <b>1992, 33, 75-81</b>   | 40  |
| 1568 | Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia. <b>1992, 81, 516-9</b>                                   | 27  |
| 1567 | Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. <b>1992, 28A, 1311-5</b>   | 19  |
| 1566 | Toremifene for recurrent and advanced endometrial carcinoma. <b>1992, 28A, 1768</b>   | 3   |
| 1565 | Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer. <b>1992, 28A, 1828-32</b>   | 11  |

|      |  |    |
|------|--|----|
| 1564 | Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer. <b>1992</b> , 28A, 1331-4   | 14 |
| 1563 | Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. <b>1992</b> , 25, 167-75                | 45 |
| 1562 | A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor. <b>1992</b> , 28A, 1073-8  | 20 |
| 1561 | Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3. <b>1992</b> , 46, 211-7                                  | 10 |
| 1560 | A comprehensive evaluation of serum ferritin levels in lung cancer patients. <b>1992</b> , 8, 85-94  | 7  |
| 1559 | Treatment of metastatic carcinoid tumour with recombinant interferon alfa. <b>1992</b> , 28A, 1650-3   | 14 |
| 1558 | Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. <b>1992</b> , 28A, 878-80   | 26 |
| 1557 | Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. <b>1992</b> , 28A, 1023-8  | 57 |
| 1556 | Oral infection as a reason for febrile episodes in lymphoma patients receiving cytostatic drugs. <b>1992</b> , 28B, 103-7  | 35 |
| 1555 | Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. <b>1992</b> , 28A, 1038-44 | 55 |
| 1554 | Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. <b>1992</b> , 28A, 1963-5                   | 9  |
| 1553 | Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck. <b>1992</b> , 28, 484-5  | 3  |
| 1552 | Serum ferritin levels in lung cancer patients. <b>1992</b> , 28, 241   | 7  |
| 1551 | Evaluation of anthralin for mycosis fungoides. <b>1992</b> , 27, 112-3   |    |
| 1550 | Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. <b>1992</b> , 28A, 1404-7                     | 54 |
| 1549 | Noninflammatory focal dermal elastolysis. <b>1992</b> , 27, 113-5  | 15 |
| 1548 | Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin. <b>1992</b> , 28A, 1670-6                               | 36 |
| 1547 | Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study. <b>1992</b> , 23, 241-4   | 17 |

|      |   |     |
|------|---|-----|
| 1546 | Failure of intensive chemotherapy in poor prognosis non-Hodgkin's lymphoma. <b>1992</b> , 22, 123-8   | 5   |
| 1545 | Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. <b>1992</b> , 47, 282-6   | 64  |
| 1544 | Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. <b>1992</b> , 46, 292-7  | 11  |
| 1543 | Malignant ovarian germ cell tumors: the experience at the Hospital de la Santa Creu i Sant Pau. <b>1992</b> , 45, 153-9   | 10  |
| 1542 | Vitamin E in the treatment of chemotherapy-induced mucositis. <b>1992</b> , 92, 481-4   | 115 |
| 1541 | Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research. <b>1992</b> , 164, 348-53       | 32  |
| 1540 | Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs. <b>1992</b> , 3, 31-5   | 5   |
| 1539 | Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer. <b>1992</b> , 3, 545-7  | 3   |
| 1538 | Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). <b>1992</b> , 3, 371-6 | 28  |
| 1537 | Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. <b>1992</b> , 3, 489-91                                   | 15  |
| 1536 | Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. <b>1992</b> , 49, 22-6   | 15  |
| 1535 | Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity. <b>1992</b> , 49, 154-6  | 1   |
| 1534 | Phase II Study with Lonidamine in the Treatment of Hormone-Refractory Prostatic Cancer Patients. <b>1992</b> , 78, 137-139  | 3   |
| 1533 | Deflazacort and Fluoximesterone in Advanced, Pretreated Breast Cancer. <b>1992</b> , 78, 266-269  |     |
| 1532 | Neoadjuvant Chemotherapy with Cisplatin, Epirubicin and VP-16 for Stage IIIA-IIIB Non-Small-Cell Lung Cancer: A Pilot Study. <b>1992</b> , 78, 377-379  | 2   |
| 1531 | Mitomycin C and Vindesine: An Ineffective Combination Chemotherapy in the Treatment of Malignant Pleural Mesothelioma. <b>1992</b> , 78, 380-382  | 12  |
| 1530 | External and interstitial radiation therapy of locally advanced carcinoma of the breast. <b>1992</b> , 31, 303-6  | 7   |
| 1529 | Weekly First-Line Chemotherapy of Metastatic Breast Cancer with Cyclophosphamide and Epirubicin. <b>1992</b> , 78, 338-340  | 1   |

|      |  |    |
|------|--|----|
| 1528 | Hyperthermia in Clinical Practice: Preliminary Results and Current Problems in the Treatment of 21 Patients. <b>1992</b> , 78, 262-265   | 1  |
| 1527 | CA-549 Serum Levels in Breast Cancer Monitoring. <b>1992</b> , 7, 217-221  | 5  |
| 1526 | High Dose Alpha-2B Interferon+Folinic Acid in the Modulation of 5-Fluorouracil. A Phase II Study in Advanced Colorectal Cancer with Evidence of An Unfavorable Cost/Benefit Ratio. <b>1992</b> , 78, 32-34             | 8  |
| 1525 | Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. <b>1992</b> , 10, 948-53  | 91 |
| 1524 | Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. <b>1992</b> , 10, 1352-8   | 28 |
| 1523 | A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. <b>1992</b> , 10, 228-36  | 82 |
| 1522 | Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. <b>1992</b> , 10, 269-74   | 35 |
| 1521 | Book review. <b>1992</b> , 3, 552  |    |
| 1520 | Application of Quality of Life Measures in Health Care Delivery. <b>1992</b> , 8, 18-21  | 3  |
| 1519 | Iodized talc pleurodesis for the treatment of pleural effusions. <b>1992</b> , 103, 881-886  | 96 |
| 1518 | Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumors. <b>1992</b> , 7, 65-67  | 13 |
| 1517 | Patient acceptance and differential perceptions of quality of life measures in a French oncology setting. <b>1992</b> , 1, 53-61   | 8  |
| 1516 | Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer. <b>1992</b> , 10, 123-8   | 5  |
| 1515 | Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study. <b>1992</b> , 10, 165-70   | 68 |
| 1514 | Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer. <b>1992</b> , 10, 171-5   | 29 |
| 1513 | Phase I study of mitonafide in solid tumors. <b>1992</b> , 10, 177-81  | 23 |
| 1512 | Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. <b>1992</b> , 10, 205-9   | 20 |
| 1511 | Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer. <b>1992</b> , 31, 81-4 | 5  |

|      |   |    |
|------|---|----|
| 1510 | A preliminary clinical study of gossypol in advanced human cancer. <b>1992</b> , 30, 480-2  | 84 |
| 1509 | Concurrent radiation and weekly cisplatin for non-small-cell lung cancer--a phase I/II study. <b>1992</b> , 30, 495-7   | 5  |
| 1508 | Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. <b>1992</b> , 29, 305-8  | 20 |
| 1507 | A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid. <b>1992</b> , 29, 354-60   | 11 |
| 1506 | A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue. <b>1992</b> , 29, 201-6   | 2  |
| 1505 | Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. <b>1992</b> , 30, 174-8   | 20 |
| 1504 | Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer. <b>1992</b> , 30, 212-4                                | 20 |
| 1503 | Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion. <b>1992</b> , 30, 226-8  | 9  |
| 1502 | Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin. <b>1992</b> , 30, 243-4   | 13 |
| 1501 | Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. <b>1992</b> , 30, 100-4   | 10 |
| 1500 | Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancer. <b>1992</b> , 30, 161-3   | 2  |
| 1499 | Primary liver cancer in Hong Kong. <b>1992</b> , 31 Suppl, S143-5   | 4  |
| 1498 | Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. <b>1992</b> , 10, 313-6   | 20 |
| 1497 | Phase II trial of pirarubicin in the treatment of advanced bladder cancer. <b>1992</b> , 10, 317-21   | 6  |
| 1496 | Phase II study of gemcitabine in advanced colorectal adenocarcinoma. <b>1992</b> , 10, 323-5  | 35 |
| 1495 | Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <b>1992</b> , 10, 327-30 | 11 |
| 1494 | A randomized trial comparing platinum-based chemotherapy followed by radiotherapy vs. radiotherapy alone in patients with locally advanced cervical cancer. <b>1992</b> , 2, 244-251                | 74 |
| 1493 | Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma. <b>1992</b> , 127, 505-8   | 7  |

|      |  |     |
|------|--|-----|
| 1492 | A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases. <b>1992</b> , 65, 913-5                                      | 10  |
| 1491 | Single agent high-dose cisplatin (200 mg m <sup>-2</sup> ) treatment in ovarian carcinoma. <b>1992</b> , 66, 717-9   | 6   |
| 1490 | Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production. <b>1992</b> , 66, 723-7               | 21  |
| 1489 | Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation. <b>1992</b> , 24, 643-50   | 37  |
| 1488 | Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. <b>1992</b> , 24, 11-5   | 149 |
| 1487 | Pentylentetrazol-induced seizures in rats: an ontogenetic study. <b>1992</b> , 346, 588-91   | 110 |
| 1486 | A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. <b>1992</b> , 249, 211-5 | 23  |
| 1485 | Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy. <b>1992</b> , 118, 157-62   | 8   |
| 1484 | Partial responses to antineoplastic drug therapy: what do they mean?. <b>1992</b> , 119, 5-6   | 3   |
| 1483 | Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. <b>1992</b> , 118, 547-50  | 100 |
| 1482 | Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study. <b>1992</b> , 12, 239-43                                       | 6   |
| 1481 | Local hyperthermia in recurrent breast cancer treatment. <b>1992</b> , 24, 218-222   | 2   |
| 1480 | Host factors associated with HIV-related oral candidiasis. A review. <b>1992</b> , 73, 181-6   | 73  |
| 1479 | Orofacial complications of chemotherapy for breast cancer. <b>1992</b> , 74, 172-8   | 28  |
| 1478 | Intensive sequential post-induction therapy for adults with acute myelogenous leukemia in first remission: long-term follow-up and results. <b>1992</b> , 16, 577-84             | 2   |
| 1477 | Total lymphoid irradiation in chronic progressive multiple sclerosis. <b>1992</b> , 13, 131-4  |     |
| 1476 | Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. <b>1992</b> , 24, 159-66  | 100 |
| 1475 | Tumor and normal tissue response to interstitial photodynamic therapy of the rat R-1 rhabdomyosarcoma. <b>1992</b> , 22, 963-72  | 21  |

|      |   |        |
|------|---|--------|
| 1474 | Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study. <b>1992</b> , 10, 23-4  | 17     |
| 1473 | Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study. <b>1992</b> , 10, 29-30  | 4      |
| 1472 | A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA. <b>1992</b> , 64, 166-72  | 21     |
| 1471 | High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age. <b>1992</b> , 64, 185-9  | 2      |
| 1470 | Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL). <b>1992</b> , 64, 83-7   | 6      |
| 1469 | Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study. <b>1992</b> , 34, 337-42  | 55     |
| 1468 | Low-dose etoposide: a potential therapy for myelodysplastic syndromes. <b>1992</b> , 82, 354-7  | 14     |
| 1467 | Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. <b>1992</b> , 82, 589-95   | 60     |
| 1466 | The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. <b>1992</b> , 80, 144-50   | 21     |
| 1465 | Triple therapy for advanced squamous cell cancer of the head and neck. <b>1992</b> , 62, 373-81   | 1      |
| 1464 | Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. <b>1992</b> , 69, 175-9   | 27     |
| 1463 | Phase II clinical trial of recombinant alpha-2 interferon for biopsy-proven metastatic or recurrent renal carcinoma. <b>1992</b> , 69, 491-4  | 3      |
| 1462 | Spinal cord compression in prostate cancer. A 10-year experience. <b>1992</b> , 69, 530-3   | 27     |
| 1461 | Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party). <b>1992</b> , 70, 161-8 | 16     |
| 1460 | Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies. <b>1992</b> , 50, 868-70   | 12     |
| 1459 | Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. <b>1992</b> , 49, 78-85   | 57     |
| 1458 | Neoadjuvant chemotherapy with cytosine arabinoside by continuous infusion and cisplatin for resectable squamous cell carcinoma of the esophagus. <b>1992</b> , 50, 118-20   | 1      |
| 1457 | Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. <i>Cancer</i> , <b>1992</b> , 69, 648-50   | 6.4 41 |



|      |  |     |     |
|------|--|-----|-----|
| 1456 | Treatment of relapsed or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , <b>1992</b> , 69, 709-16   | 6.4 | 36  |
| 1455 | Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. <i>Cancer</i> , <b>1992</b> , 69, 741-9   | 6.4 | 116 |
| 1454 | A phase II study of piritrexim in patients with advanced squamous head and neck cancer. <i>Cancer</i> , <b>1992</b> , 69, 1008-11  | 6.4 | 17  |
| 1453 | A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. <i>Cancer</i> , <b>1992</b> , 70, 1864-6   | 6.4 | 34  |
| 1452 | Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. A prospective pilot study. <i>Cancer</i> , <b>1992</b> , 70, 2615-20    | 6.4 | 30  |
| 1451 | Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy. <i>Cancer</i> , <b>1993</b> , 71, 226-30  | 6.4 | 6   |
| 1450 | Unresectable nonmetastatic squamous cell carcinoma of the esophagus managed by sequential chemotherapy (cisplatin and bleomycin) and radiation therapy. <i>Cancer</i> , <b>1993</b> , 71, 287-92   | 6.4 | 23  |
| 1449 | The results of treatment in 100 patients with limited-stage small cell lung cancer. <i>Cancer</i> , <b>1993</b> , 71, 326-314  | 6.4 | 5   |
| 1448 | Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution. <i>Cancer</i> , <b>1993</b> , 71, 796-803 | 6.4 | 4   |
| 1447 | Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. <i>Cancer</i> , <b>1993</b> , 71, 1875-81   | 6.4 | 30  |
| 1446 | A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adenocarcinoma of the stomach. <i>Cancer</i> , <b>1993</b> , 71, 2177-80  | 6.4 | 8   |
| 1445 | In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. <i>Cancer</i> , <b>1993</b> , 71, 3082-90   | 6.4 | 6   |
| 1444 | A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. <i>Cancer</i> , <b>1993</b> , 71, 3813-8             | 6.4 | 323 |
| 1443 | Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. <i>Cancer</i> , <b>1993</b> , 72, 244-8  | 6.4 | 242 |
| 1442 | Thermoradiation therapy for superficial malignant tumors. <i>Cancer</i> , <b>1993</b> , 72, 287-96   | 6.4 | 27  |
| 1441 | Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. <i>Cancer</i> , <b>1993</b> , 72, 502-5  | 6.4 | 34  |
| 1440 | Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study. <i>Cancer</i> , <b>1993</b> , 72, 564-8   | 6.4 | 8   |
| 1439 | Expression of glutathione S-transferase-pi in human squamous cell carcinomas of the pharynx and larynx. Loss after radiation therapy. <i>Cancer</i> , <b>1993</b> , 72, 569-76   | 6.4 | 20  |

|      |  |     |    |
|------|--|-----|----|
| 1438 | Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics. <i>Cancer</i> , <b>1993</b> , 72, 697-706 | 6.4 | 20 |
| 1437 | Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma. <i>Cancer</i> , <b>1993</b> , 72, 766-70  | 6.4 | 30 |
| 1436 | A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer. <i>Cancer</i> , <b>1993</b> , 72, 1564-72   | 6.4 | 13 |
| 1435 | Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. <i>Cancer</i> , <b>1993</b> , 72, 2190-7   | 6.4 | 26 |
| 1434 | Combined radiation therapy and cisplatin for locally advanced carcinoma of the urinary bladder. <i>Cancer</i> , <b>1993</b> , 72, 2213-8   | 6.4 | 14 |
| 1433 | Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer. <i>Cancer</i> , <b>1993</b> , 72, 2895-901  | 6.4 | 8  |
| 1432 | Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force. <i>Cancer</i> , <b>1993</b> , 72, 2929-35                                     | 6.4 | 19 |
| 1431 | Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , <b>1993</b> , 72, 3313-7   | 6.4 | 20 |
| 1430 | Graphic-aided study of metabolic modifications of plasma in cancer using proton magnetic resonance spectroscopy. <b>1993</b> , 6, 58-65  |     | 17 |
| 1429 | Combined use of alpha 2B-interferon, chlorambucil, and prednisone in the treatment of previously treated B-chronic lymphocytic leukemia patients. <b>1993</b> , 42, 334-5  |     | 1  |
| 1428 | Megadose methylprednisolone for Diamond-Blackfan anemia. <b>1993</b> , 42, 335   |     | 2  |
| 1427 | Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. <b>1993</b> , 43, 195-9   |     | 11 |
| 1426 | Low dose continuous infusion doxorubicin in children and young adults. <b>1993</b> , 21, 494-8   |     |    |
| 1425 | Adjuvant chemotherapy for osteogenic sarcoma of the extremity with sequential adriamycin and cisplatin. <b>1993</b> , 52, 181-4  |     | 5  |
| 1424 | Selected benefits of thoracotomy and chemotherapy for sarcoma metastatic to the lung. <b>1993</b> , 53, 54-9   |     | 23 |
| 1423 | Treatment of invasive thymoma with pleural dissemination. <b>1993</b> , 54, 180-3  |     | 30 |
| 1422 | Cisplatin, hyperthermia, and radiation (trimodal therapy) in patients with locally advanced head and neck tumors: a phase I-II study. <b>1993</b> , 26, 801-7  |     | 47 |
| 1421 | Neurotoxicity of antineoplastic agents. <b>1993</b> , 14, 61-75  |     | 37 |

|      |  |    |
|------|--|----|
| 1420 | Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies. <b>1993</b> , 3, 116-121   | 5  |
| 1419 | Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary. <b>1993</b> , 3, 299-303   | 15 |
| 1418 | Nuclear medicine in the monitoring of organ function and the detection of injury related to cancer therapy. <b>1993</b> , 20, 515-46   | 16 |
| 1417 | The human T-cell receptor beta-chain repertoire: longitudinal fluctuations and assessment in MHC matched populations. <b>1993</b> , 38, 193-8  | 15 |
| 1416 | Phase II study of NK313 in malignant lymphomas: an NK313 Malignant Lymphoma Study Group trial. <b>1993</b> , 31, 445-8   | 1  |
| 1415 | Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study. <b>1993</b> , 31, 489-94 | 9  |
| 1414 | Ifosfamide in advanced epidermoid head and neck cancer. <b>1993</b> , 31, 340-2  | 12 |
| 1413 | Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. <b>1993</b> , 32, 204-8   | 19 |
| 1412 | Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. <b>1993</b> , 31, 357-62                           | 23 |
| 1411 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. <b>1993</b> , 31, 415-8   | 2  |
| 1410 | Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. <b>1993</b> , 32, 329-31   | 6  |
| 1409 | Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD). <b>1993</b> , 25, 277-81   | 13 |
| 1408 | A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. <b>1993</b> , 11, 53-6  | 3  |
| 1407 | Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer. <b>1993</b> , 11, 71-4   | 12 |
| 1406 | Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study. <b>1993</b> , 11, 81-3                  | 3  |
| 1405 | Phase I trial of 5-fluorouracil by 24-hour infusion weekly. <b>1993</b> , 11, 181-5  | 11 |
| 1404 | A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study. <b>1993</b> , 11, 329-31   | 10 |
| 1403 | Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study. <b>1993</b> , 11, 337-41   | 10 |

|      |   |    |
|------|---|----|
| 1402 | Phase I/II study of concurrent weekly carboplatin and radiation therapy in advanced head and neck cancer. <b>1993</b> , 5, 133-8  | 4  |
| 1401 | Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck. <b>1993</b> , 5, 43-5   | 5  |
| 1400 | The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. <b>1993</b> , 67, 594-601   | 49 |
| 1399 | A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatin in the palliation of advanced and recurrent malignant tumour of the salivary glands. <b>1993</b> , 67, 112-4                | 20 |
| 1398 | 2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. <b>1993</b> , 67, 139-43  | 44 |
| 1397 | A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. <b>1993</b> , 67, 1385-90   | 24 |
| 1396 | Phase I/pharmacokinetic/biochemical study of the nitroimidazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide. <b>1993</b> , 68, 756-66                               | 6  |
| 1395 | Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. <b>1993</b> , 23, 239-48  | 49 |
| 1394 | Oral cyclophosphamide for the management of hormone-refractory prostate cancer. <b>1993</b> , 72, 625-8   | 52 |
| 1393 | Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside. <b>1993</b> , 17, 711-5  | 9  |
| 1392 | Why does a higher response rate to chemotherapy correlate poorly with improved survival?. <b>1993</b> , 119, 700-1  | 15 |
| 1391 | Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas. <b>1993</b> , 119, 160-4                                  | 4  |
| 1390 | Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. <b>1993</b> , 66, 141-6   | 33 |
| 1389 | Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers. <b>1993</b> , 26, 37-42  | 39 |
| 1388 | Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer. <b>1993</b> , 27, 621-5   | 14 |
| 1387 | Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control. <b>1993</b> , 27, 1165-72                           | 42 |
| 1386 | Induction of inflammatory cytokines in the pleural effusion of cancer patients after the administration of an immunomodulator, OK-432: role of IL-8 for neutrophil infiltration. <b>1993</b> , 5, 595-603 | 27 |
| 1385 | Randomized study of two doses of didanosine in children infected with human immunodeficiency virus. <b>1993</b> , 122, 966-73   | 11 |

|      |  |     |
|------|--|-----|
| 1384 | Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer. <b>1993</b> , 15, 8-15   | 41  |
| 1383 | Intraleural doxycycline control of malignant pleural effusions. <b>1993</b> , 55, 1115-21; discussion 1121-2   | 65  |
| 1382 | Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. <b>1993</b> , 29A, 1088-93                  | 78  |
| 1381 | Non-resectable Stage IIIa-b lung carcinoma: a phase II study on continuous infusion of cisplatin and concurrent radiotherapy (plus adjuvant surgery). <b>1993</b> , 10, 73-84  | 9   |
| 1380 | Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. <b>1993</b> , 328, 159-63   | 453 |
| 1379 | Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. <b>1993</b> , 29A, 668-71  | 23  |
| 1378 | Poor prognosis associated with elevated serum CA 19-9 level in advanced colorectal carcinoma, independent of DNA ploidy or SPF. <b>1993</b> , 29A, 1691-6  | 17  |
| 1377 | Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group. <b>1993</b> , 29A, 1406-10 | 61  |
| 1376 | Preliminary results of a phase II trial of chronic oral etoposide in breast cancer. <b>1993</b> , 19 Suppl C, 47-52  | 2   |
| 1375 | Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. <b>1993</b> , 29A, 821-5   | 68  |
| 1374 | Continuous intravenous interleukin-2 infusion and subcutaneous interferon-alpha in metastatic renal cell carcinoma. <b>1993</b> , 29A, 1313-5  | 16  |
| 1373 | Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteria. <b>1993</b> , 29A, 298-300   | 6   |
| 1372 | Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. <b>1993</b> , 29A, 1634   | 9   |
| 1371 | Patient acceptability and practical implications of pharmacokinetic studies in patients with advanced cancer. <b>1993</b> , 29A, 1707-11   | 5   |
| 1370 | A phase II study of etoposide, cisplatin plus methotrexate in patients with advanced refractory breast cancer. <b>1993</b> , 29A, 1355   |     |
| 1369 | Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. <b>1993</b> , 29A, 704-8  | 6   |
| 1368 | The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: a randomised double-blind placebo controlled trial. <b>1993</b> , 29A, 814-8                                    | 7   |
| 1367 | A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. <b>1993</b> , 29A, 1358-9   | 30  |

|      |   |     |
|------|---|-----|
| 1366 | Oral tegafur in the treatment of metastatic breast cancer: a phase II study. <b>1993</b> , 29A, 863-6   | 16  |
| 1365 | Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group. <b>1993</b> , 19 Suppl C, 79-86 | 22  |
| 1364 | Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. <b>1993</b> , 10, 209-19   | 59  |
| 1363 | Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. <b>1993</b> , 29A, 1242-8  | 9   |
| 1362 | Carboplatin in combination as first-line therapy in advanced breast cancer. <b>1993</b> , 19 Suppl C, 3-9   | 8   |
| 1361 | Cisplatin-mitomycin and vindesine in the treatment of inoperable non-small cell lung cancer groupe franais de pneumo-cancologie (GFPC). <b>1993</b> , 29A, 477  | 2   |
| 1360 | Carboquone combined with methotrexate and 5-fluorouracil for recurrent and advanced ovarian cancer. <b>1993</b> , 29A, 1633   |     |
| 1359 | Carboplatin in advanced hormone refractory prostatic cancer patients. <b>1993</b> , 29A, 2094-6   | 32  |
| 1358 | Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). <b>1993</b> , 29A Suppl 1, S51-8  | 214 |
| 1357 | Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. <b>1993</b> , 29A, 340-2   | 51  |
| 1356 | Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. <b>1993</b> , 29A, 1720-2   | 67  |
| 1355 | A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium. <b>1993</b> , 29A, 347-50  | 12  |
| 1354 | Phase II study of cysteamine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group. <b>1993</b> , 29A, 1597-9   |     |
| 1353 | Long term results of treatment in patients with extragonadal germ cell tumours. <b>1993</b> , 29A, 1002-5   | 23  |
| 1352 | Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. <b>1993</b> , 29A, 1729-31   | 13  |
| 1351 | Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC). <b>1993</b> , 29A, 350-4  | 11  |
| 1350 | Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. <b>1993</b> , 23, 683-7   | 49  |
| 1349 | Somatuline and tamoxifen in postmenopausal breast cancer patients. <b>1993</b> , 698, 362-6   | 3   |

|      |   |     |
|------|---|-----|
| 1348 | Sustained oral indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced renal cell carcinoma. <b>1993</b> , 8, 229-33  | 13  |
| 1347 | Parenteral nutrition in cancer patients receiving chemotherapy: effects on toxicity and nutritional status. <b>1993</b> , 17, 513-8   | 37  |
| 1346 | Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience. <b>1993</b> , 4 Suppl 2, 45-8  |     |
| 1345 | Esophageal carcinoma with doubtful extirpability. Value of preoperative chemotherapy plus radiotherapy. <b>1993</b> , 7, 606-11   | 8   |
| 1344 | Recombinant Human Erythropoietin Treatment: Investigational New Drug Protocol for the Anemia of the Acquired Immunodeficiency Syndrome. <b>1993</b> , 153, 2669   | 20  |
| 1343 | Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. <b>1993</b> , 306, 752-5   | 487 |
| 1342 | Aspects of quality-of-life in patients with lung-cancer - a 3 observer evaluation study. <b>1993</b> , 2, 537-44  | 2   |
| 1341 | Double-modulation of 5-Fluorouracil by methotrexate and leucovorin in advanced colorectal-carcinoma. <b>1993</b> , 3, 995-9   |     |
| 1340 | Randomized trial comparing adriamycin vincristine (av) cyclophosphamide methotrexate 5-Fluorouracil prednisone (cmfp) hybrid versus av-cmfp monthly alternated in metastatic breast-cancer. <b>1993</b> , 2, 437-42 |     |
| 1339 | Treatment of locally advanced squamous-cell carcinoma of the head and neck with concurrent radiochemotherapy - randomized comparison of Cisplatin versus Carboplatin. <b>1993</b> , 2, 185-90                       | 3   |
| 1338 | Recombinant interleukin-2 and interferon-alpha-2a in pretreated advanced soft-tissue sarcomas. <b>1993</b> , 2, 997-1001  | 2   |
| 1337 | Phase-I human clinical-trial of onconase(r) (p-30 protein) administered intravenously on a weekly schedule in cancer-patients with solid tumors. <b>1993</b> , 3, 57-64   | 18  |
| 1336 | Intensive weekly chemotherapy for advanced gastric-cancer using 5-Fluorouracil, Cisplatin, epi-Doxorubicin, 6s-leucovorin and granulocyte-colony-stimulating factor. <b>1993</b> , 3, 535-8                         | 1   |
| 1335 | Results of the association of intralesional recombinant alpha-interferon-2a (alpha-IFN) plus 13-cis-retinoic Acid (13cra) in the treatment of Basal-cell carcinomas (bcc) of the skin. <b>1993</b> , 3, 1149-54     | 1   |
| 1334 | High dose hydroxyurea in collection of Philadelphia chromosome-negative stem cells in chronic myeloid leukaemia. <b>1993</b> , 10, 73-8   | 11  |
| 1333 | Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. <b>1993</b> , 9, 211-5  | 14  |
| 1332 | Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. <b>1993</b> , 11, 135-9  | 17  |
| 1331 | Conventional versus high-dose epidoxorubicin as single agent in advanced breast cancer. <b>1993</b> , 11, 106-12  | 14  |

|      |   |    |
|------|---|----|
| 1330 | Effect of interferon-alpha 2a on malignant mesothelioma. <b>1993</b> , 13, 9-12   | 70 |
| 1329 | DNA analysis as a predictor of the outcome of induction chemotherapy in advanced head and neck carcinomas. <b>1993</b> , 119, 867-70  | 20 |
| 1328 | Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. <b>1993</b> , 67, 787-91   | 55 |
| 1327 | A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma. <b>1993</b> , 5, 47-51  | 4  |
| 1326 | A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. <b>1993</b> , 5, 186-90    | 16 |
| 1325 | EPIC: an effective low toxicity regimen for relapsing lymphoma. <b>1993</b> , 68, 599-604   | 18 |
| 1324 | Oral methotrexate for superficial transitional cell carcinoma of the bladder. <b>1993</b> , 149, 1006-9   | 2  |
| 1323 | Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. <b>1993</b> , 5, 52-5  | 17 |
| 1322 | High dose hyperfractionated radiotherapy for adults with glioblastomas. <b>1993</b> , 18, 99-105  | 2  |
| 1321 | A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma. <b>1993</b> , 32, 547-53 | 38 |
| 1320 | Treatment of renal cell carcinoma with escalating doses of alpha-interferon. <b>1993</b> , 39, 361-6  | 10 |
| 1319 | Epirubicin and ifosfamide in advanced soft tissue sarcomas. <b>1993</b> , 4, 669-72   | 22 |
| 1318 | A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Japanese Esophageal Oncology Group. <b>1993</b> , 104, 203-7   | 60 |
| 1317 | Combination Chemotherapy for a Senile Patient with Adenoid Cystic Carcinoma of the Esophagus: A Case Report. <b>1993</b> ,  |    |
| 1316 | 5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. <b>1993</b> , 4, 83-4  | 13 |
| 1315 | Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. <b>1993</b> , 4, 791-2  | 10 |
| 1314 | Mitoxantrone, Etoposide and Prednisolone (NOVEP) in Previously Untreated Elderly Patients with Non-Hodgkin's Lymphoma (NHL) and as Salvage Therapy for Refractory NHL. <b>1993</b> , 16, 440-445              |    |
| 1313 | Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results. <b>1993</b> , 4, 553-8  | 20 |



|      |  |    |
|------|--|----|
| 1312 | Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. <b>1993</b> , 4, 331-2  | 52 |
| 1311 | Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. <b>1993</b> , 23, 213-7; discussion 218  | 82 |
| 1310 | Dose intensification of cisplatin chemotherapy through biweekly administration. <b>1993</b> , 4, 221-7   | 2  |
| 1309 | Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. <b>1993</b> , 4, 235-40 | 55 |
| 1308 | Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma. <b>1993</b> , 4, 313-6  | 6  |
| 1307 | Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. <b>1993</b> , 4, 333-6   | 49 |
| 1306 | Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma. <b>1993</b> , 4, 689-91   | 8  |
| 1305 | CVM versus ACE in the treatment of small cell lung cancer. <b>1993</b> , 50 Suppl 2, 10-5  | 3  |
| 1304 | A Phase II Study of Combination Chemotherapy in Advanced Ovarian Carcinoma with Cisplatin and Cyclophosphamide plus Reduced Glutathione as Potential Protective Agent against Cisplatin Toxicity. <b>1993</b> , 79, 37-39  | 8  |
| 1303 | A Weekly Schedule of Epirubicin in Pretreated Advanced Breast Cancer. <b>1993</b> , 79, 45-48  | 8  |
| 1302 | Clinical Evaluation of Serum Aminoterminal Propeptide of Type III Procollagen as Tumor Marker in Gynecologic Malignancies. <b>1993</b> , 79, 219-223   | 2  |
| 1301 | Combined Use of Interferon Alpha-2, Chlorambucil and Prednisone in Previously Treated Patients with Low-Grade Non-Hodgkin's Lymphomas. Results of a Phase II Study. <b>1993</b> , 79, 195-197  |    |
| 1300 | The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. <b>1993</b> , 4, 597-602  | 52 |
| 1299 | Conservative Treatment for T2-T4 Bladder Cancer with Primary Chemotherapy and Radiotherapy: A Pilot Study. <b>1993</b> , 79, 53-57   | 4  |
| 1298 | A cisplatin-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year results. <b>1993</b> , 50, 92-9  | 2  |
| 1297 | Low-dose oral etoposide in epithelial cancer of the ovary. <b>1993</b> , 4, 517-9  | 20 |
| 1296 | Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. <b>1993</b> , 4, 663-7  | 14 |
| 1295 | Chemotherapy with Mitomycin C and Vinblastine in Pretreated Metastatic Breast Cancer. <b>1993</b> , 79, 254-257  | 5  |

|      |   |     |
|------|---|-----|
| 1294 | A Pilot Clinical Trial of Postoperative Adjuvant Intraperitoneal Cisplatin, 5-Fluorouracil, 6S-Leucovorin and Interferon Alpha 2b in Patients with Resected Gastric Cancer. <b>1993</b> , 79, 331-335     | 3   |
| 1293 | Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. <b>1993</b> , 11, 330-5 | 70  |
| 1292 | The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. <b>1993</b> , 11, 1300-5  | 124 |
| 1291 | A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. <b>1993</b> , 11, 1888-93                           | 51  |
| 1290 | Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. <b>1993</b> , 11, 1478-81            | 39  |
| 1289 | Ifosfamide, mesna, and nephrotoxicity in children. <b>1993</b> , 11, 173-90   | 194 |
| 1288 | Mitomycin C, 5Fluorouracil and Folinic Acid in Combination with Alpha 2b Interferon for Advanced Colorectal Cancer. <b>1993</b> , 79, 393-396   |     |
| 1287 | Phase II Study of 4Eloido-4Edeoxydoxorubicin in Patients with Advanced, Measurable Non-Small Cell Lung Cancer. <b>1993</b> , 16, 446-448  |     |
| 1286 | Neoadjuvant Chemotherapy for Infiltrating Bladder Cancer with Methotrexate, Vinblastine, Epirubicin and Cisplatin (M-VEC). <b>1993</b> , 60, 329-333  |     |
| 1285 | Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. <b>1993</b> , 106, 703-708  | 120 |
| 1284 | Accuracy of Computed Tomography in Determining Pancreatic Cancer Tumor Size. <b>1994</b> ,  |     |
| 1283 | Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. <b>1994</b> , 5, 245-8  | 21  |
| 1282 | Mitomycin «C» and Vinorelbine as Second Line Chemotherapy for Metastatic Breast Carcinoma. <b>1994</b> , 80, 33-36  | 6   |
| 1281 | High-Dose Interstitial Brachytherapy for Glioblastoma Multiforme. <b>1994</b> , 80, 44-49   | 4   |
| 1280 | Vinorelbine as Single Agent in Pretreated Patients with Advanced Breast Cancer. <b>1994</b> , 80, 280-282   | 12  |
| 1279 | A Pilot Clinical Trial of Surgical Adjuvant Treatment with High-Dose 6S-Leucovorin/5-Fluorouracil and Radiation Therapy for High-Risk Rectal Carcinoma. <b>1994</b> , 80, 335-338                         | 1   |
| 1278 | Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. <b>1994</b> , 5, 239-43  | 19  |
| 1277 | Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma. <b>1994</b> , 5, 463-5  | 34  |

|      |  |     |
|------|--|-----|
| 1276 | How does the message of cancer specialists affect routine medical practice? Only sixty percent of surgical adjuvant breast cancer treatment is based on hormone receptor status. <b>1994</b> , 5, 773-4        | 3   |
| 1275 | Phase II study of three days' fractionated dosage of ifosfamide, epirubicin and cisplatin in small cell lung cancer. <b>1994</b> , 33, 573-4   | 3   |
| 1274 | Two new cases of hyperpyrimidinuria associated with excessive 5-fluorouracil toxicity. <b>1994</b> , 5, 772-3  |     |
| 1273 | Zur Messung von Lebensqualität in der Onkologie. <b>1994</b> , 17, 547-556   | 1   |
| 1272 | Mitomycin C Etoposide and Vinorelbine (MEV II) in the Treatment of Metastatic Stage IV Non Small Cell Lung Cancer. <b>1994</b> , 80, 128-130   | 2   |
| 1271 | Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. <b>1994</b> , 12, 1764-70   | 83  |
| 1270 | Book review. <b>1994</b> , 5, 285  |     |
| 1269 | Phase II Study with Iododoxorubicin in Measurable Advanced Colorectal Adenocarcinoma. Effective Rescue Using Weekly High-Dose 5-Fluorouracil (WFU). <b>1994</b> , 80, 124-127                                  | 3   |
| 1268 | R75251 in Prostate Cancer Patients in Progression after First-Line Hormonal Treatment. <b>1994</b> , 80, 276-279   | 2   |
| 1267 | Tegafur-Uracil (UFT) Plus Folinic Acid in Advanced Rectal Cancer. <b>1994</b> ,  |     |
| 1266 | High-Dose Intra-Arterial plus Intraperitoneal Chemotherapy Combined with Hemofiltration in Liver Metastases from Colorectal Cancer. <b>1994</b> , 80, 204-208  | 1   |
| 1265 | Treatment of Patients with Metastatic Renal Cell Carcinoma with Subcutaneous Recombinant Interferon-Alpha 2b and Continuous Infusion of Recombinant Interleukin-2: A Phase II Study. <b>1994</b> , 17, 254-260 |     |
| 1264 | Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. <b>1994</b> , 12, 2288-95   | 146 |
| 1263 | Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. <b>1994</b> , 12, 2648-53  | 123 |
| 1262 | Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. <b>1994</b> , 12, 1917-22  | 65  |
| 1261 | Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. <b>1994</b> , 12, 575-9  | 76  |
| 1260 | Measurable or assessable disease in lung cancer trials: does it matter?. <b>1994</b> , 12, 2677-81   | 15  |
| 1259 | Simultaneous 5-Fluorouracil, Cisplatinum and Radiation Therapy for Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus. <b>1994</b> , 17, 498-502  |     |

|      |  |    |
|------|--|----|
| 1258 | Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. <b>1994</b> , 120, 89-95                                      | 25 |
| 1257 | High-dose cyclophosphamide, adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor. <b>1994</b> , 11, 613-23  | 11 |
| 1256 | Clinical evaluation of the pectoralis major flap for reconstruction in head and neck cancer. <b>1994</b> , 28, 217-23  | 3  |
| 1255 | Oral versus intravenous cmf in metastatic breast-cancer - a randomized study. <b>1994</b> , 4, 559-65  | 1  |
| 1254 | Type-I and type-iii procollagen metabolites and ca 125 in epithelial ovarian-cancer. <b>1994</b> , 4, 669-74   |    |
| 1253 | Elf regimen in advanced gastrointestinal malignancies - an analysis of its clinical effectiveness and toxicity. <b>1994</b> , 4, 411-5   |    |
| 1252 | High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: a pilot study. <b>1994</b> , 12, 574-87  | 4  |
| 1251 | Rates and risk factors for adverse events associated with didanosine in the expanded access program. <b>1994</b> , 19, 1076-83   | 43 |
| 1250 | Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. <b>1994</b> , 5 Suppl 2, 53-7 | 17 |
| 1249 | Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. <b>1994</b> , 5 Suppl 2, 127-32  | 63 |
| 1248 | Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. <b>1994</b> , 15, 85-90   | 3  |
| 1247 | High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. <b>1994</b> , 14, 279-83                              | 11 |
| 1246 | Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study. <b>1994</b> , 8, 91-8                                  | 9  |
| 1245 | Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study. <b>1994</b> , 9, 35-9                  | 39 |
| 1244 | Quality of life with carcinoma of the esophagus. <b>1994</b> , 18, 399-405   | 17 |
| 1243 | Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). <b>1994</b> , 2, 213-22   | 77 |
| 1242 | Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases. <b>1994</b> , 2, 253-8  | 12 |
| 1241 | Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach. <b>1994</b> , 47, 187-93   | 6  |

|      |   |     |
|------|---|-----|
| 1240 | Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer. <b>1994</b> , 4, 66-71   |     |
| 1239 | 'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation. <b>1994</b> , 4, 272-278 | 12  |
| 1238 | Phase II trial of isotretinoin and interferon alpha-2a in the treatment of advanced recurrent cervical carcinoma. <b>1994</b> , 4, 414-418  | 6   |
| 1237 | A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. <b>1994</b> , 6, 91-5   | 11  |
| 1236 | High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. <b>1994</b> , 29, 223-8   | 34  |
| 1235 | Droloxifene, a new antiestrogen: its role in metastatic breast cancer. <b>1994</b> , 31, 83-94  | 66  |
| 1234 | Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity. <b>1994</b> , 12, 277-81  | 14  |
| 1233 | Phase II trial of PALA and 6-methylmercaptapurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer. <b>1994</b> , 12, 319-21  | 11  |
| 1232 | Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. <b>1994</b> , 12, 323-5  | 23  |
| 1231 | Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. <b>1994</b> , 12, 29-34   | 373 |
| 1230 | Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study. <b>1994</b> , 12, 231-4  | 21  |
| 1229 | Phase II clinical trial of didemnin B in previously treated small cell lung cancer. <b>1994</b> , 12, 243-9   | 31  |
| 1228 | Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. <b>1994</b> , 12, 267-70  | 3   |
| 1227 | Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. <b>1994</b> , 12, 111-9  | 25  |
| 1226 | Phase II trial of intravenous melphalan in advanced colorectal carcinoma. <b>1994</b> , 12, 133-6   |     |
| 1225 | Phase II trial of topotecan in patients with advanced renal cell carcinoma. <b>1994</b> , 12, 143-5   | 32  |
| 1224 | Pilot study of sequential combination chemotherapy in advanced and recurrent retinoblastoma. <b>1994</b> , 22, 125-8  | 20  |
| 1223 | Mitoxantrone, 5-FU, and leucovorin in breast cancer. <b>1994</b> , 22, 370-4  | 2   |

|      |  |     |     |
|------|--|-----|-----|
| 1222 | High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses. <i>Cancer</i> , <b>1994</b> , 73, 79-84  | 6.4 | 26  |
| 1221 | Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. <i>Cancer</i> , <b>1994</b> , 73, 556-62                                      | 6.4 | 114 |
| 1220 | Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. <i>Cancer</i> , <b>1994</b> , 73, 1134-42   | 6.4 | 90  |
| 1219 | Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. <i>Cancer</i> , <b>1994</b> , 73, 1353-60  | 6.4 | 37  |
| 1218 | Serum glutathione S-transferase-pi level as a tumor marker for non-small cell lung cancer. Potential predictive value in chemotherapeutic response. <i>Cancer</i> , <b>1994</b> , 73, 1377-82  | 6.4 | 25  |
| 1217 | Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. <i>Cancer</i> , <b>1994</b> , 73, 1562-8                            | 6.4 | 24  |
| 1216 | Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. <i>Cancer</i> , <b>1994</b> , 73, 1932-6  | 6.4 | 21  |
| 1215 | Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. <i>Cancer</i> , <b>1994</b> , 73, 2515-9  | 6.4 | 89  |
| 1214 | Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. <i>Cancer</i> , <b>1994</b> , 73, 3015-9   | 6.4 | 37  |
| 1213 | Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution. <i>Cancer</i> , <b>1994</b> , 74, 978-84                                | 6.4 | 17  |
| 1212 | Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. <i>Cancer</i> , <b>1994</b> , 74, 1283-8  | 6.4 | 111 |
| 1211 | Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer. <i>Cancer</i> , <b>1994</b> , 74, 1874-81 | 6.4 | 9   |
| 1210 | Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. <i>Cancer</i> , <b>1994</b> , 74, 2476-82  | 6.4 | 19  |
| 1209 | Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. <i>Cancer</i> , <b>1994</b> , 74, 2873-8   | 6.4 | 46  |
| 1208 | Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule--EPIC. <b>1994</b> , 12, 125-8   |     | 5   |
| 1207 | Distribution of surviving tumor cells after chemoradiotherapy in tongue and floor of mouth carcinomas. <b>1994</b> , 16, 218-26  |     | 8   |
| 1206 | DNA measurements for monitoring chemotherapy in advanced head and neck carcinomas. <b>1994</b> , 16, 240-5   |     | 5   |
| 1205 | Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials. <b>1994</b> , 20, 643-650   |     | 77  |

|      |   |     |
|------|---|-----|
| 1204 | Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. <b>1994</b> , 28, 163-9 | 224 |
| 1203 | Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer. <b>1994</b> , 29, 45-55   | 26  |
| 1202 | Tumor extracellular pH as a prognostic factor in thermoradiotherapy. <b>1994</b> , 29, 125-32   | 48  |
| 1201 | Concurrent irradiation and intratumoral chemotherapy with cisplatin: a pilot study in dogs with spontaneous tumors. <b>1994</b> , 29, 1027-34   | 29  |
| 1200 | Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compounds. <b>1994</b> , 88, 95-7        | 21  |
| 1199 | Bladder cancer: advances in biology and treatment. <b>1994</b> , 16, 33-70  | 7   |
| 1198 | Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer. <b>1994</b> , 120, 173-8   | 4   |
| 1197 | Comparison of ondansetron versus ondansetron plus methylprednisolone as antiemetic prophylaxis during cisplatin-containing chemotherapy. <b>1994</b> , 9, 254-8   | 6   |
| 1196 | Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). <b>1994</b> , 18, 655-8  | 5   |
| 1195 | Combination therapy of drug-resistant choriocarcinoma. <b>1994</b> , 6, 284-288   |     |
| 1194 | Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer. <b>1994</b> , 37, S69-72   | 18  |
| 1193 | In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. <b>1994</b> , 69, 1130-5                                      | 26  |
| 1192 | Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. <b>1994</b> , 70, 319-23  | 129 |
| 1191 | A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases. <b>1994</b> , 70, 677-80  | 22  |
| 1190 | Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. <b>1994</b> , 69, 392-3   | 11  |
| 1189 | Conservative management of squamous cell carcinoma of the anal canal. <b>1994</b> , 64, 754-8   | 8   |
| 1188 | Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation. <b>1994</b> , 24, 541-6                                       | 4   |
| 1187 | Dose intensive therapy with autologous blood stem cell transplantation in breast cancer. <b>1994</b> , 24, 288-95   | 5   |

|      |   |    |
|------|---|----|
| 1186 | Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer. <b>1994</b> , 30A, 1611-6 | 6  |
| 1185 | Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma. <b>1994</b> , 30A, 890-1  | 9  |
| 1184 | Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon. <b>1994</b> , 30A, 1292-8  | 19 |
| 1183 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. <b>1994</b> , 30A, 460-3  | 1  |
| 1182 | Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck. <b>1994</b> , 21, 181-5   | 11 |
| 1181 | Phase II study of vinblastine and doxorubicin in advanced renal cell carcinoma. <b>1994</b> , 30A, 245  | 2  |
| 1180 | Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association. <b>1994</b> , 35, 165-8  |    |
| 1179 | Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group. <b>1994</b> , 35 Suppl, S23-6  | 4  |
| 1178 | Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. <b>1994</b> , 34, 405-10  | 26 |
| 1177 | Response rates--an evolution. <b>1994</b> , 34, 361-3   | 1  |
| 1176 | Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. <b>1994</b> , 34, 72-4   | 7  |
| 1175 | Chronic oral etoposide in advanced breast cancer. <b>1994</b> , 33, 527-9   | 17 |
| 1174 | Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. <b>1994</b> , 33, 420-4   | 39 |
| 1173 | A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma. <b>1994</b> , 33, 438-40   | 2  |
| 1172 | A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG). <b>1994</b> , 30A, 1424-31  | 14 |
| 1171 | Drug monitoring of 5-fluorouracil: in vivo <sup>19</sup> F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. <b>1994</b> , 12, 497-511   | 44 |
| 1170 | A phase II study of piritrexim in patients with advanced squamous cell carcinoma of the head and neck. <b>1994</b> , 30A, 1044-5  | 8  |
| 1169 | The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2. <b>1994</b> , 30A, 1804-9   | 25 |



|      |   |    |
|------|---|----|
| 1168 | Amonafide as first-line chemotherapy for metastatic breast cancer. <b>1994</b> , 30A, 398-400   | 15 |
| 1167 | A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma. <b>1994</b> , 30A, 530-2                            | 16 |
| 1166 | Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin. <b>1994</b> , 30A, 30-3  | 5  |
| 1165 | Efficacy of combined 5-fluorouracil and cisplatin in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. <b>1994</b> , 30A, 1263-9   | 97 |
| 1164 | A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. <b>1994</b> , 30A, 606-10               | 16 |
| 1163 | Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. <b>1994</b> , 30A, 1432-5   | 27 |
| 1162 | Multimodal treatment of locally advanced transitional cell bladder carcinoma in elderly patients. <b>1994</b> , 30A, 918-20   | 3  |
| 1161 | Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. <b>1994</b> , 30A, 1734-6        | 6  |
| 1160 | Phase II study of 4'epirubicin in advanced squamous cell oesophageal cancer. <b>1994</b> , 30A, 1908-9  |    |
| 1159 | Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha. <b>1994</b> , 30A, 420                                    | 7  |
| 1158 | Carboplatin plus epirubicin plus VP-16, concurrent 'split course' radiotherapy and adjuvant surgery for limited small cell lung cancer. Gruppo Oncologico Centro-Sud-Isole (GOCSI). <b>1994</b> , 11, 83-91 | 8  |
| 1157 | Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma. <b>1994</b> , 30A, 338-43  | 21 |
| 1156 | Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. <b>1994</b> , 11, 299-303  | 32 |
| 1155 | Mitoxantrone and 5-fluorouracil modulated by the pure (6S) stereoisomer of leucovorin as second-line chemotherapy for advanced breast cancer. <b>1994</b> , 30A, 1593-4                                     | 2  |
| 1154 | 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. <b>1994</b> , 30A, 325-8   | 27 |
| 1153 | Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant alpha-2b interferon and doxorubicin: results of a pilot study. <b>1994</b> , 30A, 1319-25                        | 5  |
| 1152 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. <b>1994</b> , 30A, 2054-6  | 7  |
| 1151 | Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatin. <b>1994</b> , 30A, 1269-75                        | 61 |

|      |   |     |
|------|---|-----|
| 1150 | Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer. <b>1994</b> , 30A, 965-9  | 17  |
| 1149 | 6-Thioguanine treatment of psoriasis: experience in 81 patients. <b>1994</b> , 30, 452-8  | 51  |
| 1148 | Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer. <b>1994</b> , 11, 283-91  | 1   |
| 1147 | Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study. <b>1994</b> , 30A, 1474-8  | 8   |
| 1146 | Clinical studies of liposome-encapsulated doxorubicin. <b>1994</b> , 33, 779-86   | 118 |
| 1145 | The aged patient with lung cancer. Management recommendations. <b>1994</b> , 4, 34-46   | 13  |
| 1144 | Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. <b>1994</b> , 9, 103-11   | 25  |
| 1143 | Carboplatin and etoposide in extensive small cell lung cancer. <b>1994</b> , 33, 921-4  | 8   |
| 1142 | A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. <b>1994</b> , 33, 925-9 | 2   |
| 1141 | Quality of life assessment in palliative care. <b>1994</b> , 5, 13-8  | 36  |
| 1140 | Oral etoposide in the treatment of malignant mesothelioma. A phase II study. <b>1994</b> , 5, 949-50  | 20  |
| 1139 | Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. <b>1994</b> , 5, 337-42                    | 99  |
| 1138 | A Double Blind Comparative Study of Tegafur (FT) and UFT (a Combination of Tegafur and Uracil) in Advanced Breast Cancer. <b>1994</b> ,   |     |
| 1137 | [Severe renal impairment of methotrexate elimination after high dose therapy]. <b>1994</b> , 206, 319-26  | 11  |
| 1136 | Thermoradiotherapy for superficial tumour deposits in the head and neck. <b>1994</b> , 10, 153-64   | 11  |
| 1135 | Clinical efficacy of doxycycline for pleurodesis. <b>1994</b> , 105, 1743-7   | 84  |
| 1134 | High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. <b>1994</b> , 5, 57-64                                     | 49  |
| 1133 | A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). <b>1994</b> , 5, 609-16                                  | 197 |

|      |   |     |
|------|---|-----|
| 1132 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. <b>1994</b> , 12, 12-9 | 2   |
| 1131 | Single institution experience with mobilization, harvesting, and reinfusion of peripheral blood stem cells in children with a solid tumor or leukemia. <b>1994</b> , 11, 215-21   | 6   |
| 1130 | Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. <b>1994</b> , 5, 182-4  | 133 |
| 1129 | Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. <b>1994</b> , 5, 423-6   | 112 |
| 1128 | Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease. <b>1994</b> , 5, 427-32  | 19  |
| 1127 | Phase I study of the novel distamycin derivative tallimustine (FCE 24517). <b>1994</b> , 5, 901-7   | 37  |
| 1126 | Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. <b>1994</b> , 121, 492-501  | 163 |
| 1125 | European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. <b>1994</b> , 12, 2654-66  | 533 |
| 1124 | Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. <b>1994</b> , 5, 283-5  | 106 |
| 1123 | Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. <b>1994</b> , 69, 385-91                             | 55  |
| 1122 | Combined chemo-immuno-hormonotherapy of advanced renal cell carcinoma. <b>1994</b> , 6, 349-53  | 5   |
| 1121 | Combination of vinorelbine, cisplatin, and etoposide in advanced non-small cell lung carcinoma: a pilot study. <b>1994</b> , 6, 67-71   | 15  |
| 1120 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. <b>1994</b> , 6, 147-51   |     |
| 1119 | A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon. <b>1994</b> , 6, 265-71   | 3   |
| 1118 | Sequential treatment with high-dose methotrexate and fluorouracil in advanced colorectal cancer. Experience of the Southern Italian Oncology Group (GOIM). <b>1994</b> , 6, 139-46  |     |
| 1117 | The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. <b>1994</b> , 70, 559-63   | 57  |
| 1116 | Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. <b>1994</b> , 5, 539-42   | 105 |
| 1115 | Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. <b>1994</b> , 5, 741-6   | 25  |

|      |   |     |
|------|---|-----|
| 1114 | Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility study. <b>1994</b> , 69, 918-21  | 22  |
| 1113 | Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. <b>1994</b> , 5, 471-2   | 27  |
| 1112 | Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma. <b>1994</b> , 152, 1124-6  | 21  |
| 1111 | Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer. <b>1994</b> , 12, 403-5   | 5   |
| 1110 | Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer. <b>1994</b> , 40, 144-8   | 4   |
| 1109 | Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University. <b>1994</b> , 56, 105-11  | 13  |
| 1108 | Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). <b>1994</b> , 5, 233-7 | 57  |
| 1107 | Concurrent carboplatin and radiotherapy in the treatment of squamous cell carcinoma of the head and neck, stage IV. Preliminary data of a phase II study. <b>1995</b> , 7, 549-53   | 1   |
| 1106 | Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. <b>1995</b> , 34, 257-9   | 24  |
| 1105 | Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial. <b>1995</b> , 6, 987-91  | 14  |
| 1104 | Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. <b>1995</b> , 6, 133-40  | 72  |
| 1103 | Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. <b>1995</b> , 6, 141-51  | 121 |
| 1102 | Ambulatory low-toxicity chemotherapy in non-small-cell lung carcinoma by continuous 28-day infusion of alternating cisplatin and 5-fluorouracil. <b>1995</b> , 6, 838-40  | 1   |
| 1101 | First-line systemic therapy for metastatic breast cancer and management of pleural effusion. <b>1995</b> , 6, 1033-43   | 8   |
| 1100 | 5-fluorouracil modulates the toxicity of high dose methotrexate. <b>1995</b> , 35, 1156-65  |     |
| 1099 | Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. <b>1995</b> , 6, 1011-7  | 10  |
| 1098 | A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. <b>1995</b> , 7, 71-7   | 23  |
| 1097 | The expression of glutathione transferase isoenzymes in human malignant lymphoma biopsies. <b>1995</b> , 34, 35-41  | 6   |

|      |   |     |     |
|------|---|-----|-----|
| 1096 | Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain. <b>1995</b> , 34, 75-82  |     | 5   |
| 1095 | Salvage radiotherapy following chemotherapy failure in Hodgkin's disease--what is its role?. <b>1995</b> , 34, 99-104   |     | 13  |
| 1094 | Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). <b>1995</b> , 6, 833-5   |     | 43  |
| 1093 | Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. <b>1995</b> , 6, 267-74  |     | 109 |
| 1092 | Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. <b>1995</b> , 71, 182-5  |     | 27  |
| 1091 | Measurement of response to treatment in colorectal liver metastases. <b>1995</b> , 71, 873-6  |     | 27  |
| 1090 | Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial. <b>1995</b> , 71, 102-5   |     | 31  |
| 1089 | Laevofofinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM). <b>1995</b> , 72, 1245-50 |     | 3   |
| 1088 | VAD chemotherapy as remission induction for multiple myeloma. <b>1995</b> , 71, 326-30  |     | 79  |
| 1087 | Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. <b>1995</b> , 71, 366-70  |     | 147 |
| 1086 | Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chronic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. <b>1995</b> , 6, 887-93                |     | 134 |
| 1085 | A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. <b>1995</b> , 6, 609-11  |     | 34  |
| 1084 | Treatment of aggressive non-Hodgkin's lymphoma in the elderly. <b>1995</b> , 49, 103-8  |     | 9   |
| 1083 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. <i>Cancer</i> , <b>1995</b> , 75, 440-3  | 6.4 | 14  |
| 1082 | A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. <i>Cancer</i> , <b>1995</b> , 75, 782-5   | 6.4 | 91  |
| 1081 | Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. <i>Cancer</i> , <b>1995</b> , 75, 831-5   | 6.4 | 14  |
| 1080 | High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. <i>Cancer</i> , <b>1995</b> , 75, 874-85                       | 6.4 | 68  |
| 1079 | A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. <i>Cancer</i> , <b>1995</b> , 75, 1038-44  | 6.4 | 44  |

|      |  |     |     |
|------|--|-----|-----|
| 1078 | Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study. <i>Cancer</i> , <b>1995</b> , 75, 908-13   | 6.4 | 17  |
| 1077 | Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. <i>Cancer</i> , <b>1995</b> , 75, 1141-50   | 6.4 | 108 |
| 1076 | Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer. <i>Cancer</i> , <b>1995</b> , 75, 1578-85   | 6.4 | 8   |
| 1075 | A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. <i>Cancer</i> , <b>1995</b> , 75, 2197-202  | 6.4 | 27  |
| 1074 | A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. <i>Cancer</i> , <b>1995</b> , 75, 2251-7  | 6.4 | 36  |
| 1073 | Phase I study of phenylacetate administered twice daily to patients with cancer. <i>Cancer</i> , <b>1995</b> , 75, 2932-8  | 6.4 | 101 |
| 1072 | Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. <i>Cancer</i> , <b>1995</b> , 76, 535-6  | 6.4 | 2   |
| 1071 | A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Cancer</i> , <b>1995</b> , 76, 559-63 | 6.4 | 21  |
| 1070 | Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. <i>Cancer</i> , <b>1995</b> , 76, 824-32  | 6.4 | 237 |
| 1069 | High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer. <i>Cancer</i> , <b>1995</b> , 76, 1126-31  | 6.4 | 6   |
| 1068 | Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. <i>Cancer</i> , <b>1995</b> , 76, 1694-9  | 6.4 | 45  |
| 1067 | High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study. <b>1995</b> , 24, 23-8   |     | 7   |
| 1066 | Response of untreated stage IV Wilms' tumor to single dose carboplatin assessed by "up front" window therapy. <b>1995</b> , 25, 8-11   |     | 10  |
| 1065 | Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy for inoperable squamous cell carcinoma of the esophagus potentially followed by surgery. <b>1995</b> , 58, 50-6   |     | 9   |
| 1064 | Results of radiotherapy and vitamin E in the treatment of Peyronie's disease. <b>1995</b> , 31, 571-6  |     | 33  |
| 1063 | A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study. <b>1995</b> , 13, 83-7  |     | 4   |
| 1062 | High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets. <b>1995</b> , 41, 271-9   |     | 4   |
| 1061 | Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. <b>1995</b> , 40, 37-47   |     | 23  |

|      |  |    |
|------|--|----|
| 1060 | Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <b>1995</b> , 13, 163-5  | 25 |
| 1059 | A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study. <b>1995</b> , 13, 171-4   | 33 |
| 1058 | Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study. <b>1996</b> , 13, 363-5  | 2  |
| 1057 | Phase I trial of ilmofosine as a 24 hour infusion weekly. <b>1995</b> , 13, 205-10   | 9  |
| 1056 | A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. <b>1995</b> , 13, 229-33   | 4  |
| 1055 | Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study. <b>1995</b> , 13, 249-52   | 3  |
| 1054 | A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. <b>1995</b> , 13, 253-5  | 19 |
| 1053 | Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial. <b>1995</b> , 33, 265-8                                     | 2  |
| 1052 | Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. <b>1995</b> , 35, 243-8   | 6  |
| 1051 | Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. <b>1995</b> , 35, 147-56   | 5  |
| 1050 | A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. <b>1995</b> , 37, 86-90  | 4  |
| 1049 | Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside. <b>1996</b> , 37, 229-34   | 3  |
| 1048 | Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study. <b>1995</b> , 5, 56-60   | 5  |
| 1047 | Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade). <b>1995</b> , 5, 134-142 | 10 |
| 1046 | Interactions of myelin basic protein with palmitoyllysophosphatidylcholine: characterization of the complexes and conformations of the protein. <b>1995</b> , 24, 39-53  | 14 |
| 1045 | Local hyperthermia and systemic chemotherapy for treatment of recurrent melanoma. <b>1995</b> , 19, 359-62   | 6  |
| 1044 | Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen. <b>1995</b> , 3, 176-82                            | 8  |
| 1043 | Neoadjuvant chemotherapy for gastric cancer: update. <b>1995</b> , 19, 509-16  | 45 |

|      |   |     |
|------|---|-----|
| 1042 | Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. <b>1995</b> , 71, 587-91 | 669 |
| 1041 | A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. <b>1995</b> , 71, 97-101   | 60  |
| 1040 | CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). <b>1995</b> , 71, 1283-7                                 | 26  |
| 1039 | A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer. <b>1995</b> , 71, 1315-8   | 3   |
| 1038 | Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. <b>1995</b> , 71, 160-5  | 57  |
| 1037 | Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. <b>1995</b> , 72, 1267-9  | 13  |
| 1036 | Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. <b>1995</b> , 72, 1531-5   | 22  |
| 1035 | Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). <b>1995</b> , 71, 363-5  | 104 |
| 1034 | Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma. <b>1995</b> , 7, 382-4   | 11  |
| 1033 | The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. <b>1995</b> , 32, 445-50   | 66  |
| 1032 | A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients. <b>1995</b> , 31, 267-72               | 43  |
| 1031 | Rationales for intraperitoneal chemotherapy: Chemosensitivity testing and pharmacokinetic considerations Clinical experience with intraperitoneal chemotherapy. <b>1995</b> , 27, 95-100                | 5   |
| 1030 | Dexverapamil to overcome epirubicin resistance in advanced breast cancer. <b>1995</b> , 121 Suppl 3, R3-6   | 8   |
| 1029 | Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: a pilot study. <b>1995</b> , 19, 899-903   | 6   |
| 1028 | 5-fluorouracil, epirubicin and cyclophosphamide, as first-line cytotoxic chemotherapy for disseminated breast carcinoma. A phase II study. <b>1995</b> , 4, 44-47                                       | 1   |
| 1027 | Intermittent interferon and polychemotherapy in metastatic melanoma. <b>1995</b> , 121, 175-80  | 15  |
| 1026 | Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha. <b>1995</b> , 121, 753-6  | 17  |
| 1025 | Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis. <b>1995</b> , 25, 202-6   | 29  |



|      |   |        |
|------|---|--------|
| 1024 | Phase II clinical trial of lastet capsule in combination chemotherapy of malignant tumors in China. <b>1995</b> , 7, 181-186  |        |
| 1023 | Concomitant cisplatin and radical radiation in locally advanced head & neck carcinoma. <b>1995</b> , 47, 306-309  |        |
| 1022 | Combined Epirubicin, 5-Fluorouracil and Folinic Acid with Allopurinol Protection for Second-Line Treatment of Advanced Gastric Cancer: A Pilot Study. <b>1995</b> , 18, 346-350   | 1      |
| 1021 | Intensive Weekly Chemotherapy for Elderly Gastric Cancer Patients, Using 5-Fluorouracil, Cisplatin, Epi-Doxorubicin, 6S-Leucovorin and Glutathione with the Support of G-CSF. <b>1995</b> , 81, 32-35   | 7      |
| 1020 | Sequential Subcutaneous Thymopentin, Interferon Alpha-2A and Interleukin-2 in Metastatic Renal Cell Cancer. <b>1995</b> , 81, 42-44   | 4      |
| 1019 | Mitomycin-C and Lonidamine as Second-Line Therapy for Colorectal Cancer: A Phase II Study. <b>1995</b> , 81, 435-437  | 5      |
| 1018 | Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma. <b>1995</b> , 6, 801-4  | 31     |
| 1017 | Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. <b>1995</b> , 13, 1623-31  | 63     |
| 1016 | Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. <b>1995</b> , 13, 1734-41  | 92     |
| 1015 | In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. <b>1995</b> , 13, 1843-50  | 76     |
| 1014 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. <b>1995</b> , 13, 2317-23  | 67     |
| 1013 | The Role of Intraoperative Therapy by Electron Beam and Combination of Adjuvant Chemotherapy and External Radiotherapy in Carcinoma of the Pancreas. <b>1995</b> , 81, 23-31  | 28     |
| 1012 | Lonidamine plus Cyclophosphamide in the Treatment of Adanced Non-Small Cell Lung Cancer in the Elderly: A Phase II Study. <b>1995</b> , 81, 48-51   | 6      |
| 1011 | Endometrial Stage I Carcinoma Treated with Surgery and Adjuvant Irradiation: A Retrospective Analysis. <b>1995</b> , 81, 256-260  | 7      |
| 1010 | Cisplatin and VP16 in Metastatic Breast Carcinoma as a Third-Line Chemotherapy: A Randomized Study Comparing Low versus High Doses of Cisplatin. <b>1995</b> , 81, 241-244  | 11     |
| 1009 | Carboplatin and Etoposide in Previously Treated Colorectal Cancer Patients. <b>1995</b> , 81, 36-38   | 4      |
| 1008 | Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial. <i>Cancer</i> , <b>1995</b> , 75, 1238-44 | 6.4 14 |
| 1007 | Angiography of Osteosarcoma. <b>1995</b> , 9, 627-632   | 1      |

|      |   |     |
|------|---|-----|
| 1006 | Mackenzie Davidson Memorial Lecture 1994: imaging of treated cancer. <b>1995</b> , 68, 1-12   | 6   |
| 1005 | Assessing Clinical Outcomes in Cutaneous T-cell Lymphoma. <b>1995</b> , 9, 1021-1029  | 15  |
| 1004 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. <b>1995</b> , 332, 1132-6  | 687 |
| 1003 | Head and neck lymphomas associated with human immunodeficiency virus infection. <b>1995</b> , 121, 210-8  | 15  |
| 1002 | A phase-I clinical-trial of a protracted continuous-infusion of 5-Fluorouracil with oral folinic Acid in patients with unresectable adenocarcinoma of the colon or rectum. <b>1995</b> , 7, 191-4                     |     |
| 1001 | CLINICAL MODULATION OF EPIRUBICIN RESISTANCE BY LONIDAMINE IN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMAS. <b>1995</b> , 6, 363   | 1   |
| 1000 | Phase-I and phase-ii trials of a laboratory-derived synergistic combination of Cisplatin and 2'-deoxy-5-azacytidine. <b>1995</b> , 6, 447-50  | 4   |
| 999  | MEASUREMENT OF EPITHELIAL AND STROMAL CHANGES IN VULVAR CARCINOMA - A CLINICAL, BIOCHEMICAL AND IMMUNOHISTOCHEMICAL STUDY. <b>1995</b> , 7, 101   |     |
| 998  | Renal cell carcinoma in childhood: a case report. <b>1995</b> , 12, 313-6   | 3   |
| 997  | Assessing the Safety of Investigational Agents in Clinical Trials. <b>1995</b> , 12, 119-129  |     |
| 996  | [Malignant pleural mesothelioma: clinical characteristics, prognostic factors and treatment]. <b>1995</b> , 31, 455-9   | 2   |
| 995  | Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy. <b>1995</b> , 17, 321-6                            | 37  |
| 994  | A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. <b>1995</b> , 332, 1457-62  | 384 |
| 993  | Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. <b>1995</b> , 68, 400-5  | 52  |
| 992  | Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. <b>1995</b> , 87, 1316-22 | 83  |
| 991  | Combination chemotherapy (RCM protocol: response-oriented cyclic multidrug protocol) for the acute or lymphoma type adult T-cell leukemia. <b>1995</b> , 18, 317-23   | 24  |
| 990  | Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. <b>1995</b> , 87, 1169-75                              | 122 |
| 989  | Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. <b>1995</b> , 18, 457-63  | 20  |

|     |   |     |
|-----|---|-----|
| 988 | A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. <b>1995</b> , 31A, 19-25 | 11  |
| 987 | Phase II study of cystemustine in advanced renal cancer. <b>1995</b> , 31A, 130-1   | 3   |
| 986 | Failure to increase 5-fluorouracil activity with interferon-alpha 2a in the treatment of advanced colorectal cancer. <b>1995</b> , 31A, 127   | 3   |
| 985 | Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma. <b>1995</b> , 31A, 315-20  | 20  |
| 984 | The treatment of advanced neuroblastoma. Results of the Spanish Neuroblastoma Study Group (SNSG) studies. <b>1995</b> , 31A, 642-5  | 16  |
| 983 | Inpatient comparison of single-agent epirubicin with or without lomidamine in metastatic breast cancer. <b>1995</b> , 31A, 1611-4   | 12  |
| 982 | A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. <b>1995</b> , 31A, 1778-80   | 5   |
| 981 | Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. <b>1995</b> , 31A, 1594-8  | 115 |
| 980 | CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. <b>1995</b> , 31A, 1615-21  | 30  |
| 979 | Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. <b>1995</b> , 31A, 1981-6   | 18  |
| 978 | Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. <b>1995</b> , 31A, 2403-5   | 29  |
| 977 | Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). <b>1995</b> , 31A, 2209-14  | 15  |
| 976 | Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. <b>1995</b> , 31A, 2215-9   | 74  |
| 975 | Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. <b>1995</b> , 31A, 2169-73   | 9   |
| 974 | Salivary immunoglobulins in cancer patients with chemotherapy-related oral mucosa damage. <b>1995</b> , 31B, 160-5  | 12  |
| 973 | A database for mucositis induced by cancer chemotherapy. <b>1995</b> , 31B, 258-60  | 19  |
| 972 | Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. <b>1995</b> , 45, 758-62  | 66  |
| 971 | Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. <b>1995</b> , 109, 917-22  | 160 |

|     |   |     |
|-----|---|-----|
| 970 | Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen. <b>1995</b> , 173, 112-9     | 32  |
| 969 | Hepatitis C virus RNA and long-term response to recombinant interferon-alpha 2b in patients with chronic hepatitis C. <b>1995</b> , 2, 97-102   | 10  |
| 968 | Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. <b>1995</b> , 25, 337-43  | 7   |
| 967 | Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. <b>1995</b> , 36, 352-5                | 11  |
| 966 | Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group. <b>1995</b> , 36, 255-8                              | 4   |
| 965 | Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. <b>1995</b> , 36, 263-5  | 32  |
| 964 | Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. <b>1995</b> , 35, 483-8  | 23  |
| 963 | Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer. <b>1995</b> , 35, 506-10  | 1   |
| 962 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. <b>1995</b> , 35, 437-40   | 6   |
| 961 | Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. <b>1995</b> , 35, 205-12  | 4   |
| 960 | Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. <b>1995</b> , 35, 249-53 | 27  |
| 959 | The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer. <b>1995</b> , 12, 45-58  | 55  |
| 958 | Combined interferon and vinblastine treatment in advanced renal cell cancer. <b>1995</b> , 34, 975-7  | 2   |
| 957 | Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma. <b>1995</b> , 27, 57-61   | 7   |
| 956 | Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma. <b>1995</b> , 34, 937-40        | 3   |
| 955 | Interferon- $\beta$ -2a. <b>1995</b> , 4, 147-168   | 1   |
| 954 | Continuous hepatic arterial infusion of 5-fluorouracil for unresectable colorectal liver metastases: phase II study. <b>1995</b> , 117, 624-8   | 19  |
| 953 | Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. <b>1995</b> , 345, 540-3                                     | 464 |

|     |  |      |
|-----|--|------|
| 952 | Trofosfamide is effective in refractory non-Hodgkin's lymphoma. <b>1995</b> , 31A, 2419-20   | 7    |
| 951 | Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases. <b>1995</b> , 21, 432-4  | 21   |
| 950 | Iridium-192 interstitial brachytherapy for equine periocular tumours: treatment results and prognostic factors in 115 horses. <b>1995</b> , 27, 117-21   | 75   |
| 949 | Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial. <b>1995</b> , 13, 295-303  | 6    |
| 948 | Phase II trial of carboplatin in combination with etoposide in locally advanced large cell carcinoma and adenocarcinoma of the lung. <b>1995</b> , 12, 259-62  | 1    |
| 947 | Palliative radiation for stage 3 non-small cell lung cancer--a prospective study of two moderately high dose regimens. <b>1995</b> , 13, 137-43  | 69   |
| 946 | Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status. <b>1995</b> , 13, 155-68  | 12   |
| 945 | Comment coder la toxicit  tardive de la radioth rapie?. <b>1995</b> , 82, 94-97  | 1    |
| 944 | Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Fran ais de Pneumo-Canc ologie'. <b>1996</b> , 14, 119-34                                      | 25   |
| 943 | Concurrent Cisplatin and Radiotherapy for Patients with Muscle Invasive Bladder Cancer Who are not Candidates for Radical Cystectomy. <b>1996</b> , 156, 1258-1262   | 38   |
| 942 | Phase II study of alternating doses of vinorelbine in combination with cisplatin for non-small cell lung cancer (NSCLC): a disappointing experience. <b>1996</b> , 16, 61-73   | 5    |
| 941 | Hyperfractionated radiotherapy and concomitant cisplatin in stage III non-small cell lung cancer: a phase II study by the AIRO-Lombardia Cooperative Group. <b>1996</b> , 15, 85-91  | 4    |
| 940 | A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. <b>1996</b> , 335, 462-7   | 1657 |
| 939 | Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy. <b>1996</b> , 23, 107-10  | 9    |
| 938 | Valeur pronostique des variations du Cyfra 21-1 s rique dans le suivi th rapeutique du cancer du poumon. <b>1996</b> , 11, 32-37   |      |
| 937 | A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. <b>1996</b> , 32A, 47-51   | 40   |
| 936 | A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy. <b>1996</b> , 32A, 52-6 | 3    |
| 935 | Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases. <b>1996</b> , 32A, 370-1   | 7    |

|                 |   |                 |
|-----------------|---|-----------------|
| 934             | Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF. <b>1996</b> , 32A, 631-5  | 3               |
| 933             | The management of retroperitoneal soft tissue sarcomas. <b>1996</b> , 32A, 622-6  | 33              |
| 932             | Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. <b>1996</b> , 32A, 730-3  | 21              |
| 931             | Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. <b>1996</b> , 32A, 1135-41   | 43 <sup>o</sup> |
| 93 <sup>o</sup> | An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor. <b>1996</b> , 32A, 1171-8                                  | 6               |
| 929             | Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group). <b>1996</b> , 32A, 1432-3 | 2               |
| 928             | A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. <b>1996</b> , 32A, 1933-7   | 24              |
| 927             | Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. <b>1996</b> , 32A, 1719-26   | 10              |
| 926             | Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. <b>1996</b> , 32A, 1822-3   | 9               |
| 925             | Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. <b>1996</b> , 32A, 1734-8  | 12              |
| 924             | Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C. <b>1996</b> , 32A, 1707-11   | 4               |
| 923             | Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. <b>1996</b> , 32A, 1712-8   | 84              |
| 922             | Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. <b>1996</b> , 32A, 1809-11  | 47              |
| 921             | Multivariate analysis of prognostic factors in 106 patients with malignant glioma. <b>1996</b> , 32A, 1918-23   | 29              |
| 920             | Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. <b>1996</b> , 32B, 278-9   | 27              |
| 919             | Neoadjuvant and adjuvant chemotherapy in the multidisciplinary treatment of oral cancer stage III or IV. <b>1996</b> , 32B, 238-41  | 5               |
| 918             | Oral health care for the cancer patient. <b>1996</b> , 32B, 281-92  | 95              |
| 917             | Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. <b>1996</b> , 58, 1777-84  | 105             |

|     |  |     |
|-----|--|-----|
| 916 | Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. <b>1996</b> , 61, 321-7          | 111 |
| 915 | Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. <b>1996</b> , 63, 89-93  | 226 |
| 914 | CT evaluation of treatment response in advanced gastric cancer. <b>1996</b> , 51, 215-20   | 15  |
| 913 | Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study. <b>1996</b> , 32A, 2064-9                                       | 18  |
| 912 | Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits. <b>1996</b> , 32A, 2256-61   | 9   |
| 911 | Symptom assessment. <b>1996</b> , 10, 21-39  | 24  |
| 910 | Adjuvant Methotrexate, Vinblastine and Cisplatin Chemotherapy for Invasive Transitional Cell Carcinoma: Taiwan Experience. <b>1996</b> , 155, 118-121  | 11  |
| 909 | Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. <b>1996</b> , 14, 353-60  | 16  |
| 908 | Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. <b>1996</b> , 38, 292-7 | 10  |
| 907 | Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. <b>1996</b> , 9, 292-306  | 27  |
| 906 | Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. <b>1996</b> , 51, 1075-92  | 86  |
| 905 | Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. <b>1996</b> , 52, 606-23   | 88  |
| 904 | A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. <b>1996</b> , 10, 504-21  | 67  |
| 903 | Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. <b>1996</b> , 12, 94-104                | 4   |
| 902 | The potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer. <b>1996</b> , 12, 197-208; discussion 209-10   | 36  |
| 901 | A Phase II Study of Mitomycin C, Vindesine and Cisplatin Combined with Alpha Interferon in Advanced Non-Small Cell Lung Cancer. <b>1996</b> , 82, 68-71  | 6   |
| 900 | Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. <b>1996</b> , 165, 424-427   | 10  |
| 899 | Combined Locoregional and Systemic Adjuvant Chemotherapy of Stage II and III Rectal Carcinoma. <b>1996</b> , 19, 147-151   | 2   |

|     |  |     |
|-----|--|-----|
| 898 | Phase II Study of Weekly High-Dose 5-Fluorouracil and Folinic Acid plus Biweekly Alternating Cisplatin and Epirubicin (FUFACE) in Patients with Advanced Gastric Carcinoma. <b>1996</b> , 19, 416-418                | 1   |
| 897 | Do the Conventional Clinicopathologic Parameters Predict for Response and Survival in Head and Neck Cancer Patients Undergoing Neoadjuvant Chemotherapy?. <b>1996</b> , 82, 560-566                                  | 3   |
| 896 | Neoadjuvant Chemotherapy with Continuous Infusion of Cisplatin and Fluorouracil in Stage II-IV, M0 Squamous Cell Carcinoma of the Head and Neck. <b>1996</b> , 82, 567-572   | 4   |
| 895 | Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. <b>1996</b> , 14, 700-8 | 256 |
| 894 | Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. <b>1996</b> , 14, 1345-52                                  | 38  |
| 893 | Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. <b>1996</b> , 14, 249-56  | 135 |
| 892 | Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. <b>1996</b> , 14, 142-8   | 67  |
| 891 | Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. <b>1996</b> , 14, 1545-51  | 312 |
| 890 | A New Regimen of Cisplatin, Epirubicin and Methotrexate (PEM-3) as Primary Chemotherapy for Locally Advanced Bladder Cancer. <b>1996</b> , 82, 364-368   | 1   |
| 889 | Phase II Trial of Oral Tegafur and Folinic Acid with Mitoxantrone as First-Line Regimen in Patients with Metastatic Breast Cancer. <b>1996</b> , 82, 61-64   | 4   |
| 888 | High-Dose-Rate Brachytherapy for Poor-Prognosis, High-Grade Glioma: (Phase II) Preliminary Results. <b>1996</b> , 82, 339-344  | 2   |
| 887 | Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. <b>1996</b> , 14, 2959-67   | 123 |
| 886 | Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. <b>1996</b> , 7, 601-5  | 9   |
| 885 | Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. <b>1996</b> , 7, 861-3   | 80  |
| 884 | Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: long-term results for 96 patients with tumors > 5 cm. <b>1996</b> , 7, 925-31                       | 10  |
| 883 | How should cancer presenting as a malignant pleural effusion be managed?. <b>1996</b> , 74, 832-5  | 20  |
| 882 | High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas. <b>1996</b> , 14, 239-42  | 13  |
| 881 | A prospective study of pulmonary function in patients receiving mitomycin. <b>1996</b> , 109, 939-44   | 34  |



|     |   |     |
|-----|---|-----|
| 880 | [Hepatopathy in patients with stage 4S neuroblastoma]. <b>1996</b> , 208, 221-8   | 7   |
| 879 | Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil. <b>1996</b> , 14, 197-201  | 3   |
| 878 | Modulation of cisplatin antitumor activity by short infusional high-dose cytosine arabinoside in advanced pretreated head and neck carcinoma: a phase II study. <b>1996</b> , 8, 304-9  | 3   |
| 877 | Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. <b>1996</b> , 7, 419-21  | 4   |
| 876 | Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole" (G.O.C.S.I.). <b>1996</b> , 7, 821-6    | 26  |
| 875 | Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies?. <b>1996</b> , 14, 498-500   | 2   |
| 874 | Dietary factors and the risk of endometrial cancer: a case--control study in Greece. <b>1996</b> , 73, 1284-90  | 70  |
| 873 | Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. <b>1996</b> , 183, 2681-6  | 241 |
| 872 | Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. <b>1996</b> , 93, 10405-10   | 147 |
| 871 | A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group. <b>1996</b> , 73, 1096-100  | 2   |
| 870 | High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index. <b>1996</b> , 73, 1272-7  | 18  |
| 869 | Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer. <b>1996</b> , 74, 1141-7 | 7   |
| 868 | Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. <b>1996</b> , 73, 549-52  | 61  |
| 867 | A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. <b>1996</b> , 73, 1260-4  | 56  |
| 866 | Placebo-Controlled Trial of Medroxy Progesterone Acetate in Gastrointestinal Malignancies and Cachexia. <b>1996</b> , 19, 164-168   | 5   |
| 865 | Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. <b>1996</b> , 109, 104-8  | 12  |
| 864 | Disease extent and response to chemotherapy in non-small cell lung cancer. <b>1996</b> , 35, 106-7  | 1   |
| 863 | Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. <b>1996</b> , 35, 141-8   | 26  |

|     |   |    |
|-----|---|----|
| 862 | Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer. <b>1996</b> , 35, 435-9   | 5  |
| 861 | Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients. <b>1996</b> , 21, 383-90  | 51 |
| 860 | Monitoring tumour response. <b>1996</b> , 6, 775-85   | 17 |
| 859 | Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. <b>1996</b> , 122, 511-2   | 28 |
| 858 | Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. <b>1996</b> , 38, 277-82  | 8  |
| 857 | Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. <b>1996</b> , 38, 289-97   | 37 |
| 856 | Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. <b>1996</b> , 39, 235-8  | 18 |
| 855 | Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group. <b>1996</b> , 40, 161-9 | 6  |
| 854 | Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. <b>1996</b> , 138, 215-20  | 11 |
| 853 | Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group. <b>1996</b> , 72, 349-55   | 16 |
| 852 | Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagus. <b>1996</b> , 37, 496-8  | 11 |
| 851 | Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. <b>1996</b> , 38, 487-94               | 9  |
| 850 | Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer. <b>1996</b> , 38, 561-5              | 3  |
| 849 | Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study. <b>1996</b> , 39, 150-6   | 66 |
| 848 | Combination adoptive immunotherapy with chemoradiotherapy in oral carcinomas. <b>1996</b> , 1, 150-156  | 3  |
| 847 | Radiation treatment of superior sulcus lung carcinoma. <b>1996</b> , 40, 55-60  | 17 |
| 846 | The efficacy of doxycycline as a pleural sclerosing agent in malignant pleural effusion: a prospective study. <b>1996</b> , 1, 69-72  | 28 |
| 845 | Relief of jaundice by 5-fluorouracil and folinic acid in patients with recurrent gastric cancer. <b>1996</b> , 5, 177-81  | 1  |

|     |  |     |     |
|-----|--|-----|-----|
| 844 | Neoadjuvant chemotherapy in locally advanced breast cancer. <b>1996</b> , 61, 38-41  |     | 6   |
| 843 | Preoperative simultaneous cisplatin- or carboplatin-based chemotherapy and radiotherapy for squamous cell carcinoma of the oral cavity. <b>1996</b> , 63, 240-8  |     | 15  |
| 842 | High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. <b>1996</b> , 27, 534-9   |     | 16  |
| 841 | The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research. <i>Cancer</i> , <b>1996</b> , 77, 245-50 | 6.4 | 12  |
| 840 | Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. <i>Cancer</i> , <b>1996</b> , 77, 402-8   | 6.4 | 224 |
| 839 | Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. <i>Cancer</i> , <b>1996</b> , 77, 1363-6   | 6.4 | 50  |
| 838 | Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. <i>Cancer</i> , <b>1996</b> , 77, 1978-85   | 6.4 | 67  |
| 837 | Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcoma. <i>Cancer</i> , <b>1996</b> , 77, 2117-22   | 6.4 | 9   |
| 836 | Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. <i>Cancer</i> , <b>1996</b> , 77, 2127-31                   | 6.4 | 28  |
| 835 | Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. <i>Cancer</i> , <b>1996</b> , 77, 2302-7  | 6.4 | 20  |
| 834 | Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. <i>Cancer</i> , <b>1996</b> , 77, 2371-8          | 6.4 | 74  |
| 833 | A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma. <i>Cancer</i> , <b>1996</b> , 77, 2520-8  | 6.4 | 2   |
| 832 | Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. <i>Cancer</i> , <b>1996</b> , 77, 2550-9                       | 6.4 | 15  |
| 831 | Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. <i>Cancer</i> , <b>1996</b> , 77, 2622-9  | 6.4 | 179 |
| 830 | CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?. <i>Cancer</i> , <b>1996</b> , 78, 118-27  | 6.4 | 26  |
| 829 | Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial. <i>Cancer</i> , <b>1996</b> , 78, 63-9   | 6.4 | 14  |
| 828 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. <i>Cancer</i> , <b>1996</b> , 78, 211-6                       | 6.4 | 24  |
| 827 | Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. <i>Cancer</i> , <b>1996</b> , 78, 416-21   | 6.4 | 63  |

|     |  |     |     |
|-----|--|-----|-----|
| 826 | Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. <i>Cancer</i> , <b>1996</b> , 78, 789-93  | 6.4 | 11  |
| 825 | Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer. <i>Cancer</i> , <b>1996</b> , 78, 1125-30  | 6.4 | 3   |
| 824 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). <i>Cancer</i> , <b>1996</b> , 78, 1300-7 | 6.4 | 34  |
| 823 | Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma. <i>Cancer</i> , <b>1996</b> , 78, 1646-1650   | 6.4 | 13  |
| 822 | Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. <i>Cancer</i> , <b>1996</b> , 78, 1740-7  | 6.4 | 116 |
| 821 | Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas. <i>Cancer</i> , <b>1996</b> , 78, 1794-1797  | 6.4 | 12  |
| 820 | Correlation between computed tomographic density of lymph node metastases and response to cisplatin-based chemotherapy in patients with head and neck squamous cell carcinoma in an area in which betel quid chewing is prevalent. <i>Cancer</i> , <b>1996</b> , 78, 1972-9                            | 6.4 | 12  |
| 819 | Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma. <i>Cancer</i> , <b>1996</b> , 78, 2087-93  | 6.4 | 11  |
| 818 | Modified type IV-V radical hysterectomy with systematic pelvic and aortic lymphadenectomy in the treatment of patients with stage III cervical carcinoma. Feasibility, technique, and clinical results. <i>Cancer</i> , <b>1996</b> , 78, 2359-65  | 6.4 | 38  |
| 817 | Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. <b>1996</b> , 65, 450-3  |     | 78  |
| 816 | Cell kinetics and tumor regression during radiotherapy in head and neck squamous-cell carcinomas. <b>1996</b> , 68, 151-5  |     | 20  |
| 815 | Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases. <b>1996</b> , 34, 155-9  |     |     |
| 814 | Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. <b>1996</b> , 34, 1019-28   |     | 57  |
| 813 | Comparison of mitozantrone and epirubicin in advanced breast cancer. <b>1996</b> , 8, 363-6  |     | 6   |
| 812 | Oral indomethacin and ranitidine in advanced melanoma: a phase II study. <b>1996</b> , 8, 112-5  |     | 6   |
| 811 | CNS-85 trial: a cooperative pediatric CNS tumor study--results of treatment of medulloblastoma patients. <b>1996</b> , 12, 87-96   |     | 10  |
| 810 | Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group. <b>1996</b> , 94, 333-41                               |     | 8   |
| 809 | A Phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer. <b>1996</b> , 6, 257-260   |     | 1   |

|     |  |    |
|-----|--|----|
| 808 | Phase II study of mitonafide in non-small cell lung cancer (NSCLC). <b>1996</b> , 14, 415-7  | 9  |
| 807 | Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study. <b>1996</b> , 14, 419-21  | 1  |
| 806 | Increased levels of nm23 H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate. <b>1996</b> , 14 Suppl 1, S21-5   | 14 |
| 805 | Phase II study of Mitonafide in advanced and relapsed colorectal cancer. <b>1996</b> , 14, 223-5   | 2  |
| 804 | An exploratory study of frequent pain measurement in a cancer clinical trial. <b>1996</b> , 5, 503-7   | 21 |
| 803 | Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. <b>1996</b> , 73, 1080-5  | 14 |
| 802 | Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. <b>1996</b> , 73, 1227-32   | 43 |
| 801 | Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study. <b>2020</b> , 11, 251-258  | 1  |
| 800 | The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. <b>2020</b> , 10,   | 6  |
| 799 | Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma. <b>2020</b> , 4, 61-69   | 1  |
| 798 | Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation. <b>2020</b> , 8, 388  | 12 |
| 797 | Kanglaite injection plus fluorouracil-based chemotherapy on the reduction of adverse effects and improvement of clinical effectiveness in patients with advanced malignant tumors of the digestive tract: A meta-analysis of 20 RCTs following the PRISMA guidelines. <b>2020</b> , 99, e19480 | 5  |
| 796 | β-Phellandrene attenuates tissular damage, oxidative stress, and TNF-β levels on acute model ifosfamide-induced hemorrhagic cystitis in mice. <b>2020</b> , 393, 1835-1848   | 5  |
| 795 | Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. <b>2020</b> , 8,   | 26 |
| 794 | Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <b>2020</b> , 21, e317-e329   | 31 |
| 793 | Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. <b>2020</b> , 105, 1948-1956   | 3  |
| 792 | Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease. <b>2020</b> , 20, 466  | 1  |
| 791 | A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. <b>2020</b> , 22, 57   | 25 |

|     |  |     |
|-----|--|-----|
| 790 | Multi-energy computed tomography and material quantification: Current barriers and opportunities for advancement. <b>2020</b> , 47, 3752-3771  | 4   |
| 789 | Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. <b>2020</b> , 136, 144-147   | 85  |
| 788 | Intrathoracic infusion therapy with Lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials. <b>2020</b> , 76, 153260                               | 6   |
| 787 | The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. <b>2020</b> , 56, 380-389   |     |
| 786 | COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <b>2020</b> , 136, 489-500   | 642 |
| 785 | Two-staged gamma knife radiosurgery for treatment of numerous (>10) brain metastases. <b>2020</b> , 195, 105847  | 1   |
| 784 | Daily received support and relational functioning in HCT survivors and their caregivers. <b>2020</b> , 29, 1329-1337   | 1   |
| 783 | Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease. <b>2020</b> , 122, 619  | 5   |
| 782 | Compound Kushen injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 37 RCTs following the PRISMA guidelines. <b>2020</b> , 11, 1883-1898                             | 12  |
| 781 | Isolated limb infusion: Institutional protocol and implementation. <b>2020</b> , 122, 99-105   | 3   |
| 780 | Core Rehabilitation Outcome Set for Single Sided Deafness (CROSSSD) study: protocol for an international consensus on outcome measures for single sided deafness interventions using a modified Delphi survey. <b>2020</b> , 21, 238 | 5   |
| 779 | Risk factors for bleeding in haemato-oncology patients-a nested case-control study: The BITE study protocol (Bleeding In Thrombocytopenia Explained). <b>2020</b> , 10, e034710  | 2   |
| 778 | Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. <b>2020</b> , 14, 2423-2433  | 19  |
| 777 | A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy. <b>2020</b> , 12, 142   | 63  |
| 776 | Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <b>2020</b> , 16, 2059-2073  | 1   |
| 775 | Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). <b>2020</b> , 2020, 5784876  | 17  |
| 774 | The Hepatorenal Toxicity and Tumor Response of Chemotherapy With or Without Aidi Injection in Advanced Lung Cancer: A Meta-Analysis of 80 Randomized Controlled Trials. <b>2020</b> , 42, 515-543.e31                                | 13  |
| 773 | Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. <b>2020</b> , 13, 100742                 | 8   |

|     |  |    |
|-----|--|----|
| 772 | Updates of colorectal cancer liver metastases therapy: review on DEBIRI. <b>2020</b> , 7, HEP16  | 17 |
| 771 | Total Marrow Irradiation. <b>2020</b> ,  | 1  |
| 770 | Transfusion Challenges in Patients with Hematological Malignancies in Sub-Saharan Africa: A Prospective Observational Study from the Uganda Cancer Institute. <b>2020</b> , 10, 2825   |    |
| 769 | Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer. <b>2020</b> , 44, 100557   | 3  |
| 768 | A new tool for comprehensive geriatric assessment in elderly patients with acute myeloid leukemia: a pilot study from China. <b>2020</b> , 133, 381-387  | 1  |
| 767 | Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. <b>2020</b> , 190, 105-114                                | 6  |
| 766 | Clinical efficacy and safety of aidi injection combination with vinorelbine and cisplatin for advanced non-small-cell lung carcinoma: A systematic review and meta-analysis of 54 randomized controlled trials. <b>2020</b> , 153, 104637  | 11 |
| 765 | Bleeding assessment and bleeding severity in thrombocytopenic patients undergoing invasive procedures. <b>2020</b> , 60, 637-649   | 3  |
| 764 | First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection. <b>2020</b> , 86, 1113-1124  | 19 |
| 763 | PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia. <b>2020</b> , 13, 227-234   | 1  |
| 762 | Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. <b>2020</b> , 4, 1648-1655   | 8  |
| 761 | Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. <b>2021</b> , 110, 188-195   | 80 |
| 760 | Rotational thromboelastometry parameters as predicting factors for bleeding in immune thrombocytopenic purpura. <b>2021</b> , 14, 27-32  |    |
| 759 | Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors. <b>2021</b> , 148, 140-149   | 5  |
| 758 | Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab. <b>2021</b> , 127, 90-95 | 2  |
| 757 | Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. <b>2021</b> , 1875, 188446  | 8  |
| 756 | Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy. <b>2021</b> , 61, 286-293  | 2  |
| 755 | MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review. <b>2021</b> , 21, 425-449   | 3  |

|     |  |   |
|-----|--|---|
| 754 | Evaluating the appropriateness of platelet transfusions compared with evidence-based platelet guidelines: An audit of platelet transfusions at 57 hospitals. <b>2021</b> , 61, 57-71                       | 1 |
| 753 | On the properties of the toxicity index and its statistical efficiency. <b>2021</b> , 40, 1535-1552  | 4 |
| 752 | Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey. <b>2021</b> , 106, 362-370  | 2 |
| 751 | Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia - a nested case-control study. <b>2021</b> , 100, 261-271            | 2 |
| 750 | Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <b>2021</b> , 62, 659-668 | 1 |
| 749 | Investigation of fibrinogen in early bleeding of patients with newly diagnosed acute promyelocytic leukemia. <b>2021</b> , 32, 677-683   | 4 |
| 748 | Methodological studies. <b>2021</b> , 227-237  |   |
| 747 | Bleeding in Critically Ill Children-Review of Literature, Knowledge Gaps, and Suggestions for Future Investigation. <b>2021</b> , 9, 611680  |   |
| 746 | Analysis of Curcumin as a Radiosensitizer in Cancer Therapy with Serum Survivin Examination: Randomised Control Trial. <b>2021</b> , 22, 139-143   | 3 |
| 745 | The Value of Early Tumor Size Response to Chemotherapy in Pediatric Rhabdomyosarcoma. <b>2021</b> , 13,  | 1 |
| 744 | Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Post-Radiotherapy Setting. <b>2021</b> , 59-81   |   |
| 743 | Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms. <b>2021</b> , 25, 319-331            | 4 |
| 742 | Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. <b>2021</b> , 59, 1260-1275                       | 1 |
| 741 | Evaluation and Assessment of the Radio-Peptide Treatment Efficacy. <b>2021</b> , 163-170   |   |
| 740 | Automatic brain lesion segmentation on standard magnetic resonance images: a scoping review. <b>2021</b> , 11, e042660   | 3 |
| 739 | Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. <b>2021</b> , 28, 1499-1510  | 1 |
| 738 | Image-Guided Brachytherapy: Follow-Up. Imaging and Clinical Management. <b>2021</b> , 63-73  |   |
| 737 | MRI and Diffusion-Weighted MRI in Treatment Response Evaluation Overview. <b>2021</b> , 17-26  |   |



|     |   |    |
|-----|---|----|
| 736 | Efficacy of ginseng and its ingredients as adjuvants to chemotherapy in non-small cell lung cancer. <b>2021</b> , 12, 2225-2241   | 6  |
| 735 | Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. <b>2021</b> , 83-99   |    |
| 734 | Stem-Cell Therapy Following High-Dose Chemotherapy in Advanced Retinoblastoma: A Systematic Review. <b>2021</b> , 10, 397-407   | 1  |
| 733 | A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future Research. <b>2021</b> , 11, 620070  | 3  |
| 732 | Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients. <b>2021</b> , 11,   | 3  |
| 731 | Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. <b>2021</b> , 42, 566-574 | 2  |
| 730 | Rotational thromboelastometry (ROTEM) profiling of COVID-19 patients. <b>2021</b> , 32, 690-696   | 11 |
| 729 | The Effectiveness and Safety of Cinobufotalin Injection as an Adjunctive Treatment for Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <b>2021</b> , 2021, 8852261  | 2  |
| 728 | Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. <b>2020</b> , 7, FSO644   | 0  |
| 727 | Clinical and biochemical markers in CIPN: A reappraisal. <b>2021</b> , 177, 890-907   | 4  |
| 726 | Investigation of singlet oxygen production property of peripherally tetra-substituted In(III)Cl phthalocyanine for photodynamic therapy. 281-290  |    |
| 725 | PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. <b>2021</b> , 48, 3975-3989  | 6  |
| 724 | Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore. <b>2021</b> , 19, 14  | 2  |
| 723 | Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia. <b>2021</b> , 31, 133-139   | 1  |
| 722 | Assessing Toxicity in Drug Trials in Liver Disease. <b>2021</b> , 41, 277-284   | 0  |
| 721 | Efficacy of Herbal Medicines Intervention for Colorectal Cancer Patients With Chemotherapy-Induced Gastrointestinal Toxicity - a Systematic Review and Meta-Analysis. <b>2021</b> , 11, 629132  | 2  |
| 720 | Hepatocellular carcinoma progression during bridging before liver transplantation. <b>2021</b> , 5,   | 2  |
| 719 | Diagnostic accuracy of Liver Imaging Reporting and Data System locoregional treatment response criteria: a systematic review and meta-analysis. <b>2021</b> , 31, 7725-7733   | 3  |

|     |   |   |
|-----|---|---|
| 718 | Prediction of tumor size in patients with invasive ductal carcinoma using FT-IR spectroscopy combined with chemometrics: a preliminary study. <b>2021</b> , 413, 3209-3222  | 1 |
| 717 | Comparison of Measurement Techniques and Response Criteria for MR Imaging Follow-up in Adult Primary Central Nervous System Lymphoma. <b>2021</b> , 42, 1415-1420   | 1 |
| 716 | Alkaline phosphatase, lactic dehydrogenase, inflammatory variables and apparent diffusion coefficients from MRI for prediction of chemotherapy response in osteosarcoma. A cross sectional study. <b>2021</b> , 64, 102228  | 1 |
| 715 | The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer. <b>2021</b> , 11, 641304   | 3 |
| 714 | MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. <b>2021</b> , 23, 1949-1960   | 6 |
| 713 | Anticoagulation in Patients with Platelet Disorders. <b>2021</b> , 41, 112-119  | 0 |
| 712 | Development of an Illustrated Scale for Acute Radiation Dermatitis in Breast Cancer Patients. <b>2021</b> , 11, 168-176   | 1 |
| 711 | Optimal Chinese herbal injections plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A systematic review and Bayesian network meta-analysis. <b>2021</b> , 1, 100031   | 1 |
| 710 | Anterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer. <b>2021</b> , 108, 644-651  | 1 |
| 709 | The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials. <b>2021</b> , 12, 582447   | 4 |
| 708 | Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. <b>2021</b> , 91, S19-S25 | 6 |
| 707 | Severe bleeding in the ICU. <b>2021</b> , 34, 530-536   | 1 |
| 706 | Absolute Circulating Leukemic Cells as a Risk Factor for Early Bleeding Events in Patients with Non-High-Risk Acute Promyelocytic Leukemia. <b>2021</b> , 13, 4135-4146   | 0 |
| 705 | Imaging Assessment of Tumor Response in the Era of Immunotherapy. <b>2021</b> , 11,   | 1 |
| 704 | CAR T-Cell Therapy: An Update for Radiologists. <b>2021</b> , 217, 1461-1474  | 4 |
| 703 | Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience. <b>2021</b> , 11, 656146   | 1 |
| 702 | Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer. <b>2021</b> , 19, 37   | 0 |
| 701 | Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. <b>2021</b> , 74, 1483-1488   | 9 |

|     |  |    |
|-----|--|----|
| 700 | Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. <b>2021</b> , 19, 2348-2354         | 1  |
| 699 | Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <b>2021</b> , 19, 2082-2088                                  | 3  |
| 698 | Drug-Induced Peripheral Neuropathy: Diagnosis and Management. <b>2021</b> ,  | 0  |
| 697 | Expected individual benefit of prophylactic platelet transfusions in hemato-oncology patients based on bleeding risks. <b>2021</b> , 61, 2578-2587   | 1  |
| 696 | Tranexamic acid evidence and controversies: An illustrated review. <b>2021</b> , 5, e12546   | 13 |
| 695 | Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up. <b>2021</b> , 8, 695222   | 3  |
| 694 | Thyroid Dysfunction in Patients With Immune Thrombocytopenia: Prevalence and it's Impact On Outcome.. <b>2022</b> , 38, 173-177  | 0  |
| 693 | Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma. <b>2021</b> , 9, 1130  | 0  |
| 692 | Eltrombopag in the Treatment of Immune Thrombocytopenia: Two-Center Experience from Istanbul.. <b>2022</b> , 38, 327-332   | 0  |
| 691 | Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. <b>2021</b> , 154, 187-196        | 1  |
| 690 | Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria. <b>2021</b> , 1                                  | 1  |
| 689 | Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. <b>2021</b> , 29, 389-403  | 0  |
| 688 | Neurophysiologic assessment of small fibre damage in chemotherapy-induced peripheral neuropathy. <b>2021</b> , 132, 1947-1956  | 1  |
| 687 | Surgical resection versus stereotactic radiosurgery on local recurrence and survival for patients with a single brain metastasis: a systematic review and meta-analysis. <b>2021</b> , 1-11                | 0  |
| 686 | Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <b>2021</b> , 30, e13504 | 0  |
| 685 | Diagnosing Inherited Platelet Disorders: Modalities and Consequences. <b>2021</b> ,  | 0  |
| 684 | Efficacy and Safety of -Containing Traditional Chinese Medicine Combined With Platinum-Based Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. <b>2021</b> , 11, 632168      | 2  |
| 683 | Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis. <b>2021</b> , 11, 649999                        | 1  |

|     |  |    |
|-----|--|----|
| 682 | Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial. <b>2021</b> , 39, 2979-2990        | 7  |
| 681 | Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors. <b>2021</b> , 94, 20210228   | 0  |
| 680 | Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 100, e27161   | 0  |
| 679 | Immune PET Imaging. <b>2021</b> , 59, 875-886  | 0  |
| 678 | Soft Tissue Sarcomas: The Role of Quantitative MRI in Treatment Response Evaluation. <b>2021</b> ,   | 2  |
| 677 | Efficacy and Safety of Chinese Herbal Medicine on Treatment of Breast Cancer: A Meta-analysis of Randomized Controlled Trials. <b>2021</b> , 49, 1557-1575   | 0  |
| 676 | Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials. <b>2021</b> , 23, 100827   |    |
| 675 | Management of acquired hemophilia A: results from the Spanish registry. <b>2021</b> , 5, 3821-3829   | 1  |
| 674 | Short-Term Clinical Efficacy of Neoadjuvant Chemotherapy Combined With Laparoscopic Gastrectomy for Locally Advanced Siewert Type II and III Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Propensity Score-Matched Study. <b>2021</b> , 11, 690662                                   | 0  |
| 673 | Systemic treatment of hepatocellular carcinoma: An EASL position paper. <b>2021</b> , 75, 960-974  | 49 |
| 672 | Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. <b>2021</b> , 78, 194-200  | 1  |
| 671 | Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. <b>2021</b> , 161, 60-67   |    |
| 670 | Effectiveness of crocin of saffron ( <i>Crocus sativus</i> L.) against chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial. <b>2021</b> , 281, 114511  | 1  |
| 669 | Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study. <b>2021</b> , 32, e73 | 1  |
| 668 | Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis. <b>2021</b> , 28, 100440  |    |
| 667 | AIM and Brain Tumors. <b>2021</b> , 1-16   |    |
| 666 | PET Diagnosis and Response Monitoring in Oncology. <b>2021</b> , 1049-1076   |    |
| 665 | Conventional Radiological and PET-CT Assessment of Treatment Response Evaluation in Chemotherapy Setting. <b>2021</b> , 49-57  |    |

|     |  |     |    |
|-----|--|-----|----|
| 664 | Verification of the Efficacy of New Diagnostic Criteria for Retropharyngeal Nodes in a Cohort of Nasopharyngeal Carcinoma Patients. <b>2021</b> , 18, 3463-3469                                  |     | 0  |
| 663 | Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. <b>2021</b> , 20, 15330338211042139 |     | 1  |
| 662 | Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. <i>Cancer</i> , <b>1998</b> , 82, 301-8                               | 6.4 | 13 |
| 661 | Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings. 127-199  |     | 5  |
| 660 | Radiologic Assessment of Mesothelioma. <b>2005</b> , 433-453   |     | 1  |
| 659 | Computed Tomography Imaging for Tumor Ablation. <b>2005</b> , 104-120  |     | 2  |
| 658 | Medulläres Schilddrüsenkarzinom. <b>2006</b> , 4071-4091   |     | 2  |
| 657 | Fever, Pyrogens and Cancer. <b>2006</b> , 276-337  |     | 7  |
| 656 | Chemotherapy-Induced Alopecia: Overview and Methodology for Characterizing Hair Changes and Regrowth. <b>2010</b> , 381-386  |     | 1  |
| 655 | Modeling Tumor Growth in Oncology. <b>2011</b> , 1-19  |     | 9  |
| 654 | Clinical Trials in Genitourinary Oncology: What Have They Achieved?. <b>1989</b> , 225-253   |     | 5  |
| 653 | How to Choose a Relevant Endpoint. <b>1998</b> , 303-319   |     | 6  |
| 652 | Psychosocial aspects of patients with lung cancer in controlled clinical trials. <b>1989</b> , 45, 325-55  |     | 2  |
| 651 | Clinical Evaluation of Anticancer Treatments: Phase II Clinical Trials. <b>1987</b> , 175-197  |     | 4  |
| 650 | Phase I and Early Phase II Trials of 4-Carboxyphthalato (1,2 Diaminocyclohexane) Platinum (II). <b>1984</b> , 310-320  |     | 4  |
| 649 | New developments in the treatment of gastric carcinoma. <b>1991</b> , 55, 363-73   |     | 9  |
| 648 | Fractionation in boron neutron capture therapy. <b>1989</b> , 50, 53-61  |     | 3  |
| 647 | Applications of Small-Animal Molecular Imaging in Drug Development. <b>2014</b> , 715-752  |     | 1  |

|     |  |    |
|-----|--|----|
| 646 | Contribution of Chemotherapy to the Toxicity of Pelvic Irradiation. <b>2015</b> , 87-110   | 1  |
| 645 | Endpoints for Determination of Efficacy of Antiangiogenic Agents in Clinical Trials. <b>1999</b> , 341-353   | 3  |
| 644 | Cancer Imaging in Immunotherapy. <b>2020</b> , 1244, 309-324   | 2  |
| 643 | Comparative effectiveness in hepatic malignancies. <b>2015</b> , 164, 195-219  | 1  |
| 642 | Nebenwirkungen. <b>2006</b> , 229-284  | 1  |
| 641 | Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction. <b>2010</b> , 182, 167-77                                  | 6  |
| 640 | Translational/Clinical Studies in Children and Adults with Neurofibromatosis Type 1. <b>2012</b> , 625-657   | 2  |
| 639 | Assessment of Tumor Remission Based on Imaging Data (One-, Two-, Three-Dimensional) in Adenoid-Cystic Carcinoma of the Minor Salivary Glands After Neutron Radiotherapy. <b>1992</b> , 765-773 | 1  |
| 638 | Systemic and local chemotherapy in palliative and adjuvant treatment of hepatic metastases of colorectal origin. <b>1992</b> , 109-128   | 3  |
| 637 | Treatment of Chronic and Acute Phase Chronic Myelogenous Leukemia with Interferon- $\beta$ 2b and, Interferon- $\alpha$ 1988, 119-128  | 1  |
| 636 | Pirarubicin [A New Anthracycline with High Activity in Untreated Patients with Small-Cell Cancer of the Lung. <b>1989</b> , 280-283  | 1  |
| 635 | Treatment of relapsed or refractory acute leukemia: comparison of two different regimens. <b>1990</b> , 33, 614-8  | 4  |
| 634 | Locally Advanced Breast Cancer: The National Cancer Institute Experience. <b>1991</b> , 416-434  | 1  |
| 633 | Forschungsinstrumente zur Erfassung der Lebensqualität bei Krebs [Ein Überblick. <b>1989</b> , 45-58   | 5  |
| 632 | Treatment of Relapsed or Refractory Adult Acute Lymphocytic Leukemia. <b>1992</b> , 472-480  | 1  |
| 631 | Chemotherapeutic results in small cell lung cancer. <b>1985</b> , 97, 127-45   | 12 |
| 630 | Hyperthermia and drugs. <b>1987</b> , 104, 136-203   | 97 |
| 629 | Two versus six hyperthermia treatments in combination with radical irradiation for fixed metastatic neck nodes: progress report. <b>1988</b> , 107, 123-8                                      | 8  |

|     |   |    |
|-----|---|----|
| 628 | Summary of recent clinical experience in whole-body hyperthermia combined with chemotherapy. <b>1988</b> , 107, 200-4   | 9  |
| 627 | Phase-II-study with EAP (etoposide, adriamycin, cis-platinum) in patients with primary inoperable gastric cancer and advanced disease. <b>1988</b> , 110, 198-206   | 6  |
| 626 | 5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group. <b>1988</b> , 110, 212-8        | 3  |
| 625 | Lebensqualität in der urologischen Onkologie. <b>1997</b> , 871-882   | 1  |
| 624 | Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management. <b>2011</b> , 95-105   | 1  |
| 623 | Combined Modality Treatment for Locally Advanced Squamous Cell Esophageal Carcinoma Located at or Above the Level of the Tracheal Bifurcation. <b>1993</b> , 877-883  | 3  |
| 622 | Assessment of Therapeutic Response Through Clinical Assessment Measures. <b>2014</b> , 407-417  | 1  |
| 621 | The Necessity for Staging Liver Metastases and Standardizing Treatment-Response Criteria. The Case of Secondaries of Colo-Rectal Origin. <b>1984</b> , 154-168  | 17 |
| 620 | Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. <b>2004</b> , 53, 25-32  | 5  |
| 619 | A phase I safety and dose escalation trial of docetaxel combined with GEM-231, a second generation antisense oligonucleotide targeting protein kinase A R1 in patients with advanced solid cancers. <b>2006</b> , 24, 125 | 1  |
| 618 | Colorectal Cancer. <b>2014</b> , 1278-1335.e14  | 1  |
| 617 | The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. <b>2020</b> , 56, 380-389  | 2  |
| 616 | Analysis of plasma lipids by NMR spectroscopy: application to modifications induced by malignant tumors. <b>1993</b> , 34, 1009-1019  | 47 |
| 615 | Use of standard criteria for assessment of cancer vaccines. <b>2005</b> , 6, 3-4  | 9  |
| 614 | Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. <b>1999</b> , 79, 1800-1805  | 55 |
| 613 | Evaluation of the histologic effect of chemoradiation therapy for squamous cell carcinomas of the esophagus by assessing morphologic features of surgical specimens. <b>2000</b> , 13, 293-300                            | 18 |
| 612 | Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. <b>2000</b> , 10, 358-365   | 6  |
| 611 | Cytokeratin markers in malignant pleural mesothelioma. <b>1998</b> , 22, 416-21   | 9  |

|     |   |    |
|-----|---|----|
| 610 | Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term results. <b>1999</b> , 23, 172-6   | 7  |
| 609 | Neuron-specific enolase, thymidine kinase, and tissue polypeptide-specific antigen in diagnosis and response to chemotherapy of small-cell lung cancer. <b>1999</b> , 23, 309-15                              | 3  |
| 608 | Dose Escalation of Ara-C May Improve Response Rates in a Subgroup of Chronic Myeloid Leukemia Patients with Poor Response to Interferon- $\beta$ and Low-dose Ara-C. <b>2001</b> , 42, 1283-1288              | 2  |
| 607 | Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. <b>1996</b> , 19, 10-7 | 20 |
| 606 | Cisplatin and UFT modulated with leucovorin for the treatment of Advanced non-small-cell lung cancer. <b>1996</b> , 19, 121-4   | 4  |
| 605 | Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. <b>1996</b> , 19, 132-5   | 37 |
| 604 | Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer. <b>1996</b> , 19, 140-3  | 3  |
| 603 | Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. <b>1996</b> , 19, 149-53   | 13 |
| 602 | Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. <b>1996</b> , 19, 212-6  | 31 |
| 601 | The role of neoadjuvant intraarterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer. <b>1996</b> , 19, 255-9  | 54 |
| 600 | Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM). <b>1996</b> , 19, 278-80             | 8  |
| 599 | Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. <b>1996</b> , 19, 301-4  | 14 |
| 598 | M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. <b>1996</b> , 19, 344-8   | 11 |
| 597 | Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. <b>1996</b> , 19, 371-4  | 40 |
| 596 | A combination of vinblastine and doxorubicin with interferon alpha. <b>1996</b> , 19, 384-5   | 3  |
| 595 | Effect of 13-cis-retinoic acid with neoadjuvant chemotherapy in patients with squamous cervical carcinoma. <b>1996</b> , 19, 442-4  | 1  |
| 594 | Phase II trial of decapeptyl (D-TRP-6), a potent luteinizing hormone-releasing hormone analogue in untreated advanced breast cancer. <b>1996</b> , 19, 455-8  | 7  |
| 593 | 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial. <b>1996</b> , 19, 517-21                        | 7  |



|     |  |    |
|-----|--|----|
| 592 | Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain. <b>1996</b> , 19, 577-80   | 8  |
| 591 | Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. <b>1996</b> , 19, 584-8  | 7  |
| 590 | Activity of standard-dose carboplatin, cyclophosphamide, and etoposide in patients with metastatic breast cancer with previous exposure to anthracyclines. <b>1997</b> , 20, 166-8   | 5  |
| 589 | Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. <b>1997</b> , 20, 184-8 | 16 |
| 588 | Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II study. <b>1997</b> , 20, 276-81  | 11 |
| 587 | A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma. <b>1997</b> , 20, 289-92   | 7  |
| 586 | Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma. <b>1997</b> , 20, 311-4   | 26 |
| 585 | A phase II trial of cisplatin and interferon alpha 2b in patients with advanced bladder cancer. <b>1997</b> , 20, 319-21   | 4  |
| 584 | Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients. <b>1997</b> , 20, 404-6  | 12 |
| 583 | The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer. <b>1997</b> , 20, 477-8  | 18 |
| 582 | Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. <b>1997</b> , 20, 484-9                                     | 10 |
| 581 | Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide. <b>1997</b> , 20, 522-6   | 8  |
| 580 | Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study. <b>1998</b> , 21, 67-71   | 30 |
| 579 | Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer. <b>1998</b> , 21, 94-8   | 2  |
| 578 | Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. <b>1998</b> , 21, 151-4   | 4  |
| 577 | Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. <b>1998</b> , 21, 226-32   | 20 |
| 576 | Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study. <b>1998</b> , 21, 263-9  | 1  |
| 575 | High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. <b>1998</b> , 21, 369-75   | 10 |

|     |   |    |
|-----|---|----|
| 574 | Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma. <b>1998</b> , 21, 452-7   | 10 |
| 573 | Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. <b>1998</b> , 21, 470-4  | 28 |
| 572 | The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study. <b>1998</b> , 21, 491-7  | 11 |
| 571 | Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group. <b>1998</b> , 21, 509-12     | 11 |
| 570 | Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in non-Hodgkin lymphoma. <b>1999</b> , 22, 47-50  | 2  |
| 569 | Carboplatin, ifosfamide, and vinorelbine in the treatment of advanced non-small-cell lung cancer: a phase II study. <b>1999</b> , 22, 57-61   | 3  |
| 568 | Induction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small-cell carcinoma of the lung. <b>1999</b> , 22, 203-8        | 10 |
| 567 | Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM). <b>1999</b> , 22, 262-6  | 5  |
| 566 | Treatment of malignant pheochromocytomas with <sup>131</sup> I metaiodobenzylguanidine and chemotherapy. <b>1999</b> , 22, 364-70   | 79 |
| 565 | Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent. <b>1999</b> , 22, 485-8   | 11 |
| 564 | Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer. <b>1999</b> , 22, 495-8   | 6  |
| 563 | Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma. <b>1999</b> , 22, 559-67  | 19 |
| 562 | Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. <b>1999</b> , 22, 593-600 | 10 |
| 561 | Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study. <b>2000</b> , 23, 22-5  | 7  |
| 560 | Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. <b>2000</b> , 23, 132-9  | 37 |
| 559 | A phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer. <b>2000</b> , 23, 197-202  | 1  |
| 558 | Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus. <b>2000</b> , 23, 233-8                     | 16 |
| 557 | Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. <b>2000</b> , 23, 425-8  | 96 |

|     |   |     |
|-----|---|-----|
| 556 | Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. <b>1996</b> , 224, 509-20; discussion 520-2  | 698 |
| 555 | Place of cryosurgery in the treatment of malignant liver tumors. <b>1997</b> , 225, 39-8; discussion 48-50  | 204 |
| 554 | Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. <b>1997</b> , 226, 688-701; discussion 701-3   | 390 |
| 553 | First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. <b>1997</b> , 226, 714-23; discussion 723-4 | 51  |
| 552 | Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial. <b>1998</b> , 227, 380-9  | 102 |
| 551 | Case study of quality assurance in the administration of chemotherapy. <b>1996</b> , 19, 447-54   | 5   |
| 550 | Dipyridamole modulated Tc-99m sestamibi lung SPECT in small cell lung cancer. <b>1999</b> , 24, 97-101  | 8   |
| 549 | FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy. <b>1999</b> , 24, 261-3   | 7   |
| 548 | The impact of 2D versus 3D quantitation of tumor bulk determination on current methods of assessing response to treatment. <b>1996</b> , 20, 930-7  | 62  |
| 547 | Focal nodular hyperplasia: natural course observed with CT and MRI. <b>2000</b> , 24, 61-6  | 48  |
| 546 | SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. <b>2000</b> , 408  | 25  |
| 545 | Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate Cancer. <b>2002</b> , 2444-2450  | 3   |
| 544 | A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. <b>1997</b> , 64, 999-1006  | 40  |
| 543 | Lymphoproliferative disorders after organ transplantation in children. <b>1999</b> , 67, 990-8  | 84  |
| 542 | An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. <b>1996</b> , 12, 182-6   | 71  |
| 541 | Hydroxyurea treatment in HIV-infected patients. <b>1996</b> , 13, 462-4   | 22  |
| 540 | Phase Ia/Ib Chemo-Radiation Trial of Gemcitabine and Dose-Escalated Thoracic Radiation in Patients with Stage III A/B Non-small Cell Lung Cancer. <b>2006</b> , 1, 434-440  | 31  |
| 539 | The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline. <b>2006</b> , 1, 591-601  | 70  |

|     |  |     |
|-----|--|-----|
| 538 | Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules. <b>2010</b> , 33, 137-43  | 13  |
| 537 | Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response. <b>2010</b> , 31, 1008-15  | 4   |
| 536 | Four cases of bacteraemia caused by <i>Fusobacterium nucleatum</i> in febrile, neutropenic patients. <b>2011</b> , 60, 1046-1049   | 12  |
| 535 | Uncertainties in RECIST as a measure of volume for lung nodules and liver tumors. <b>2012</b> , 39, 2628-37  | 3   |
| 534 | A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors. <b>2002</b> , 63, 213-8   | 6   |
| 533 | Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. <b>1997</b> , 29, 1133-9  | 133 |
| 532 | Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. <b>2006</b> , 116, 1994-2004  | 105 |
| 531 | Measuring bleeding as an outcome in clinical trials of prophylactic platelet transfusions. <b>2012</b> , 2012, 157-160   | 12  |
| 530 | Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. <b>2000</b> , 96, 2049-2054               | 4   |
| 529 | Computed tomography-guided 125I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases. <b>2015</b> , 13,   | 2   |
| 528 | Imaging of tumour response to immunotherapy. <b>2020</b> , 4, 2  | 42  |
| 527 | High-Dose Static and Dynamic Intensity-Modulated Radiotherapy Combined with Chemotherapy for Patients with Locally Advanced Nasopharyngeal Carcinoma Improves Survival and Reduces Brainstem Toxicity. <b>2018</b> , 24, 8849-8859 | 8   |
| 526 | How difficult is the validation of clinical biomarkers?. <b>2015</b> , 4, 101  | 10  |
| 525 | Biological behavior of mucoepidermoid carcinoma of the esophagus. <b>2003</b> , 70, 401-7  | 14  |
| 524 | A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. <b>2011</b> , 6, e16694   | 85  |
| 523 | Serum microRNA-155 as a potential biomarker to track disease in breast cancer. <b>2012</b> , 7, e47003   | 154 |
| 522 | Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. <b>2013</b> , 8, e58489  | 29  |
| 521 | Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis. <b>2014</b> , 9, e85357  | 6   |

|     |  |    |
|-----|--|----|
| 520 | Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. <b>2014</b> , 9, e86532  | 7  |
| 519 | [ <b>18</b> ]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. <b>2014</b> , 9, e87629                      | 22 |
| 518 | Multi-modal glioblastoma segmentation: man versus machine. <b>2014</b> , 9, e96873   | 92 |
| 517 | Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability. <b>2014</b> , 9, e109400   | 68 |
| 516 | An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. <b>2014</b> , 9, e111886     | 74 |
| 515 | Evaluating outcomes used in cardiothoracic surgery interventional research: a systematic review of reviews to develop a core outcome set. <b>2015</b> , 10, e0122204                                   | 19 |
| 514 | High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients. <b>2015</b> , 10, e0142466   | 16 |
| 513 | Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm. <b>2015</b> , 10, e0143531  | 7  |
| 512 | PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer. <b>2017</b> , 12, e0172911  | 10 |
| 511 | Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. <b>2015</b> , 2,           | 5  |
| 510 | Classical Taxane versus the New Generation, Nab-Paclitaxel Chemotherapy in the Treatment of Breast Cancer. <b>2017</b> , 4,  | 0  |
| 509 | Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China. <b>2020</b> , 25, e1202-e1208                           | 4  |
| 508 | Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review. <b>2016</b> , 7, 58105-58110   | 22 |
| 507 | The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome. <b>2016</b> , 7, 67412-67424  | 13 |
| 506 | Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. <b>2017</b> , 8, 30477-30494  | 14 |
| 505 | Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis. <b>2016</b> , 7, 86500-86510 | 16 |
| 504 | Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials. <b>2017</b> , 8, 1329-1342 | 21 |
| 503 | Unidimensional measurement may be superior to assess primary tumor response after neoadjuvant chemotherapy for nasopharyngeal carcinoma. <b>2017</b> , 8, 46937-46945                                  | 2  |

|     |   |    |
|-----|---|----|
| 502 | An endoscopic ultrasonography-guided interstitial brachytherapy based special treatment-planning system for unresectable pancreatic cancer. <b>2017</b> , 8, 79099-79110                  | 6  |
| 501 | Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. <b>2017</b> , 8, 46624-46634          | 18 |
| 500 | Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. <b>2017</b> , 8, 81967-81977         | 27 |
| 499 | Artesunate-modified nano-graphene oxide for chemo-photothermal cancer therapy. <b>2017</b> , 8, 93800-93812   | 17 |
| 498 | An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. <b>2017</b> , 8, 101795-101807 | 24 |
| 497 | Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer. <b>2018</b> , 9, 17735-17755   | 2  |
| 496 | Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. <b>2016</b> , 7, 13680-7  | 12 |
| 495 | The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. <b>2019</b> , 16, 655-670  | 39 |
| 494 | Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors?. <b>2018</b> , 6, 222  | 12 |
| 493 | The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. <b>2018</b> , 6, 201                                  | 17 |
| 492 | Surrogate study endpoints in the era of cancer immunotherapy. <b>2018</b> , 6, S27  | 12 |
| 491 | Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer. <b>2016</b> , 28, 161-7   | 1  |
| 490 | Early prediction of pathological outcomes to neoadjuvant chemotherapy in breast cancer patients using automated breast ultrasound. <b>2016</b> , 28, 478-485                              | 14 |
| 489 | Synthetic and External Controls in Clinical Trials - A Primer for Researchers. <b>2020</b> , 12, 457-467  | 35 |
| 488 | Reliability and Validity Analysis of an Instrument for Pattern Identification and Evaluation in Chemotherapy-Induced Peripheral Neuropathy. <b>2016</b> , 37, 631-644                     | 3  |
| 487 | Diseases of the Lungs and Pleura. <b>2008</b> , 127-227   | 1  |
| 486 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <b>2019</b> , 20, 1042-1113                         | 96 |
| 485 | [Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis]. <b>2007</b> , 13, 378-86            | 12 |

|     |   |     |
|-----|---|-----|
| 484 | [Practice guidelines for management of hepatocellular carcinoma 2009]. <b>2009</b> , 15, 391-423  | 213 |
| 483 | Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <b>2020</b> , 12,   | 3   |
| 482 | [Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial]. <b>2008</b> , 6, 134-8  | 75  |
| 481 | Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. <b>2005</b> , 11, 3245-9   | 41  |
| 480 | Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. <b>2005</b> , 11, 6104-9   | 58  |
| 479 | Radiation therapy for portal venous invasion by hepatocellular carcinoma. <b>2005</b> , 11, 7237-41   | 43  |
| 478 | Tumor vaccine against recurrence of hepatocellular carcinoma. <b>2005</b> , 11, 700-4   | 27  |
| 477 | Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer?. <b>2007</b> , 13, 4306-9  | 8   |
| 476 | Usefulness of two independent histopathological classifications of tumor regression in patients with rectal cancer submitted to hyperfractionated pre-operative radiotherapy. <b>2007</b> , 13, 515-24      | 2   |
| 475 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. <b>2007</b> , 13, 6231-5 | 17  |
| 474 | Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?. <b>2012</b> , 18, 4944-58  | 57  |
| 473 | Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. <b>2012</b> , 18, 498-506   | 45  |
| 472 | A new endoscopic ultrasonography image processing method to evaluate the prognosis for pancreatic cancer treated with interstitial brachytherapy. <b>2013</b> , 19, 6479-84                                 | 13  |
| 471 | New approaches for precise response evaluation in hepatocellular carcinoma. <b>2014</b> , 20, 3059-68   | 9   |
| 470 | [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia]. <b>2016</b> , 37, 94-9                             | 1   |
| 469 | Treatment outcome of nasal natural killer/T-cell lymphoma. <b>2011</b> , 29, 174-80   | 5   |
| 468 | Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis. <b>2019</b> , 34, 608-617                                      | 8   |
| 467 | GUIDELINE FOR THE USE OF PLATELET TRANSFUSION CONCENTRATES BASED ON SCIENTIFIC EVIDENCE: UPDATE 2019. <b>2019</b> , 65, 544-561   | 2   |

|     |   |    |
|-----|---|----|
| 466 | Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Macao. <b>2014</b> , 26, 148-58  | 10 |
| 465 | Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution. <b>2015</b> , 36, 255-60   | 8  |
| 464 | Adoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysis. <b>2016</b> , 143, S1-S10  | 7  |
| 463 | Evaluating the effectiveness of topical application of natural honey and benzydamine hydrochloride in the management of radiation mucositis. <b>2012</b> , 18, 190-5  | 36 |
| 462 | Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility. <b>2015</b> , 9, 117-23  | 21 |
| 461 | Systematic analysis of measurement variability in lung cancer with multidetector computed tomography. <b>2017</b> , 12, 95-100  | 7  |
| 460 | Long-term quality of life after intensified multi-modality treatment of oral cancer including intra-arterial induction chemotherapy and adjuvant chemoradiation. <b>2015</b> , 5, 26-31   | 11 |
| 459 | Hypofractionated Radiotherapy for Palliation in Locally Advanced Head and Neck Cancer. <b>2017</b> , 23, 313-316  | 3  |
| 458 | Oxaliplatin/5-FU without leucovorin chemotherapy in metastatic colorectal cancer. <b>2005</b> , 37, 212-5   | 3  |
| 457 | Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer. <b>2005</b> , 37, 279-83  | 12 |
| 456 | Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. <b>2005</b> , 37, 290-3  | 39 |
| 455 | The safety and efficacy of second-line single docetaxel (75 mg/m <sup>2</sup> ) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum-based chemotherapy. <b>2005</b> , 37, 339-43                            | 4  |
| 454 | Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer. <b>2008</b> , 40, 101-5   | 8  |
| 453 | Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. <b>2009</b> , 41, 12-8 | 23 |
| 452 | Analysis of the prognostic factors for distant metastasis after induction chemotherapy followed by concurrent chemoradiotherapy for head and neck cancer. <b>2015</b> , 47, 46-54   | 14 |
| 451 | The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis. <b>2016</b> , 48, 917-27  | 16 |
| 450 | Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review. <b>2020</b> , 12, 228-236   | 5  |
| 449 | Quantitative measurement of contrast enhancement of esophageal squamous cell carcinoma on clinical MDCT. <b>2012</b> , 4, 179-85  | 4  |



|     |  |     |
|-----|--|-----|
| 448 | Can imaging patterns of neuroendocrine hepatic metastases predict response yttrium-90 radioembolotherapy?. <b>2013</b> , 5, 241-7  | 10  |
| 447 | Prediction of complete necrosis of hepatocellular carcinoma treated with transarterial chemoembolization prior to liver transplantation. <b>2009</b> , 3, 285-91   | 16  |
| 446 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <b>2019</b> , 13, 227-299  | 151 |
| 445 | The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <b>2020</b> , 14, 765-774             | 8   |
| 444 | Preventive effect of rebamipide gargle on chemoradiotherapy-induced oral mucositis in patients with oral cancer: a pilot study. <b>2012</b> , 2, e3  | 19  |
| 443 | Objective response rate assessment in oncology: Current situation and future expectations. <b>2020</b> , 11, 53-73   | 16  |
| 442 | Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma. <b>2011</b> , 33, 10-4   | 1   |
| 441 | Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission. <b>2011</b> , 33, 179-84  | 2   |
| 440 | Effective palliation of melanoma with procarbazine and radiotherapy given by a low-dose fractionation schedule. <b>1986</b> , 144, 126-8   | 3   |
| 439 | Preliminary experience with a combined-modality approach to the management of oesophageal cancer. <b>1988</b> , 148, 9-13  | 20  |
| 438 | High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. <b>1989</b> , 151, 379-86  | 11  |
| 437 | Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer. <b>1992</b> , 156, 698-700   | 2   |
| 436 | Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. <b>2012</b> , 10, 821-9   | 79  |
| 435 | Quantitative Imaging Assessment for Clinical Trials in Oncology. <b>2019</b> , 17, 1505-1511   | 3   |
| 434 | Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. <b>2010</b> , 1, 80-92  | 161 |
| 433 | Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma. <b>2012</b> , 13, 2669-73  | 9   |
| 432 | Comparison of WHO and RECIST criteria for evaluation of clinical response to chemotherapy in patients with advanced breast cancer. <b>2012</b> , 13, 3213-8  | 25  |
| 431 | Prediction of chemotherapeutic response in unresectable non-small-cell lung cancer (NSCLC) patients by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. <b>2013</b> , 14, 3057-62 | 1   |

|     |  |    |
|-----|--|----|
| 430 | Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. <b>2013</b> , 14, 3223-8                     | 12 |
| 429 | Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?. <b>2013</b> , 14, 3711-7                                  | 16 |
| 428 | Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. <b>2013</b> , 14, 4661-6                    | 14 |
| 427 | Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?. <b>2014</b> , 15, 9739-45  | 17 |
| 426 | Evidence based analysis of Cisplatin for treating patients with cutaneous squamous cell carcinoma. <b>2014</b> , 15, 9813-5  | 9  |
| 425 | Anti-VEGF Therapy with Bevacizumab--limited cardiovascular toxicity. <b>2014</b> , 15, 10769-72  | 3  |
| 424 | Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience. <b>2014</b> , 15, 1145-8 | 6  |
| 423 | Importance of volumetric measurement processes in oncology imaging trials for screening and evaluation of tumors as per response evaluation criteria in solid tumors. <b>2014</b> , 15, 2375-8           | 3  |
| 422 | Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system. <b>2014</b> , 15, 2465-72                                       | 14 |
| 421 | Central Nervous System Malignancies. <b>2021</b> , 731-754   |    |
| 420 | Characterization of Anti-angiogenic Chemo-sensitization via Longitudinal Ultrasound Localization Microscopy in Colorectal Carcinoma Tumor Xenografts. <b>2021</b> , PP,                                  | 0  |
| 419 | Evaluation of Chemotherapy-Induced Peripheral Neuropathy. <b>2021</b> , 53-93  |    |
| 418 | Heterocyclic Schiff base derivatives containing pyrazolone moiety: Synthesis, characterization, and in vitro biological studies. <b>2021</b> , 68, 2355  | 5  |
| 417 | Inclusion of participants from low-income and middle-income countries in core outcome sets development: a systematic review. <b>2021</b> , 11, e049981   | 0  |
| 416 | Characterization and Prognosis of Temozolomide-Induced Aplastic Anemia in Patients with Central Nervous System Malignancies. <b>2021</b> ,   | 0  |
| 415 | Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?. <b>2021</b> , 7, 139   | 0  |
| 414 | Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis. <b>2021</b> , 16, 743-752   | 1  |
| 413 | Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. <b>2021</b> , 100, 2879-2887  | 1  |

412 Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. **2021**, 10, 8272-8287 1

411 Phase I Trial of Docetaxel (Taxotere) for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML). **2001**, 477-481

410 A Case of Adenocarcinoma of the Anal Canal Responded to Chemoradiotherapy. **2002**, 35, 219-223

409 Funktioneller Status. **2002**, 129-140 2

408 Doxorubicin and Ifosfamide in Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Phase II Study of the Genitourinary Group of the French Federation of Cancer Centers. **2002**, 959-961 1

407 Pankreaskarzinom. **2003**, 85-98

406 Lung Cancer. **2004**, 149-165

405 Zytostatische Chemotherapie. **2004**, 399-424

404 Pediatric Lymphoma. **2004**, 247-288

403 Phase I Trial Design and Methodology for Anticancer Drugs. **2004**, 351-362

402 Data Driven Brain Tumor Segmentation in MRI Using Probabilistic Reasoning over Space and Time. **2004**, 301-309 2

401 Anticancer Drugs. **2005**, 401-419

400 Methoden klinischer Studien in der Onkologie. **2006**, 2517-2538

399 Peripheral Neuropathy Due to Chemotherapy and Radiation Therapy. **2006**, 107-121

398 Empfehlungen zur Klassifizierung und Graduierung unerwünschter Ereignisse und Therapienebenwirkungen. **2006**, 6493-6578

397 Evaluation of cardiac function by tissue Doppler imaging in children with cancer. **2006**, 49, 417

396 Optimal duration of chemotherapy for advanced non-small cell lung cancer.

395 EFFECT OF AGE ON CHARACTERISTICS AND CLINICAL BEHAVIOR OF ADULT AGGRESSIVE NON-HODGKIN'S LYMPHOMA. **2006**, 3,

394 Radiotherapy of Liver Tumors. **2007**, 1246-1268

393 Principles of Oncological Radiology. **2008**, 1793-1807

392 Advanced Pancreatic Cancer Successfully Treated with Biweekly Low-Dose Gemcitabine. **2008**, 16, 21-22

391 Radiological Detection and Assessment of Tumor Response. **2008**, 93-106

390 Concurrent Chemoradiotherapy with Biweekly Gemcitabine and Cisplatin in Patients with Locally Advanced Non-small Cell Lung Cancer. **2008**, 26, 160

389 Outcome of Locally Advanced Esophageal Cancer Treated with Concurrent Chemo-radiotherapy. **2009**, 27, 71

388 Pleura and Chest Wall. **2009**, 1037-1070

387 Treatment of Hepatocellular Carcinoma with Thalidomide: Assessment with Power Doppler Ultrasound. **2009**, 277-286

386 Measuring and Reporting Toxicity. **2009**, 251-258

385 Richtlinien zur radiologischen Befunddokumentation häufiger Tumorerkrankungen. **2009**, 3-11

384 General Considerations. **2009**, 1-58

383 The Results of Radiotherapy in Locally Advanced, Unresectable Pancreatic Cancer. **2009**, 27, 145

382 Principles of Clinical Trials. **2009**, 68-88

1

381 Taxane schedules for non-small cell lung cancer.

380 Méthodes radiologiques d'évaluation de la réponse thérapeutique en cancérologie. **2010**, 41-52

379 Hypofractionated Radiotherapy for Small-sized Hepatocellular Carcinoma as Salvage Therapy: Sustained Local Control and Safety. **2010**, 28, 85

1

378 Volumetry of Artificial Pulmonary Nodules in Ex Vivo Porcine Lungs: Comparison of Semi-automated Volumetry and Radiologists' Performance. **2010**, 62, 447

377 Imaging as a Localized Biomarker: Opportunities and Challenges. 1

376 Phase I Cancer Clinical Trials. **2010**, 1011-1015

375 Evaluation of Response After Radiotherapy for Hodgkin Lymphoma. **2011**, 161-166

374 Imaging in Gastrointestinal Cancer. **2011**, 1-20

373 Phase II Trials with Anticancer Agents. **2011**, 141-161

372 Induction Intra-arterial Chemotherapy (IAC) with Epirubicin and Mitoxantrone in Locally Advanced Breast Cancer. **2011**, 139-149

371 Headache as an Adverse Reaction to Medication. **2011**, 651-663

370 Systèmes d'évaluation et de prédiction des effets tardifs des radiations ionisantes. **2011**, 167-172

369 Magnetic Resonance. **2011**, 71-86

368 "Short Course" of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumab as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07). **2011**, 2, 245-251

367 Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) Regimen with Rotational CMFEV Regimen (E=Epirubicin, V=Vincristine) as Adjuvant Chemotherapy in Moderate Risk Operable Breast Carcinoma. **2011**, 02, 342-353

366 Onkologische Erkrankungen (Bersichtskapitel). **2011**, 247-258

365 EVALUATION OF PLATELET TRANSFUSION TRIGGERS. **2011**, 57, 436-441

364 Transfusion Support of the Patient with Hematologic Malignancy. **2012**, 293-308

363 Angiogenesis Inhibitor Therapy in Renal Cell Cancer. **2012**, 197-207

362 Measured Responses: British Clinical Researchers and Therapies for Advanced Breast Cancer in the 1960s and 1970s. **2012**, 130-160

361 Clinical Issues and Treatment of Lung Cancer in Mexico.

360 Incidentally Discovered Meningiomas: Growth Rates and Patterns. **2012**, 87-94

1

359 Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma. **2012**, 13, 517-20

8

358 Taxane schedules for non-small cell lung cancer.

357 Optimal duration of chemotherapy for advanced non-small cell lung cancer.

356 Assessment and Grading of Cancer Chemotherapy-Induced Neuropathic Pain. **2012**, 11-18

355 Biologic and Systemic Therapies for the Treatment of Hepatocellular Carcinoma. **2013**, 363-372

354 Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics. **2014**, 29-57

353 Biograding of Normal Tissue TNM Toxicity Taxonomy: Scoring the Adverse Effects of Cancer Treatment. **2014**, 93-101 1

352 Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned?. **2014**, 91-100

351 Allgemeines. **2014**, 1-30

350 Monitoring Responses to Therapy in Oncology. **2014**, 155-171

349 Neuroimaging in Clinical Trials. **2014**, 197-235

348 Clinical Assessment. **1982**, 1-13

347 Referenzen. **1984**, 211-220

346 Newer concepts regarding staging of gastrointestinal malignancy. **1984**, 35-57

345 A Complete Oncological Data Base: Digital Images and Data Synthesis. **1985**, 329-334

344 Vindesine in Renal Cancer: An EORTC Study. **1985**, 307-309

343 Kann das Ansprechen auf eine intraarterielle Chemotherapie bei Lebermetastasen colorectaler Carcinome vorhergesagt werden?. **1986**, 331-335 1

342 The Subrenal Capsule Assay as a Predictor of Tumour Response in Gynaecological Oncology. **1986**, 9-15

341 Gynecologic Malignancy. **1987**, 368-379

340 Analysis of Clinical Trial Data. **1987**, 199-210

339 Recombinant Interferon Alpha (2A) Combined with Dacarbazine in Treatment of Metastatic Melanoma. **1987**, 371-377

338 Clinical Evaluation: Noninvasive Methods. **1987**, 55-83

337 Neue Aspekte in der Chemotherapie des fortgeschrittenen Magenkarzinoms. **1988**, 197-214

1

336 Strahlentherapie des Harnblasenkarzinoms. **1988**, 37-50

1

335 Hepatic Arterial Infusion of Cisplatin as a Single Agent or in Combination with Vinblastine for Breast Cancer Metastatic to the Liver. **1988**, 473-478

334 Chemotherapie beim metastasierten malignen Melanom. **1988**, 266-273

333 Buserelin as a Single Agent or in Combination with the Antiandrogen Flutamide in the Treatment of Advanced Male Breast Cancer. **1988**, 168-182

332 Quality of Life and Palliation Treatment in Urological Cancer. **1989**, 255-263

331 Thermal neutron capture therapy: the Japanese-Australian clinical trial for malignant melanoma. **1989**, 50, 69-73

3

330 Clinical Experience with a Multifrequency Hyperthermia System and Chemotherapy in the Treatment of Superficial Metastases. **1990**, 247-251

329 Overview of whole body hyperthermia experience at American International Hospital. **1990**, 267, 203-8

328 Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC). **1990**, 7, 219-22

1

327 Induced hyperglycemia and tumor chemotherapy: experimental and clinical studies. **1990**, 7, 249-56

3

326 Faster response and survival advantage with Neo-Adjuvant Cisplatin and 5-Fluorouracil infusion versus Cisplatin and Bleomycin in advanced non-small cell lung cancer. **1991**, 449-453

325 Radiotherapy (RT) with concomitant Cisplatin (CDDP) in the management of locally advanced or recurrent head and neck cancer (LARHNC). **1991**, 66-68

324 A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. **1991**, 2 Suppl 2, 49-54

2

323 Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I-II clinical trial. **1991**, 8, 39-43

18

- 322 5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity. **1991**, 8, 69-73 2
- 321 Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer. **1991**, 8, 99-103 5
- 320 Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin's Lymphoma. **1992**, 656-660
- 319 Ein modifiziertes Schema von 5-Fluorouracil (5-FU) mit Leucovorin (LV) mit guter Verträglichkeit. **1992**, 305-309
- 318 Etoposid, Adriamycin, Cisplatin beim fortgeschrittenen Magenkarzinom – Langzeitergebnisse bei 145 Patienten. **1992**, 129-136
- 317 Treatment of High-Risk Relapsing or Refractory AML with M-AMSA and ID-ARAC. **1992**, 450-457
- 316 Treatment of Patients with Myelodysplastic Syndromes with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor: A Phase I/II Trial. **1992**, 300-314
- 315 Treatment with Human Recombinant Tumor Necrosis Factor- $\alpha$  of Patients with Acute Myeloid Leukemia and Chronic Myeloid Leukemia in its Accelerated or Blastic Phase. **1992**, 693-706 1
- 314 Pharmacology of High-Dose 1,2,4-Triglycidylurazol in Preparative Regimens for Bone Marrow Transplantation: Preclinical Evaluation and First Clinical Results. **1992**, 359-367
- 313 Interferon- $\beta$ 2b in the Treatment of Chronic Myeloid Leukemia. **1992**, 647-660
- 312 Chemotherapie des Plattenepithelkarzinoms der Speiseröhre im interdisziplinären Konzept. **1992**, 31-59 2
- 311 Stadiengerechte Chemotherapie des Magenkarzinoms. **1993**, 413-420
- 310 Folinic Acid and 5-Fluorouracil + Interferon Alfa-2b in the Treatment of Advanced Colorectal Cancer: Preliminary Results of a Randomized Study. **1993**, 353-358
- 309 Thymosin  $\alpha$ 1 and  $\beta$ -Interferon with Cisplatin and Etoposide in Advanced Non-Small-Cell Lung Cancer: A Phase II Study. **1993**, 149-153
- 308 Stage-Adjusted Chemotherapy of Gastric Cancer. **1993**, 380-387 1
- 307 A phase II study of weekly 48 hours infusion with high-dose Fluorouracil (FU) in colorectal cancer. **1994**, 422-427
- 306 Unkonventionelle Krebstherapieverfahren unter besonderer Berücksichtigung urologischer Malignome. **1994**, 639-679
- 305 Phase I-II study of oral Etoposide and modulation of drug resistance with ketoconazole in small cell lung cancer. **1994**, 331-335 1



- 304 5-FU + Folinic Acid (FA, Rescuvolin<sup>®</sup>) i.a., 5-FU + FA i.v., 5-FUDR i.a., or 5-FUDR i.a. + i.v. for treatment of non-resectable colorectal liver metastases ?. **1994**, 639-648
- 303 Intensive chemotherapy for inflammatory breast cancer: how much clinical value ?. **1994**, 135-145
- 302 Primary (Neo-Adjuvant) combined modality therapy in the management of locally advanced squamous cell carcinoma of the head and neck. **1994**, 201-206
- 301 Escalating doses of Epirubicin in combination with Ifosfamide and GM-CSF in previously untreated soft tissue sarcoma patients; a phase III study. **1994**, 573-576
- 300 Continuous Intravenous Pentoxifylline in Bone Marrow Transplant Recipients: First Results of a Pilot Study. **1994**, 700-704
- 299 Concomitant  $\alpha$ -Interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck. **1994**, 234-236
- 298 Intensive weekly chemotherapy for advanced gastric cancer using 5-Fluorouracil, Cisplatin, Epirubicin, 6S-Leucovorin and Granulocyte-colony stimulating factor. **1994**, 405-410
- 297 The European-Canadian study of paclitaxel in ovarian cancer. High vs low dose; long vs short infusion. **1995**, 225-229
- 296 Combination chemotherapy with cyclophosphamide, vincristine, cisplatin and etoposide (COPE) combined with radiotherapy for small cell lung cancer. **1995**, 10, 32-7
- 295 The Monitoring and Reporting of Clinical Trials. **1995**, 354-369
- 294 Langzeittherapie mit liposomal verkapseltem Doxorubicin beim HIV-assoziierten Kaposi-Sarkom. **1995**, 282-288 3
- 293 Adjuvant Methotrexate, Vinblastine and Cisplatin Chemotherapy for Invasive Transitional Cell Carcinoma. **1996**, 118-121
- 292 Methoden klinischer Studien in der Onkologie. **1996**, 1353-1372
- 291 Intraperitoneal 5-fluorouracil and mitomycin C as adjuvants to resectable gastric cancer: a status report. **1996**, 81, 177-83 1
- 290 Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer. **1996**, 19, 483-6
- 289 Concurrent Cisplatin and Radiotherapy for Patients with Muscle Invasive Bladder Cancer Who are not Candidates for Radical Cystectomy. **1996**, 1258-1262
- 288 A phase I study of methotrexate administration following 5-fluorouracil. **1996**, 19, 492-9
- 287 Unkonventionelle Krebstherapieverfahren unter besonderer Berücksichtigung urologischer Malignome. **1997**, 741-781

- 286 First-line systemic therapy for metastatic breast cancer and management of pleural effusion. **1997**, 121-131
- 285 Phase II Clinical Trials in Oncology. **1997**, 249-270
- 284 Poor-Risk Acute Myelogenous Leukemia Patients Undergoing the Fludarabine [Cytosine Arabinoside [Filgrastim Regimen: Multidrug Resistance Expression, Granulocyte Colony-Stimulating Factor Priming Activity and Clinical Response. **1997**, 846-851
- 283 Phase I Trial Design and Methodology. **1997**, 227-247 1
- 282 Modeling and Computation in Pharmaceutical Statistics when Analysing Drug Safety. **1997**, 221-232
- 281 Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lung cancer. **1997**, 20, 31-5
- 280 WHO-, AJCC- und ECOG-Performance Status Scale und Karnofsky-Index zur Quantifizierung des Allgemeinzustandes. **1998**, 11-17
- 279 A randomized controlled study on immunotherapy for gastric cancer assigned according to CEA and acute-phase reactants levels. **1998**, 7, 43-49 1
- 278 Isolierte hypoxische Perfusion mit Mitomycin C bringt keinen Benefit für Patienten mit fortgeschrittenem Pankreaskarzinom. **1998**, 1351-1353
- 277 WHO Toxicity Criteria. **1998**, 30-34
- 276 Einleitung. **1998**, 1-10
- 275 5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study. **1998**, 21, 313-6
- 274 Multimodal Therapies for Pancreatic Ductal Adenocarcinoma. **1999**, 417-430
- 273 Neoadjuvant Chemotherapy of Gastric Cancer with UFT. **1999**, 131-140
- 272 Neoadjuvant Systemic Chemotherapy for Advanced Gastric Cancer with Noncurative Clinical Factors. **1999**, 141-147
- 271 Designing a Clinical Antisense Study. **1999**, 191-201
- 270 Neoadjuvant Chemotherapy with FLEP Therapy for Advanced Gastric Cancer: Evaluation of Intraaortic and Intravenous FLEP Infusions. **1999**, 108-112
- 269 PHASE II STUDY OF ALL-TRANS RETINOIC ACID ADMINISTERED INTERMITTENTLY FOR HORMONE REFRACTORY PROSTATE CANCER. **1999**, 173-175

- 268 A Phase II Trial of Carboplatin and Etoposide for Relapsed or Metastatic Carcinoma of the Cervix. **1999**, 39, 87-90
- 267 The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study. **2014**, 2, 020413 1
- 266 Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. **2014**, 15, 8495-7 8
- 265 Pilocarpine and Prevention of Radiation Induced Xerostomia in HNSCC. **2014**, 1, 1
- 264 Angiogenesis Inhibitor Therapy in Renal Cell Cancer. **2015**, 281-294
- 263 Immunogenic Cell Death Markers in Liver Cancer. **2015**, 303-324
- 262 Immunotherapy for Pediatric Solid Tumors. **2015**, 47-67
- 261 Post-therapy Surveillance of Bone Tumors. **2015**, 211-219
- 260 Evaluation of Response in Malignant Tumors Treated with Targeted Agents. **2015**, 43-55
- 259 Treatment Results of Adjuvant Brachytherapy as Monotherapy in Endometrial Cancer: A Retrospective Study from Faculty of Medicine, Chiang Mai University. **2015**, 06, 34-39 1
- 258 Adjuvant External Beam Radiotherapy & Brachytherapy in Endometrial Cancer: A Retrospective Study from Faculty of Medicine, Chiang Mai University. **2015**, 06, 115-121
- 257 Adverse effects of Imatinib Mesylat: 5-year follow-up of 55 patients with chronic myeloid leukemia in Dakar (Senegal). **2015**, 6, 1
- 256 Electrochemotherapy of Basal Cell Carcinoma. **2016**, 1-12
- 255 The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study. **2016**, 07, 297-302
- 254 Novel Translational Research of Neo-adjuvant Endocrine Therapy. **2016**, 189-216
- 253 RE: Ultrasonic Measurement of Testicular Tumors and the Correlation with Pathologic Specimen Sizes. **2016**, 42, 172-3 1
- 252 The use of postprocedural imaging in the medical management of patients. **2016**, 281-299
- 251 Imaging Biomarker Measurements. **2017**, 87-99 1

- 250 Basics and Advances of Quantitative PET Imaging. **2017**, 303-322 1
- 249 Retrospective Analysis of Epsilon-Amino-Caproic Acid (EACA) Therapy in Patients with Hypoproliferative Thrombocytopenia. **2017**, 4, 0
- 248 Electrochemotherapy of Basal Cell Carcinoma. **2017**, 1831-1842
- 247 Correlation Analysis of Organic Acid Comprehensive Profile Markers with Chemotherapy Induced Peripheral Neuropathy in Cancer Patients. **2017**, 38, 72-80
- 246 COMPARISON OF WHO AND RECIST RESPONSE CRITERIA IN LOCALLY ADVANCED BREAST CANCER A DESCRIPTIVE STUDY. **2017**, 6, 4695-4698
- 245 Incidence of Cardiotoxicity in Treated Cases of Paediatric Hodgkin Lymphoma. **2017**, 5,
- 244 Treatment Response Evaluation in Hepatic Tumors using CT and MRI: Road Map for Radiologist. **2017**, 49-62
- 243 GPIIB ALLELIC POLYMORPHISM AS A FACTOR ASSOCIATED WITH THE PROBABILITY OF IMMUNE THROMBOCYTOPENIA AND THE SEVERITY OF HEMORRHAGIC SYNDROME. **2018**, 13, 93-99
- 242 Measuring Malignant Pleural Mesothelioma. **2019**, 153-166
- 241 Allgemeines. **2019**, 1-43
- 240 Pain Associated with Radiation Treatment for Breast Cancer. **2019**, 39-82
- 239 Immunotherapy. **2020**, 237-269
- 238 Comparison of Different Radiotherapy Techniques for Locally Advanced Pancreatic Tumors. **2020**, 1283-1290 0
- 237 Immunotherapy and Gliomas. **2020**, 251-265
- 236 Opportunities and limitations of CT - assessment of neoadjuvant chemoradiation therapy of gastric cancer. **2019**, 6, 92-101
- 235 Identifying and treating high blood pressure in men under 55 years with grade 1 hypertension: the TREAT CASP study and RCT. **2019**, 6, 1-90 0
- 234 Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab. **2020**, 17, 1
- 233 Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluorouracil and capecitabine. **2020**, 30, 8970

- 232 Quantitative Musculoskeletal Tumor Imaging. **2020**, 24, 428-440 0
- 231 Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. **2021**, 39, 7052-7057 6
- 230 4?-EPI-Adriamycin in Metastatic Renal Cancer. **1983**, 699-703
- 229 Kleinzelliges Bronchialkarzinom [M]glichkeiten und Ergebnisse der Behandlung im Tumorrezidiv. **1983**, 69-79
- 228 Salvage Irradiation for Patients with Recurrent Brain Metastases. **2020**, 371-378
- 227 Efficacy of Chinese herbal injections combined with fluoropyrimidine and oxaliplatin-based chemotherapy for advanced colorectal cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. **2020**, 99, e23550 2
- 226 The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy. **2020**, 31, e36 3
- 225 Response Evaluations for Precision Cancer Therapy and Immunotherapy. **2020**, 15-27
- 224 When and How to Use Imaging in Brain Tumors, Protocols. **2020**, 15-28
- 223 Therapy Response Imaging in Hepatobiliary and Pancreatic Malignancies. **2020**, 117-137
- 222 Advanced Nanomaterials in the Clinical Scenario: Virtues and Consequences. **2020**, 427-449
- 221 Response Assessment and Follow-Up by Imaging in Breast Tumors. **2020**, 451-474
- 220 Improved Clinical Outcome After Total Marrow Irradiation Conditioning Stem Cell Transplantation for Hematologic Malignancies. **2020**, 161-175 1
- 219 Assessment of Tumor Response with MRI and CT After Radioembolization. **2020**, 1001-1009
- 218 Conventional Tumor Response Criteria and Limitations. **2020**, 3-14
- 217 Response Assessment and Follow-Up by Imaging in Lung Tumours. **2020**, 417-449
- 216 Comparing Conventional Chemotherapy to Chronomodulated Chemotherapy for Cancer Treatment: Protocol for a Systematic Review (Preprint).
- 215 A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis. **2021**, 2021, 2292907 0

- 214 Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy. **2020**, 6, 1
- 213 Ecografia e oncologia. **2007**, 1-25
- 212 Anatomical Measure of Tumor Growth with Computed Tomography and Magnetic Resonance Imaging. **2007**, 33-46 1
- 211 [18F]Fluorodeoxyglucose Positron Emission Tomography Assessment of Response. **2007**, 103-120 1
- 210 Measurement of Tumor Proliferation with Positron Emission Tomography and Treatment Response. **2007**, 121-142
- 209 Therapeutic Counseling for the Medical Management of Renal Cell Carcinoma. **2008**, 515-534
- 208 Systemic Treatment of Thymoma. **2007**, 91-97
- 207 Diseases of the Pleura and the Chest Wall. **2009**, 291-305
- 206 Normal Tissue TNM Toxicity Taxonomy. **2008**, 99-107
- 205 Detection of disease recurrence and monitoring of therapy. **2008**, 177, 105-10
- 204 Immunotherapy response. **2020**, 707-714
- 203 Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. **2020**, 04, 373-381
- 202 Dosing Of Thromboprophylaxis And Mortality In Critically Ill Covid-19 Patients.
- 201 Commonly Used Chemotherapeutic Agents. **1987**, 14, 293-315
- 200 Cancer Care in the 1980s. **1987**, 14, 243-254
- 199 Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trails. **1999**, 318, 224-8 7
- 198 Breast liver metastases--incidence, diagnosis and outcome. **1991**, 84, 714-6 52
- 197 Palliation of malignant dysphagia: an alternative to surgery. **1996**, 78, 457-62 11

|     |  |    |
|-----|--|----|
| 196 | The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. <b>2008</b> , 2, 287-94   | 14 |
| 195 | Change detection & characterization: a new tool for imaging informatics and cancer research. <b>2007</b> , 4, 1-11   | 1  |
| 194 | Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. <b>2006</b> , 4, Doc02 | 4  |
| 193 | Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. <b>2007</b> , 1, 377-92  | 27 |
| 192 | TAK1 mRNA expression in the tumor tissue of locally advanced head and neck cancer patients. <b>2008</b> , 2, 63-70   |    |
| 191 | Breast cancer (metastatic). <b>2007</b> , 2007,  | 1  |
| 190 | 2 Platelet Concentrates. <b>2009</b> , 36, 372-382   | 13 |
| 189 | Role of positron emission tomography-computed tomography in staging and early chemotherapy response evaluation in children with neuroblastoma. <b>2010</b> , 25, 147-55    | 5  |
| 188 | Palliative Hypofractionated Radiotherapy For Non-small-cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy. <b>2009</b> , 1, 5-10               | 4  |
| 187 | Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes. <b>2011</b> , 4, 122-7  | 13 |
| 186 | An approach for assessment of tumor volume from mammography in locally advanced breast cancer. <b>2008</b> , 15, 37-41   | 2  |
| 185 | ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. <b>2012</b> , 5, 186-94   | 13 |
| 184 | How should we describe the benefits of palliative radiotherapy?. <b>2006</b> , 13, 230-4   | 3  |
| 183 | A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. <b>2012</b> , 5, 185-9                       | 7  |
| 182 | Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy. <b>2013</b> , 6, 71-7                      | 26 |
| 181 | Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. <b>2014</b> , 12, 180-6                 | 8  |
| 180 | Palliative Hypo-fractionated Radiotherapy in Locally Advanced Head and Neck Cancer with Fixed Neck Nodes. <b>2012</b> , 5, 178-82  | 4  |
| 179 | Stereological Evaluation of Tumor Regression Rates in Lung Cancer Using CT Via the Cavalieri Method. <b>2008</b> , 40, 109-14  | 1  |

|     |   |    |
|-----|---|----|
| 178 | Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies. <b>2014</b> , 7, 3833-42   | 4  |
| 177 | The impact of hemoglobin level and transfusion on the outcomes of chemotherapy in gastric cancer patients. <b>2015</b> , 8, 4228-35   | 9  |
| 176 | Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer. <b>2015</b> , 8, 4106-12  | 8  |
| 175 | Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. <b>2015</b> , 12, 126-39   | 19 |
| 174 | Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication. <b>2016</b> , 8, 3288-98  | 20 |
| 173 | Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party. <b>2016</b> , 14, 521-526 | 3  |
| 172 | Quality assessment and transfusion efficacy of buffy coat-derived platelet concentrates washed with platelet additive solution. <b>2018</b> , 16, 273-278   | 2  |
| 171 | Multiple electrode aggregometry and thromboelastography in thrombocytopenic patients with haematological malignancies. <b>2019</b> , 17, 181-190  | 1  |
| 170 | [Comprehensive geriatric assessment can predict the clinical outcomes of elderly patients with diffuse large B cell lymphoma in China]. <b>2018</b> , 39, 271-276   | 0  |
| 169 | [Mutation of ANKRD26 is responsible for thrombocytopenia 2 (THC2) : a family report in China]. <b>2018</b> , 39, 870-872  | 1  |
| 168 | Real-world experience of eltrombopag in immune thrombocytopenia. <b>2020</b> , 10, 240-251  | 10 |
| 167 | An audit of platelet transfusion indications in acute leukaemia patients: six-year experience at an Academic Centre. <b>2021</b> , 19, 37-44  | 1  |
| 166 | Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynx. <b>2004</b> , 25, 1092-8   | 25 |
| 165 | Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?. <b>2005</b> , 26, 770-6  | 87 |
| 164 | New Horizons in the Treatment of Osteosarcoma. <b>2021</b> , 385, 2066-2076   | 29 |
| 163 | Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <b>2021</b> , 23, 369-402  | 3  |
| 162 | Factors influencing recurrence after complete remission in children with hepatoblastoma: A 14-year retrospective study in China. <b>2021</b> , 16, e0259503   | 0  |
| 161 | Clinical observation on effect of yiqi huoxue recipe in comprehensive treatment on advanced stage of esophageal cancer. <b>2000</b> , 6, 25-28  | 1  |



|     |  |   |
|-----|--|---|
| 160 | Effectiveness and Safety of Chinese Herbal Injections Combined with Fluoropyrimidine and Oxaliplatin-based Chemotherapy for Advanced Colorectal Cancer: A Systematic Review and Meta-analysis of 63 Randomized Controlled Trials. <b>2021</b> , 12, 7237-7254                                  | 0 |
| 159 | Cancer Imaging in Immunotherapy.. <b>2021</b> , 1342, 431-447  |   |
| 158 | In Vitro Anticancer Screening and Preliminary Mechanistic Study of A-Ring Substituted Anthraquinone Derivatives.. <b>2022</b> , 11,  | 2 |
| 157 | Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases.. <b>2022</b> , 14, 107-122   | 0 |
| 156 | Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.. <b>2021</b> , 11, 800547   | 0 |
| 155 | Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia.. <b>2021</b> , 210, 33-41   | 1 |
| 154 | Metal-based nano-vaccines for cancer immunotherapy. <b>2022</b> , 455, 214345  | 3 |
| 153 | Cisplatin and vinorelbine combination chemotherapy in inoperable non small cell lung cancer (NSCLC) : a multicenter phase II trial. <b>2000</b> , 2, 84-90   | 1 |
| 152 | Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer. <b>2000</b> , 2, 154-158   | 2 |
| 151 | Carcinoma de nasofaringe localmente avanzado: resultados finales del tratamiento de quimiorradioterapia seguido de quimioterapia complementaria. <b>2000</b> , 2, 301-308  |   |
| 150 | Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: a multicenter phase II study. <b>2002</b> , 4, 385-390   |   |
| 149 | Tratamiento conservador del carcinoma epidermoide del canal anal con radioquimioterapia concomitante: experiencia 1989-2000. <b>2002</b> , 4, 370-377  |   |
| 148 | Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Results. <b>2021</b> , 274, e465-e472 | 1 |
| 147 | Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response.. <b>2021</b> , 11, 691638   |   |
| 146 | Comparative efficacy of 10 Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC a systematic review and network meta-analysis.. <b>2022</b> , 13, 465-480  | 0 |
| 145 | A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion.. <b>2022</b> ,   | 0 |
| 144 | Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.. <b>2022</b> , 22, 94  | 0 |
| 143 | Plasma and Platelet Transfusion Strategies in Critically Ill Children With Malignancy, Acute Liver Failure and/or Liver Transplantation, or Sepsis: From the Transfusion and Anemia EXPertise Initiative-Control/Avoidance of Bleeding.. <b>2022</b> , 23, e37-e49                             | 5 |

- 142 The addition of oxaliplatin to the mayo clinic schedule significantly increases its toxicity: a retrospective analysis of patients with advanced colorectal cancer. **2003**, 5, 88-92
- 141 Phase 2 Study of Avatrombopag in Japanese Patients with Chronic Liver Disease and Thrombocytopenia.. **2022**, 1
- 140 Identification of Halogen-Based Derivatives as Potent Inhibitors of Estrogen Receptor Alpha of Breast Cancer: An In-Silico Investigation. 1-25 1
- 139 Efficiency of anti-VEGF therapy in central nervous system AML relapse: A case report and literature review.. **2022**, 10, e05367 0
- 138 Phase II trial of gemcitabine and vinorelbine in patients with stage III B and IV non small cell lung cancer. **2003**, 5, 21-26
- 137 Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. **1989**, 6, 285-9 23
- 136 Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine. **1987**, 4, 67-73 2
- 135 Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. **1986**, 3, 15-24 4
- 134 Electrochemotherapy vs radiotherapy in the treatment of primary cutaneous malignancies or cutaneous metastases from primary solid organ malignancies: a protocol for a systematic review and meta-analysis. **2022**, 2022,
- 133 AIM and Brain Tumors. **2022**, 1717-1732
- 132 PET imaging of lung and pleural cancer. **2022**,
- 131 Nuclear Medicine Therapy in primary liver cancers. **2022**,
- 130 Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.. **2022**, 12, 828450 0
- 129 Local tumour response to neoadjuvant therapy with 2-aminoethyl dihydrogen phosphate in dogs with soft tissue sarcoma.. **2022**, 0
- 128 Calixarenes: recent progress in supramolecular chemistry for application in cancer therapy. 1 0
- 127 A multicentre, open-label, single-arm phase II trial of the efficacy and safety of sclerotherapy using 3% polidocanol foam to treat second-degree haemorrhoids (SCLEROFOAM).. **2022**, 1 1
- 126 Efficacy and Safety of Chinese Patent Medicine for the Prevention and Treatment of Radiotherapy and Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.. **2022**, 13, 812085 0
- 125 The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.. **2022**, 4, vdac032

|     |  |   |
|-----|--|---|
| 124 | Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinoradiological response outcomes.. <b>2022,</b>                            | 1 |
| 123 | Survival Analysis of Surgically Resected ypN2 Lung Cancer after Neoadjuvant Therapy.. <b>2022,</b>   |   |
| 122 | Deep learning-based automatic assessment of radiation dermatitis in nasopharyngeal carcinoma (NPC) patients.. <b>2022,</b>   | 0 |
| 121 | Epimedium for Osteoporosis Based on Western and Eastern Medicine: An Updated Systematic Review and Meta-Analysis.. <b>2022,</b> 13, 782096   | 0 |
| 120 | Evaluation and simplification of risk factors in FIGO 2000 scoring system for gestational trophoblastic neoplasia: a 19-year retrospective analysis.. <b>2022,</b> 23, 218-229                                 |   |
| 119 | Interobserver and intraobserver variability of RECIST assessment in ovarian cancer.. <b>2022,</b>  | 0 |
| 118 | The intrapleural administration with thymic peptides in malignant pleural effusion: A clustered systematic review and meta-analysis.. <b>2022,</b> 107, 108688   | 0 |
| 117 | An open-label, single-arm, multi-center, phase II clinical trial of single-dose [I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. <b>2021,</b> 36, 267      | 1 |
| 116 | Proposing Response Evaluation Criteria in Solid Tumors Based on Genomic Profiling or Genomic RECIST: A Retrospective Study on the Liquid Biopsy Results of 29 Cancer Patients.                                 |   |
| 115 | Compound Capsule Combined with Chemotherapy for Non-Small-Cell Lung Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials.. <b>2021,</b> 2021, 9535061                | 0 |
| 114 | Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.. <b>2021,</b> 11, 764189 | 3 |
| 113 | An observational study of intermediate or high dose thromboprophylaxis for critically ill COVID-19 patients. <b>2021,</b>  | 0 |
| 112 | Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence.. <b>2021,</b>   | 0 |
| 111 | Neoadjuvant treatment strategies for hepatocellular carcinoma.. <b>2021,</b> 13, 1550-1566   | 2 |
| 110 | Immediate results of treatment of patients with metastatic uveal melanoma using isolated liver chemoperfusion. The first domestic experience. <b>2021,</b> 117-123   | 1 |
| 109 | Fighting with Cancer: A Common Man's Dilemma. <b>2022,</b> 3-11  |   |
| 108 | Efficacy of non-platinum chemotherapy in platinum-resistant ovarian cancer: a meta-analysis. <b>2022,</b> 12, 21-35  |   |
| 107 | Preliminary Results of the First 50 Patients Undergoing Sclerotherapy for II-Degree Hemorrhoidal Disease Using an Automated Device.. <b>2022,</b> 9, 882030  | 0 |

- 106 High-dose therapy and posttransplantation symptom burden: striking a balance. 224-236
- 105 High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets. **1995**, 41, 271-279 1
- 104 ACTH 1-17 effects in the chemotherapy of advanced solid tumors. **1984**, 14, 211-20 0
- 103 TNO-6 has no effect in gastrointestinal cancer: N-acetyl-glucosaminidase shows renal damage. **1986**, 3, 25-8 3
- 102 An oriented phase-II trial of D-Trp6-LH-RH in patients with prostatic carcinoma. **1984**, 1, 119-22 7
- 101 Presurgery chemotherapy (CT) in locally advanced bladder carcinoma: a feasible and possibly effective approach. **1989**, 6, 179-82 1
- 100 Role of rapid arc-image-guided radiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis: A study from tertiary care center in Punjab, India. **2022**,
- 99 Association of P-glycoprotein expression and response to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer. **2022**, 31, 62-9
- 98 Intrapleural Perfusion With Staphylococcal Enterotoxin C for Malignant Pleural Effusion: A Clustered Systematic Review and Meta-Analysis.. **2022**, 9, 816973
- 97 Volumetric reduction of brain metastases after stereotactic radiotherapy: Prognostic factors and effect on local control.. **2022**, 0
- 96 Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India.. **2022**, 8, e2100383
- 95 Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.. **2022**, 108, 108803 0
- 94 MRI for evaluation of preoperative chemotherapy in osteosarcoma.. **2022**, 28, 593-604
- 93 Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy.. **2022**, 42, 1-18 0
- 92 First-line chemotherapy in advanced intrabdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.. *Cancer*, **2022**, 6.4 0
- 91 CPI Adult Cancer Imaging Special Edition Module. **2019**,
- 90 Monitoring Gastrointestinal Tumor Response to Therapy. **2015**, 2295-2305
- 89 The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases [A multicenter cohort study. **2022**, 0

|    |   |   |
|----|---|---|
| 88 | Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. <b>2022</b> , 107, 1243-1263  | 2 |
| 87 | Treatment of drug-induced immune thrombocytopenias. <b>2022</b> , 107, 1264-1277  | 3 |
| 86 | Genetic Variation of PD-L1 Gene Affects its Expression and Is Related to Clinical Outcome in Epithelial Ovarian Cancer. <b>2022</b> , 12,   | 0 |
| 85 | Gingivectomy with high-power laser for correction of the gummy smile resulting from altered passive eruption: a case series.  | 0 |
| 84 | Traditional Chinese medicines and capecitabine-based chemotherapy for colorectal cancer treatment: A meta-analysis.   |   |
| 83 | RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. <b>2022</b> , 12, e052294  | 0 |
| 82 | Phase I clinical and pharmacokinetic study of N 4-behenoyl-1-β-D-arabinofuranosylcytosine. <b>1986</b> , 3,   | 3 |
| 81 | Phase I clinical and pharmacokinetic study of orally administered N 4-palmitoyl-1-β-D-arabinofuranosylcytosine. <b>1987</b> , 4, 67-73  | 1 |
| 80 | Imaging response assessment for oncology: An algorithmic approach. <b>2022</b> , 9, 100426  | 0 |
| 79 | Effectiveness of topical application of honey in the management of radiation induced oral mucositis. <b>2022</b> , 34, 141  |   |
| 78 | Evaluation of cancer outcome assessment using MRI: A review of deep learning methods.   |   |
| 77 | A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. Publish Ahead of Print,   |   |
| 76 | Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo controlled, randomized clinical trial.  | 2 |
| 75 | Integrating the Patient's Voice in Toxicity Reporting and Treatment Decisions for Breast Radiotherapy. <b>2022</b> , 32, 207-220  |   |
| 74 | Intraarterial Therapies for the Management of Hepatocellular Carcinoma. <b>2022</b> , 14, 3351  | 1 |
| 73 | Criteria for assessing the response to treatments in solid tumor in the era of new oncology: what radiologists should know. <b>2022</b> , 9,  |   |
| 72 | Efficacy and Safety of EGFR Tyrosine Kinase Inhibitors Combined with Cranial Radiotherapy for Brain Metastases from Non-Small-Cell Lung Cancer: A Protocol for a Systematic Review and Meta-Analysis. <b>2022</b> , 2022, 1-7 |   |
| 71 | Assessing Response to Therapy. <b>2023</b> , 28-38  |   |

- 70 A Multidisciplinary Approach to Cancer: A Radiologist's View. **2023**, 1-6
- 69 PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients. **2022**, 17, e0271539
- 68 Clinical performance evaluation of O-Ring Halcyon Linac: A real-world study. **2022**, 10, 7728-7737
- 67 Clinical efficacy and safety of NSCLC ancillary treatment with compound Kushen injection through immunocompetence regulation: A systematic review and meta-analysis. **2022**, 104, 154315
- 66 Application of Rotational Thromboelastometry in Patients with Acute Promyelocytic Leukemia. **2022**, 28, 107602962211198
- 65 The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors.
- 64 Platelet transfusions and thrombocytopenia in intensive care units: Protocol for an international inception cohort study (PLOT-ICU). ○
- 63 Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. **2022**, 33, 752-757
- 62 Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study. ○
- 61 Computed Tomography Evaluation of In Vivo Pulmonary Cryoablation Zone Sizes. **2022**,
- 60 Efficacy and safety of a colostrum- and Aloe vera-based oral care protocol to prevent and treat severe oral mucositis in patients undergoing hematopoietic stem cell transplantation: a single-arm phase II study.
- 59 Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. Volume 9, 1011-1027 ○
- 58 Insighting the inhibitory potential of novel modafinil drug derivatives against estrogen alpha (ER $\alpha$ ) of breast cancer through a triple hybrid computational methodology. **2022**, 366, 120234 ○
- 57 Oral Cancer Management. **2022**, 1009-1055 ○
- 56 Pseudo-progression in neuro-oncology. **2022**, 821-839 ○
- 55 Belt electrode-skeletal muscle electrical stimulation during early hematopoietic post-transplantation to prevent skeletal muscle atrophy and weakness. **2022**, ○
- 54 The Gray Years: Technological Advancement and Legislative Change, 1968-1981. **2022**, 63-87 ○
- 53 Chinese patent medicine Kanglaite injection for non-small-cell lung cancer: An overview of systematic reviews. **2022**, 115814 1

|    |   |   |
|----|---|---|
| 52 | Tumor response assessment on imaging following immunotherapy. 12,   | 0 |
| 51 | Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients. 9,   | 0 |
| 50 | 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. <b>2022</b> , 28, 583-705   | 3 |
| 49 | Sclerotherapy with 3% polidocanol foam to treat second-degree haemorrhoidal disease: 3-year follow-up of a multicentre, single arm, IDEAL phase 2b trial.   | 0 |
| 48 | Intratumoral injection of holmium-166 microspheres as neoadjuvant therapy of soft tissue sarcomas in dogs. 9,   | 0 |
| 47 | A quantitative and comparative evaluation of stereotactic spine radiosurgery local control: proposing a consistent measurement methodology. <b>2022</b> , 53, E10   | 0 |
| 46 | The research status and progress of core outcome set in oral health. <b>2022</b> ,  | 0 |
| 45 | Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond).  | 0 |
| 44 | Clinical Experience with Thermotron RF-8 Capacitive Heating for Bulky Tumors: University of Minnesota Experience. <b>1989</b> , 27, 543-558   | 1 |
| 43 | Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay. 25, | 0 |
| 42 | 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <b>2022</b> , 23, 1126  | 4 |
| 41 | Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <b>2022</b> , 24, 269-304  | 0 |
| 40 | 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.   | 0 |
| 39 | Imaging of pediatric extragonadal pelvic soft tissue tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.   | 0 |
| 38 | Multicentered analysis of percutaneous sclerotherapies in venous malformations of the face. 9,  | 0 |
| 37 | Association of HLA-G 3'UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer. <b>2022</b> , 14, 2737  | 0 |
| 36 | Efficacy and Safety of Chinese Herbal Injection Thoracic Perfusion combined with Cisplatin chemotherapy for Lung Cancer Malignant Pleural Effusion: A Systematic Review and Meta-Analysis.                    | 0 |
| 35 | A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two Year Outcomes.  | 0 |

- 34 Assessment of immunotherapy response in intracranial malignancy using semi-automatic segmentation on magnetic resonance images. 13, ○
- 33 Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis. **2023**, 15, 39 ○
- 32 Pseudoprogession after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report. 12, ○
- 31 When Less is More: Can We Abandon Prophylactic Platelet Transfusion in Dengue Fever?. **2011**, 40, 539-545 ○
- 30 Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer. ○
- 29 Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients. **2022**, 100009 ○
- 28 Grundlagen der medikamentösen Tumorthherapie. **2022**, 1-23 ○
- 27 Efficacy and Safety of East Asian Herbal Medicine for Brain Metastases in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis Protocol to Identify Specific Herbs. **2023**, 22, 153473542211500 ○
- 26 Injectable Polypeptide Hydrogel Depots Containing Dual Immune Checkpoint Inhibitors and Doxorubicin for Improved Tumor Immunotherapy and Post-Surgical Tumor Treatment. **2023**, 15, 428 ○
- 25 Auriculothrapy to manage chemotherapy-induced nausea and vomiting in patients with cancer: a systematic review. 1-11 ○
- 24 Ginseng-containing traditional medicine preparations in combination with fluoropyrimidine-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis. **2023**, 18, e0284398 ○
- 23 A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma. **2022**, 62, 202-207 ○
- 22 A systematic review and network meta-analysis of randomised controlled trials comparing neoadjuvant treatment strategies for stage II and III rectal cancer. **2023**, 183, 103927 ○
- 21 Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials. ○
- 20 Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. **2023**, 24, 3151 1
- 19 Value of the FDP/FIB ratio in predicting early severe bleeding events in patients with newly diagnosed acute promyelocytic leukemia. **2023**, 102, 787-794 ○
- 18 Immune checkpoint inhibition: a future guided by radiology. ○
- 17 Palifermin Compared to Supersaturated Calcium Phosphate Rinse in Prevention of Severe Oral Mucositis after Stem Cell Transplantation in Patients Receiving Radiotherapy-Based Myeloablative Conditioning. **2023**, 4, 58-67 ○



- 16 Long-term follow-up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities. ○
- 15 Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. **2023**, 8, ○
- 14 Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. **2023**, 24, e133-e143 ○
- 13 Multisystem Imaging Recommendations/Guidelines: In the Pursuit of Precision Oncology. **2023**, 44, 002-025 ○
- 12 Use of split-course hypofractionated radiotherapy in palliative treatment of head and neck cancers: how does our regimen compare with others?. **2023**, 22, ○
- 11 Thoracic Malignancies. **2023**, 333-350 ○
- 10 BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. **2023**, 14, ○
- 9 Imaging Features of Immunotherapy. **2023**, 169-176 ○
- 8 Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy plus Bevacizumab as Frontline Therapy in Advanced Ovarian Cancer. ○
- 7 Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population. ○
- 6 Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment. ○
- 5 Effectiveness of Scalp Cooling to Prevent Chemotherapy-Induced Alopecia in Patients Undergoing Breast Cancer Treatment. Publish Ahead of Print, ○
- 4 Efficacy and safety of Propionibacterium extract gel versus glyceryl trinitrate ointment in the treatment of chronic anal fissure: a randomized controlled trial. ○
- 3 Stem Cell Therapy in Cancer. **2023**, 905-933 ○
- 2 Description and efficacy of a response-based QUAD cyclical hypofractionated palliative-intent radiation protocol in dogs with macroscopic solid tumours: 108 cases. ○
- 1 The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion: A clustered systematic review and meta-analysis. **2023**, 115, 154847 ○